

ALL  
In re Application of CECH et al.  
Application Number 08/974,584  
Filing Date November 19, 1997  
For: Telomerase Reverse Transcriptase  
Attorney Docket No. 15389-002950

**Substitute Specification**  
**(Clean Copy)**

Randolph T. Apple  
TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300

0

Attorney Docket No: 015389-002950US

## **TELOMERASE REVERSE TRANSCRIPTASE**

The present application is a continuation-in-part application ("CIP") of Patent Convention Treaty (PCT) International Application Serial No:PCT/US97/17618, for "Telomerase Reverse Transcriptase" (attorney docket No.:015389-002940PC) and PCT Application Serial No. PCT/US97/17885 for "Human Telomerase Catalytic Subunit" (attorney docket no. 015389-002600PC), both filed in the U.S. receiving office on October 1, 1997, which are CIPs of U.S. Patent Applications Serial No. ("USSN") 08/915,503, filed August 14, 1997, USSN 08/912,951, filed August 14, 1997, and USSN 08/911,312, filed August 14, 1997; all three of which are CIPs of USSN 08/854,050, filed May 9, 1997, which is CIP of USSN 08/851,843, filed May 6, 1997, which is a CIP application of USSN 08/846,017, filed April 25, 1997, which is a CIP of USSN 08/844,419, filed April 18, 1997, which is a CIP of USSN 08/724,643, filed on October 1, 1996. Each of the aforementioned applications is explicitly incorporated herein by reference in their entirety and for all purposes.

This invention was made with Government support under Grant No.GM28039, awarded by the National Institute of Health. The Government has certain rights in this invention.

### **20 FIELD OF THE INVENTION**

The present invention provides novel genus of telomerase enzyme genes and proteins and relates to the cloning and characterization of the catalytic protein component of telomerase, referred to as telomerase reverse transcriptase ("TRT").

The present invention is directed to a genus of polypeptides, nucleic acids and sequences relating to telomerase enzyme and TRT isolated from *Euplotes*, in particular, the two polypeptide subunits of *E. aediculatus* telomerase of 123 and 43 kDa,

*Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and mammals, including TRT homologs, isoforms and alleles.

This invention pertains generally to cell proliferation and aging, including the fields of age-related diseases, such as cancer and cell biology. The invention also  
5 pertains to methods of screening for novel telomerase and TRT activity modulators. The invention further includes means of decreasing the proliferative capacity of a cell, or mortalizing cells; a means of increasing the proliferative capacity of cells, thereby creating an indefinitely proliferating state, or an immortal state, as with normal, diploid cells; such means using the novel reagents, proteins, nucleic acids, enzymes and  
10 methods of the invention.

## **BACKGROUND OF THE INVENTION**

Telomeres, the protein-DNA structures physically located on the ends of the eukaryotic organisms, are required for chromosome stability and are involved in  
15 chromosomal organization within the nucleus (*See e.g.*, Zakian (1995) *Science* 270:1601; Blackburn (1978) *J. Mol. Biol.* 120:33; Oka (1980) *Gene* 10:301; and Klobutcher (1981) *Proc. Natl. Acad. Sci. USA* 78:3015). Telomeres are believed to be essential in such organisms as yeasts and probably most other eukaryotes, as they allow cells to distinguish intact from broken chromosomes, protect chromosomes from  
20 degradation, and act as substrates for novel replication mechanisms. Telomeres are generally replicated in a complex, cell cycle, and developmentally regulated manner by "telomerase," a telomere-specific DNA polymerase. However, telomerase-independent means for telomere maintenance have been described. In recent years, much attention has been focused on telomeres, as telomere loss has been associated with chromosomal  
25 changes such as those that occur in cancer and aging.

### **Telomeric DNA**

In most organisms, telomeric DNA has been reported to consist of a tandem array of very simple sequences, which in many cases are short and precise. Typically, telomeres consist of simple repetitive sequences rich in G residues in the strand that  
30 runs 5' to 3' toward the chromosomal end. For example, telomeric DNA in

*Tetrahymena* is comprised of sequence T<sub>2</sub>G<sub>4</sub>, while in *Oxytricha*, the sequence is T<sub>4</sub>G<sub>4</sub> (SEQ ID NO:44), and in humans the sequence is T<sub>2</sub>AG<sub>3</sub> (See e.g., Zakian (1995) *Science* 270:1601; and Lingner (1994) *Genes Develop.* 8:1984). However, heterogenous telomeric sequences have been reported in some organisms (e.g., the sequence TG<sub>1-3</sub> in *Saccharomyces*). In addition, the repeated telomeric sequence in some organisms is much longer, such as the 25 base pair sequence of *Kluyveromyces lactis*. Moreover, the telomeric structure of some organisms is completely different. For example, the telomeres of *Drosophila* are comprised of a transposable element (See, Biessman (1990) *Cell* 61:663; and F.-m Sheen (1994) *Proc. Natl. Acad. Sci. USA* 91:12510).

The telomeric DNA sequences of many organisms have been determined (See e.g., Zakian (1995) *supra*). However, it has been noted that as more telomeric sequences become known, it is becoming increasingly difficult to identify even a loose consensus sequence to describe them (Zakian, *supra*). Furthermore, it is known that the average amount of telomeric DNA varies between organisms. For example, mice may have as many as 150 kb (kilobases) of telomeric DNA per telomere, while the telomeres of *Oxytricha* macronuclear DNA molecules are only 20 bp in length (Kipling (1990) *Nature* 347:400; Starling (1990) *Nucleic Acids Res.* 18:6881; and Klobutcher (1981) *supra*). Moreover, in most organisms, the amount of telomeric DNA fluctuates. For example, the amount of telomeric DNA at individual yeast telomeres in a wild-type strain may range from approximately 200 to 400 bp, with this amount of DNA increasing and decreasing stochastically (Shampay (1988) *Proc. Natl. Acad. Sci. USA* 85:534). Heterogeneity and spontaneous changes in telomere length may reflect a complex balance between the processes involved in degradation and lengthening of telomeric tracts. In addition, genetic, nutritional and other factors may cause increases or decreases in telomeric length (Lustig (1986) *Proc. Natl. Acad. Sci. USA* 83:1398; and Sandell (1994) *Cell* 91:12061). The inherent heterogeneity of virtually all telomeric DNAs suggests that telomeres are not maintained via conventional replicative processes.

In addition to the telomeres themselves, the regions located adjacent to telomeres have been studied. For example, in most organisms, the sub-telomeric regions immediately internal to the simple repeats consist of middle repetitive sequences, designated as telomere-associated ("TA") DNA. These regions bear some  
5 similarity with the transposon telomeres of *Drosophila*. In *Saccharomyces*, two classes of TA elements, designated as "X" and "Y," have been described (Chan (1983) *Cell* 33:563). These elements may be found alone or in combination on most or all telomeres.

### **Telomeric Structural Proteins**

10 Various structural proteins that interact with telomeric DNA have been described which are distinct from the protein components of the telomerase enzyme. Such structural proteins comprise the "telosome" of *Saccharomyces* chromosomes (Wright (1992) *Genes Develop.* 6:197) and of ciliate macronuclear DNA molecules (Gottschling (1984) *Cell* 38:501; and Blackburn (1981) *Proc. Natl. Acad. Sci. USA*  
15 78:2263). The telosome is a non-nucleosomal, but discrete, chromatin structure that encompasses the entire terminal array of telomeric repeats. In *Saccharomyces*, the DNA adjacent to the telosome is packaged into nucleosomes. However, these nucleosomes are reported to differ from those in most other regions of the yeast genome, as they have features that are characteristic of transcriptionally inactive  
20 chromatin (Wright (1992) *supra*; and Braunstein (1993) *Genes Develop.* 7:592). In mammals, most of the simple repeated telomeric DNA is packaged in closely spaced nucleosomes (Makarov (1993) *Cell* 73:775; and Tommerup (1994) *Mol. Cell. Biol.* 14:5777). However, the telomeric repeats located at the very ends of the human chromosomes are found in a telosome-like structure.

### **Telomere Replication**

25 Complete replication of the ends of linear eukaryotic chromosomes presents special problems for conventional methods of DNA replication. For example, conventional DNA polymerases cannot begin DNA synthesis *de novo*, rather, they require RNA primers which are later removed during replication. In the case of  
30 telomeres, removal of the RNA primer from the lagging-strand end would necessarily

leave a 5'-terminal gap, resulting in the loss of sequence if the parental telomere was blunt-ended (Watson (1972) *Nature New Biol.* 239:197; Olovnikov (1973) *Theor. Biol.* 41:181). However, the described telomeres have 3' overhangs (Klobutcher (1981) *supra*; Henderson (1989) *Mol. Cell. Biol.* 9:345; and Wellinger (1993) *Cell* 72:51). For these molecules, it is possible that removal of the lagging-strand 5'-terminal RNA primer could regenerate the 3' overhang without loss of sequence on this side of the molecule. However, loss of sequence information on the leading-strand end would occur, because of the lack of a complementary strand to act as template in the synthesis of a 3' overhang (Zahler (1988) *Nucleic Acids Res.* 16:6953; Lingner (1995) *Science* 269:1533).

Nonetheless, complete replication of the chromosomes must occur. While conventional DNA polymerases cannot accurately reproduce chromosomal DNA ends, specialized factors exist to ensure their complete replication. Telomerase is a key component in this process. Telomerase is a ribonucleoprotein (RNP) particle and polymerase that uses a portion of its internal RNA moiety as a template for telomere repeat DNA synthesis (U.S. Patent No. 5,583,016; Yu (1990) *Nature* 344:126; Singer (1994) *Science* 266:404; Autexier (1994) *Genes Develop.* 8:563; Gilley (1995) *Genes Develop.* 9:2214; McEachern (1995) *Nature* 367:403; Blackburn (1992) *Ann. Rev. Biochem.* 61:113; Greider (1996) *Ann. Rev. Biochem.* 65:337). The activity of this enzyme depends upon both its RNA and protein components to circumvent the problems presented by end replication by using RNA (*i.e.*, as opposed to DNA) to template the synthesis of telomeric DNA. Telomerases extend the G strand of telomeric DNA. A combination of factors, including telomerase processivity, frequency of action at individual telomeres, and the rate of degradation of telomeric DNA, contribute to the size of the telomeres (*i.e.*, whether they are lengthened, shortened, or maintained at a certain size). *In vitro*, telomerases may be extremely processive, with the *Tetrahymena* telomerase adding an average of approximately 500 bases to the G strand primer before dissociation of the enzyme (Greider (1991) *Mol. Cell. Biol.* 11:4572).

Importantly, telomere replication is regulated both by developmental and cell cycle factors. It has been hypothesized that aspects of telomere replication may act as signals in the cell cycle. For example, certain DNA structures or DNA-protein complex formations may act as a checkpoint to indicate that chromosomal replication has been completed (*see e.g.*, Wellinger (1993) *Mol. Cell. Biol.* 13:4057). In addition, it has been observed that, in humans, telomerase activity is not detectable in most somatic tissues, although it is detected in many tumors (U.S. Patent No. 5,583,016, *supra*). Thus, telomere length is believed serve as a mitotic clock, which limits the replication potential of cells *in vivo* and/or *in vitro*. What remains needed in the art are additional methods to study the role of telomeres and their replication in normal as well as abnormal cells (*i.e.*, cancerous cells). An understanding of telomerase and its function is needed to develop better means for use of telomerase as a target for cancer therapy or anti-aging processes.

## **SUMMARY OF THE INVENTION**

This invention has for the first time provided for the cloning, characterization, synthesis, purification and recombinant expression of a genus of telomerase reverse transcriptase ("TRT") and telomerase enzyme complexes including, also for the first time, the important human telomerase reverse transcriptase protein ("hTRT"), as well as novel methods and reagents complementing this significant achievement.

The present invention provides compositions and methods for purification and use of TRT and telomerase enzyme. In particular, the present invention is directed to telomerase enzyme, including TRT, and co-purifying polypeptides obtained from *Euplotes*, as well as other organisms, *e.g.*, *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals, including human. The present invention also provides methods useful for the detection and identification of TRT and telomerase enzyme homologs in other species and genera of organisms.

The present invention relates to the cloning and characterization of the catalytic protein component of telomerase, referred to as TRT. In one aspect, the present invention provides TRT genes and proteins from ciliates, fungi, and vertebrates,

especially mammals. In one important aspect, the present invention relates to the cloning and characterization of the catalytic protein component of hTRT.

5 In one aspect, the present invention provides reagents and methods for identifying and cloning novel TRTs using: nucleic acid probes and primers generated or derived from the TRT polynucleotides for cloning TRT genes and cDNAs; and, antibodies that specifically recognize TRTs, including the motifs or other TRT epitopes, and such antibodies are useful for expression cloning of TRT genes, identification and purification of the genus of TRT polypeptides, and other applications as disclosed herein.

10 The present invention provides heretofore unknown telomerase TRT of *Euplotes*, particularly the *E. aediculatus* TRT of approximately 123 kDa (SEQ ID NO:2) and 43 kDa (SEQ ID NO:152-222), as measured on SDS-PAGE. The present invention provides isolated and substantially purified *E. aediculatus* 123 kDa and 43 kDa telomerase enzyme TRT protein subunits.

15 One aspect of the invention features isolated and substantially purified polynucleotides which encode telomerase enzyme components, including TRT, obtained from *Euplotes* (*i.e.*, *E. aediculatus* 123 kDa and 43 kDa TRT), *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals, including human. In a particular aspect, the polynucleotide is the *E. aediculatus* nucleotide sequence of SEQ ID NO:1 (DNA sequence of the *E. aediculatus* telomerase gene encoding the 123 kDa TRT), or variants thereof. In an alternative embodiment, the present invention provides fragments of the isolated and substantially purified polynucleotide encoding the *E. aediculatus* telomerase 123 kDa subunit of at least 10, at least 20, at least 30, and at least 50 amino acid residues in length. The invention further contemplates fragments of this polynucleotide sequence (*i.e.*, SEQ ID NO:1) that are at least 6 nucleotides, at least 25 nucleotides, at least 30 nucleotides, at least 100 nucleotides, at least 250 nucleotides, and at least 500 nucleotides in length. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1, or fragments thereof. The present invention further

20

25

contemplates a polynucleotide sequence comprising the complement of the nucleic acid of SEQ ID NO:1, or variants thereof.

5 The present invention also provides the polynucleotide with the sequence of SEQ ID NO:3 ( DNA sequence of the gene encoding the *E. aediculatus* 43 kDa telomerase enzyme protein subunit). In particular, the present invention provides the polynucleotide sequence comprising at least a portion of the nucleic acid sequence of SEQ ID NO:3, or variants, thereof. In one embodiment, the present invention provides fragments of the isolated and substantially purified polynucleotide encoding the *E. aediculatus* telomerase enzyme 43 kDa subunit of at least 10, at least 20, at least 30, and at least 50 amino acid residues in length. The invention also provides an isolated polynucleotide sequence encoding the *E. aediculatus* polypeptide of SEQ ID NOS:152-222 (the amino acid sequences of all three open reading frames of the *E. aediculatus* 43 kDa telomerase enzyme protein subunit), or variants thereof. The invention further contemplates fragments of this polynucleotide sequence (*i.e.*, SEQ ID NO:3) that are at least 5 nucleotides, at least 20 nucleotides, at least 100 nucleotides, at least 250 nucleotides, and at least 500 nucleotides in length. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:3, or fragments thereof. The present invention further contemplates a polynucleotide sequence comprising the complement of the nucleic acid of SEQ ID NO:3, or variants, alleles or homologues thereof.

20 The present invention provides an isolated and substantially purified *E. aediculatus* polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO:2 (123 kDa *E. aediculatus* telomerase enzyme TRT subunit), or variants thereof. In one embodiment, the portion of the polypeptide sequence comprises fragments of SEQ ID NO:2, having a length at least 10, at least 20, at least 30, and at least 50 amino acid residues in length.. However, the invention also contemplates polypeptide sequences of various lengths, the sequences of which are included within SEQ ID NO:2, ranging from 5 to 500 amino acids. The present invention also provides an isolated polynucleotide sequence encoding the polypeptide of SEQ ID NO:2, or variants, thereof. The invention further contemplates fragments of this polynucleotide

sequence that are at least 5 nucleotides, at least 20 nucleotides, at least 100 nucleotides, at least 250 nucleotides, and at least 500 nucleotides in length.

The present invention provides an isolated and substantially purified *E. aediculatus* polypeptide comprising at least a portion of the amino acid sequence selected from the group consisting of SEQ ID NO:152-222 (open reading frames of the *E. aediculatus* 43 kDa telomerase enzyme protein subunit), or variants thereof. In one embodiment, the portion of the polypeptide comprises fragments of SEQ ID NO:152-176, SEQ ID NO:177-198 and SEQ ID NO:199-222 having lengths of at least 10, at least 20, at least 30, and at least 50 amino acid residues in length. The present invention also contemplates polypeptide sequences of various lengths, the sequences of which are included within SEQ ID NOS:152-176, 177-198, and/or 199-222 (*Euplotes aediculatus* 43 kDa polypeptide open reading frames shown in SEQ ID NOS:152-222), ranging from 5 to 500 amino acids.

The present invention also provides a telomerase enzyme complex comprising one isolated recombinant 123 kDa telomerase protein subunit, one isolated recombinant 43 kDa telomerase protein subunit, and isolated recombinant telomerase enzyme-associated RNA. One embodiment includes a telomerase enzyme complex comprised of at least one isolated recombinant *E. aediculatus* 123 kDa telomerase protein subunit, at least one isolated recombinant *E. aediculatus* 43 kDa telomerase protein subunit, and isolated recombinant RNA. In one embodiment, the telomerase enzyme complex comprises an 123 kDa and/or telomerase protein subunit obtained from *Euplotes aediculatus*. It is contemplated that the 123 kDa telomerase protein subunit of the *E. aediculatus* telomerase enzyme complex can be encoded by SEQ ID NO:1. It is also contemplated that the 123 kDa *E. aediculatus* telomerase protein subunit of the telomerase enzyme complex be comprised of amino acids as shown in SEQ ID NO:2. It is also contemplated that the 43 kDa telomerase protein subunit of the telomerase enzyme complex can be obtained by purification from *E. aediculatus*. It is further contemplated that the 43 kDa telomerase protein subunit of the telomerase enzyme complex can be encoded by SEQ ID NO:3. It is also contemplated that the 43 kDa telomerase protein subunit of the telomerase enzyme complex be comprised of amino

acids in the sequence selected from the group consisting of SEQ ID NO:152-176, SEQ ID NO:177-198, and SEQ ID NO:199-222. It is contemplated that the isolated RNA of the telomerase enzyme complex be comprised of the RNA encoded by such sequences as those disclosed by, *e.g.*, Linger (1994) *Genes Develop.* 8:1985.

5 In a preferred embodiment, the telomerase enzyme complex if the invention is capable of binding to and/or replicating telomeric DNA *in vitro* and *in vivo*.

The present invention also provides methods for identifying a genus of telomerase protein subunits, including TRT, in eukaryotic organisms other than *E. aediculatus*. These methods are comprised of multiple steps. The first step is the  
10 synthesis of at least one probe or primer oligonucleotide that encodes (is identical or complementary to) at least a portion of a known TRT coding sequence, such as a portion of the coding sequence for the amino acid sequence of SEQ ID NOS:152-176, 177-198, or 199-222. In the alternative, the synthesized probe or primer  
15 oligonucleotides are complementary to at least a portion of a known TRT, such as *E. aediculatus* coding sequence for the amino acid sequence of SEQ ID NO:2, 152-176, 177-198 or 199-222. The next step comprises exposing at least one of the probe or primer oligonucleotide(s) to nucleic acid from the genome or, in the alternative, the expressed portion of the genome of the other organism (*i.e.*, the organism with the TRT specie to be identified by the methods and reagents of the invention), under conditions  
20 suitable for the formation of nucleic acid hybrids. Next, the hybrids are identified with or without amplification, such as by probe labeling or by using a DNA polymerase (*e.g.*, *Taq*, or any other suitable polymerase known in the art) for amplification. Finally, the sequence of the hybrids are determined using methods known in the art, and the sequences of the derived amino acid sequences analyzed for their similarity to a  
25 known TRT of the invention, such as, *e.g.*, SEQ ID NOS:2, 152-176, 177-198 or 199-222.

The present invention also provides methods for identifying any member of the genus of nucleic acid sequences encoding telomerase protein subunits, including TRT, in eukaryotic organisms comprising the steps of: providing a sample believed to contain  
30 nucleic acid encoding an eukaryotic telomerase protein subunit; contacting the same

with at least one oligonucleotide primer identical or complementary to the nucleic acid sequence encoding at least a region of a known protein subunit, such as an *E.*

*aediculatus* TRT, and a polymerase; incubating under conditions such that the nucleic acid encoding the eukaryotic telomerase protein subunit is amplified by primer  
5 extension; determining the sequence of the eukaryotic telomerase protein subunit; and comparing the sequence of the eukaryotic telomerase protein subunit and a known telomerase subunit, such as the *E. aediculatus* TRT.

In one preferred embodiment, the *E. aediculatus* TRT comprises at least a portion of SEQ ID NO:1. In an alternative preferred embodiment, the *E. aediculatus*  
10 TRT comprises at least a portion of SEQ ID NO:3.

Thus, the present invention also provides methods for identification of a genus of telomerase enzymes and TRTs in eukaryotic organisms other than *E. aediculatus*, including *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals, including human. The present invention allows one to compare known  
15 TRT, e.g., *E. aediculatus* amino acid sequences of SEQ ID NOS:2, 152-176, 177-198 or 199-222, and amino acid sequences derived from gene sequences of other organisms or obtained by direct amino acid sequence analysis of protein. The amino acid sequences shown to have the greatest degree of sequence identity (*i.e.*, homology) to a known TRT, such as SEQ ID NOS:2, 152-176, 177-198, 199-222, can then be selected  
20 for further testing.

Sequences of particular importance are those that share sequence identity with the reverse transcriptase (RT) or other motifs characteristic of the known TRT species of the invention, as discussed below. Once identified, the proteins and nucleic acids with the sequences showing the greatest degree of sequence identity may  
25 be tested for their role in telomerase enzyme activity by genetic or biochemical methods, including the methods set forth in the Examples below.

The present invention also provides methods for purification of the telomerase enzyme and TRT genus of the invention comprising the steps of providing a sample containing; exposing the sample to an affinity oligonucleotide under conditions wherein  
30 the affinity oligonucleotide binds to a telomerase enzyme, or a TRT or a telomerase-

associated nucleic acid to form a telomerase-oligonucleotide complex; and exposing the oligonucleotide-telomerase complex to a displacement oligonucleotide under conditions such that the telomerase component is released from the template. In a preferred embodiment, the method comprises the further step of eluting the telomerase component. In another preferred embodiment, the affinity oligonucleotide comprises an antisense oligonucleotide portion and a biotin residue. It is contemplated that, in one embodiment, during the exposing step, a biotin residue on the affinity oligonucleotide binds to an avidin bead and the antisense portion binds to the telomerase enzyme or telomerase component-encoding (*e.g.*, TRT) nucleic acid. It is also contemplated that, during the exposing step, the displacement oligonucleotide binds to the affinity oligonucleotide.

The present invention further provides isolated and substantially purified TRT polypeptides comprising amino acid sequences including SEQ ID NOS: 58 (*Oxytricha*), 63 (*Schizosaccharomyces pombe*), 64 (yeast, *S. cerevisiae*), 65 (*Euplotes aediculatus*), 67 (human telomerase motifs), and 69 (*Schizosaccharomyces*). In another embodiment, the present invention also provides isolated polynucleotide TRT sequences encoding polypeptides comprising the amino acid sequences of SEQ ID NOS:58, 63, 64, 65, 67, and 69. The present invention contemplates that the oligonucleotides may encode (or be identical or complementary to) any portion of a sequence that encodes portions or fragments of SEQ ID NOS:58, 63, 64, 65, 67, and 69, of various lengths. In one embodiment, the portion of the polypeptide, including fragments of lengths greater than about 5, 10 or more amino acids. However, the present invention also contemplates polynucleotides that encode and the polypeptides encoded of sequences of various lengths, the sequences of which are included within SEQ ID NOS:58, 63, 64, 65, 67, and 69, ranging from 5 to 500 amino acids (as appropriate, based on the length of SEQ ID NOS:58, 63, 64, 65, 67, and 69).

The present invention also provides nucleic acid sequences identical, complementary to or comprising SEQ ID NOS:55 (*S. cerevisiae*), 62 (human telomerase motifs), 66 (*S. cerevisiae*), and 68 (*Schizosaccharomyces*), or variants thereof. The present invention further provides fragments of the isolated

polynucleotide sequences that are at least 6 nucleotides, at least 10, at least 20, at least 25 nucleotides, at least 30 nucleotides, at least 50 nucleotides, at least 100 nucleotides, at least 250 nucleotides, and at least 500 nucleotides in length (as appropriate for the length of the sequence of SEQ ID NOS:55, 62, 66, and 68, or variants thereof and the intended application).

In particularly preferred embodiments, the polynucleotide hybridizes specifically to an individual species of the genus of TRT telomerase sequences, wherein the TRT sequences are selected from the group consisting of mammalian (*i.e.*, human, mouse), *Euplotes*, *Oxytricha*, *Schizosaccharomyces*, *Saccharomyces* and other yeast, TRT sequences. In other preferred embodiments, the present invention provides polynucleotide sequences comprising the complement of nucleic acid sequences selected from the group consisting of SEQ ID NOS:55, 62, 66, and 68, or variants thereof. In yet other preferred embodiments, the present invention provides polynucleic acid sequences that hybridize under stringent conditions to at least one nucleic acid sequence selected from the group consisting of SEQ ID NO:55, 62, 66, and 68. In a further embodiment, the polynucleotide sequence comprises a isolated, synthetic nucleotide sequence having a length of about ten to thirty nucleotides.

In alternative preferred embodiments, the present invention provides polynucleotide sequences corresponding to hTRT, the human telomerase enzyme catalytic subunit, comprising the sequence as set forth in SEQ ID NOS:113 and 117 (human), and their complementary sequences. The invention further contemplates fragments of these polynucleotide sequence (*i.e.*, SEQ ID NOS:113, and 117) that are at least 5 nucleotides, at least 20 nucleotides, at least 100 nucleotides, at least 250 nucleotides, and at least 500 nucleotides in length. The invention further contemplates fragments of the complements of these polynucleotide sequences (*i.e.*, SEQ ID NOS:113, and 117) that are at least 5 nucleotides, at least 20 nucleotides, at least 100 nucleotides, at least 250 nucleotides, and at least 500 nucleotides in length. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to SEQ ID NOS:113 and 117, and/or fragments, and/or the complementary sequences thereof. The present invention further contemplates a polynucleotide

sequence comprising the complement of the nucleic acids of SEQ ID NOS:113 and 117, or variants thereof. In a further embodiment, the polynucleotide sequence comprises a isolated, synthetic nucleotide sequence corresponding to a fragment of SEQ ID NOS:113 and/or 117, having a length of about ten to thirty nucleotides. The present invention further provides plasmid pGRN121 (ATCC accession # 209016), and the lambda clones 25-1.1 (ATCC accession # 209024) and GΦ5 (ATCC accession # 98505).

The present invention further provides isolated and substantially purified hTRT polypeptides comprising the amino acid sequence comprising SEQ ID NOS:316-365, and 118 (human). In another embodiment, the present invention also provides isolated polynucleotide sequences encoding the polypeptides comprising the amino acid sequences of SEQ ID NOS:316-365, and 118. The present invention contemplates portions or fragments of SEQ ID NOS:316-365, and 118, of various lengths. In one embodiment, the portion of polypeptide comprises fragments of lengths greater than 10 amino acids. However, the present invention also contemplates polypeptide sequences of various lengths, the sequences of which are included within SEQ ID NOS:316-365, and 118, ranging from 5 to 1100 amino acids (as appropriate, based on the length of SEQ ID NOS:316-365, and 118).

The present invention also provides methods for detecting the presence of nucleotide sequences encoding at least a portion of a TRT in a biological sample, comprising the steps of, providing: a biological sample suspected of containing nucleic acid corresponding to the nucleotide sequence of a TRT, for example, as set forth in SEQ ID NOS:1 (*Euplotes*), 3 (*Euplotes*), 53 (*Tetrahymena*), 62 (human), 66 (*S. cerevisiae*), 68 (*Schizosaccharomyces*), 117 (human); the nucleotide of SEQ ID NO:1, 3, 53, 62, 66, 68, 117 or fragment(s) thereof; combining the biological sample with the nucleotide under conditions such that a hybridization complex is formed between the nucleic acid and the nucleotide; and detecting the hybridization complex.

In one embodiment of the method, the nucleic acid corresponding to the nucleotide sequence of a TRT, for example, as set forth in SEQ ID NOS:1, 3, 53, 62, 66, 68, 117, is ribonucleic acid, while in an alternative embodiment, the nucleotide

sequence is deoxyribonucleic acid. In yet another embodiment of the method, the detected hybridization complex correlates with expression of the polynucleotide of a TRT, for example, as set forth in SEQ ID NOS:1, 3, 53, 62, 66, 68, 117, in the biological sample. In yet another embodiment of the method, detection of the hybridization complex comprises conditions that permit the detection of nucleic acids with alterations, as compared to the polynucleotide of a TRT, for example, as set forth in SEQ ID NOS:1, 3, 53, 62, 66, 68, 117, in the biological sample.

The present invention also provides antisense molecules comprising the nucleic acid sequence complementary to at least a portion of a TRT polynucleotide, for example, as set forth in SEQ ID NO:1, 3, 62, 66, 68 and 117. In an alternatively preferred embodiment, the present invention also provides pharmaceutical compositions comprising antisense molecules of SEQ ID NO:1, 3, 62, 66, 68 and 117, and a pharmaceutically acceptable excipient and/or other compound (*e.g.*, adjuvant).

In yet another embodiment, the present invention provides TRT polynucleotide sequences contained on recombinant expression vectors. In one embodiment, the expression vector containing a TRT polynucleotide sequence is contained within a host cell.

The present invention also provides methods for producing TRT polypeptides comprising, for example, amino acid sequences as shown in SEQ ID NOS:2 (*Euplotes*), 152-222 (*Euplotes*), 52 (*Tetrahymena*), 58 (*Oxytricha*), 63 (*Schizosaccharomyces*), 64 (*S. cerevisiae*), 65 (*Euplotes*), 67 (human), 69 (*Schizosaccharomyces*), or 118 (human), the method comprising the steps of: culturing a host cell under conditions suitable for the expression of the TRT polypeptide; and recovering or purifying the polypeptide from the host cell culture.

The present invention also provides isolated antibodies that bind specifically to a polypeptide comprising at least a portion of the amino acid sequence of a TRT specie, including, for example, as shown in SEQ ID NOS:2, 152-222, 52, 58, 63, 64, 65, 67, 69 and/or 118. In one embodiment, the present invention provides a pharmaceutical composition comprising at least one antibody, and a pharmaceutically acceptable excipient.

The present invention further provides methods for the detection of a TRT or a telomerase enzyme in a biological sample comprising the steps of: providing a biological sample suspected of expressing telomerase enzyme or TRT protein; and at least one antibody that binds specifically to at least a portion of an amino acid sequence of a TRT, for example, as shown in SEQ ID NOS:2, 152-222, 52, 55, 63, 64, 65, 67, 69 and/or 118; combining the biological sample and antibody(ies) under conditions such that an antibody:protein complex is formed; and detecting the complex wherein the presence of the complex correlates with the expression of the protein in the biological sample.

The present invention further provides isolated and substantially purified peptides of TRT species, including, for example, peptides comprising all or a portion of the amino acid sequence selected from the group consisting of SEQ ID NOS:71, 73, 75, 77, 79, 82 (all *Tetrahymena*), 83 (*S. cerevisiae*), 84 (*Euplotes*), 85 (*Tetrahymena*), 86, and 101 (human). In an alternative embodiment, the present invention provides isolated polynucleotide sequences encoding the polypeptides corresponding to these sequences. In preferred embodiments, the polynucleotide hybridizes specifically to TRT sequences, wherein the TRT sequences are selected from the group consisting of mammalian (e.g., human, mouse), *Euplotes aediculatus*, *Oxytricha*, *Schizosaccharomyces*, *Saccharomyces* and *Tetrahymena* sequences. In yet another embodiment, the polynucleotide sequence comprises the complement of a nucleic acid sequence selected from the group consisting of SEQ ID NOS:70, 72, 74, 76, 78, 80, 81 (all *Tetrahymena*), 100 (hTRT), 113 (hTRT), 117 (hTRT), and variants thereof. In a further embodiment, the polynucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence selected from the group consisting of SEQ ID NOS:66 (*S. cerevisiae*), 69 (*Schizosaccharomyces*), 80 (*Tetrahymena*), and 81 (*Tetrahymena*). In yet another embodiment, the polynucleotide sequence is selected from the group consisting of: SEQ ID NOS:70, 72, 74, 76, 78 (all *Tetrahymena*); 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 (all hTRT); 102, 103, 104, 105, 106 (all *S. pombe*); 107 (Adapt SfiI), 108 (Adapt SfiII), 109 (*S. pombe*), 110 (*S. pombe*), 111 (*Tetrahymena*), 113 (hTRT), and 117 (hTRT). In an alternative embodiment, the

nucleotide sequence comprises an isolated, synthetic nucleotide sequence having a length of about ten to fifty nucleotides.

The present invention also provides methods for detecting the presence of nucleotide sequences encoding at least a portion of a TRT in a biological sample, comprising the steps of, providing: a biological sample suspected of containing nucleic acid corresponding to the nucleotide sequence of a TRT, for example, as shown in SEQ ID NO:100, and/or SEQ ID NO:113, and/or SEQ ID NO:117; the nucleotide of SEQ ID NO:100, and/or SEQ ID NO:113, and/or SEQ ID NO:117, or fragment(s) thereof; combining the biological sample with the nucleotide under conditions such that a hybridization complex is formed between the nucleic acid and the nucleotide; and detecting the hybridization complex.

In one embodiment of the method, the TRT nucleic acid corresponding to the nucleotide sequence of SEQ ID NO:100, and/or SEQ ID NO:113, and/or SEQ ID NO:117, is ribonucleic acid, while in an alternative embodiment, the nucleotide sequence is deoxyribonucleic acid. In yet another embodiment of the method, the detected hybridization complex correlates with expression of the polynucleotide of SEQ ID NO:100, and/or SEQ ID NO:113, and/or SEQ ID NO:117, in the biological sample. In yet another embodiment of the method, detection of the hybridization complex comprises incubation under conditions that permit the detection of alterations in the nucleic acid, as compared to the polynucleotide of SEQ ID NO:100 and/or SEQ ID NO:113, and/or SEQ ID NO:117, in the biological sample.

The present invention also provides antisense molecules comprising nucleic acid sequences, for example, complementary to at least a portion of TRT polynucleotides, including, for example, as shown in SEQ ID NO:82 (*Tetrahymena*), 100, 113, and 117 (all hTRT). In an alternatively preferred embodiment, the present invention also provides pharmaceutical compositions comprising antisense molecules of SEQ ID NOS:82, 100, 113, 117, and a pharmaceutically acceptable excipient and/or other compound (*e.g.*, adjuvant).

In yet another embodiment, the present invention provides TRT polynucleotide sequences contained in recombinant expression vectors. In one embodiment, the

expression vector containing the polynucleotide sequence is contained within a host cell.

The present invention also provides methods for producing TRT polypeptides comprising, for example, the amino acid sequence of SEQ ID NOS:82, 83, 84, 85, 86, 101, 316-343, 344-356, 357-365, and/or 118, the method comprising the steps of:  
5 culturing a host cell under conditions suitable for the expression of the polypeptide; and recovering or purifying the polypeptide from the host cell culture.

The present invention also provides isolated antibodies that binds specifically to a TRT polypeptide comprising at least a portion of the TRT amino acid sequence of, for  
10 example, SEQ ID NOS:2, 152-222, 71, 73, 75, 77, 79, 82, 83, 84, 85, 86, 101, 316-343, 344-356, 357-365, and/or 118. In one embodiment, the present invention provides a pharmaceutical composition comprising at least one antibody, and a pharmaceutically acceptable excipient.

The present invention further provides methods for the detection of TRT in a  
15 biological sample comprising the steps of: providing a biological sample suspected of expressing TRT protein; and at least one antibody that binds specifically to at least a portion of the amino acid sequence of the TRT, for example, SEQ ID NOS:71, 73, 75, 77, 79, 82, 83, 84, 85, 86, 87, 101, 316-343, 344-356, 357-365, and/or 118, combining the biological sample and antibody(ies) under conditions such that an antibody:protein  
20 complex is formed; and detecting the complex wherein the presence of the complex correlates with the expression of the telomerase enzyme and/or TRT in the biological sample.

The present invention provides an isolated telomerase enzyme complex comprised of at least one TRT, a telomerase-associated nucleic acid moiety used as a  
25 template for telomere repeat DNA synthesis, and optionally other telomerase enzyme complex-associated proteins, such as co-purifying proteins and other proteins that regulate enzyme activity. In one embodiment, the telomerase enzyme complex is comprised of components of human origin, including human telomerase enzyme (comprising hTRT, encoded by the cDNA of SEQ ID NO:117), a human telomerase  
30 enzyme-associated RNA (hTR) moiety and telomerase-associated proteins. In one

embodiment, the complex comprises an hTRT protein of about 127 kd, having the sequence of SEQ ID NO:118, encoded by the cDNA SEQ ID NO:117.

5 The present invention also provides a number of different methods for expressing and isolating telomerase enzyme, TRT, and other telomerase-associated compounds that can be employed, in one or more aspects, as reagents and methodologies.

The methods and reagents of the present invention provide TRT genes and sequences that can be used to knock out homologous genes in cells. The novel reagents and methods of the invention thus provide TRT knockout cells and animals and  
10 methods for making such cells and transgenic mammals.

One aspect of the invention is the use of a polynucleotide that is at least ten nucleotides to about 10 kb or more in length and comprises a contiguous sequence of at least 10, at least 20, at least 30, at least 50 nucleotides that is identical, complementary to or comprising a contiguous sequence in a naturally occurring TRT gene or TRT mRNA  
15 in assaying or screening for an TRT gene sequence or TRT mRNA, or in preparing a recombinant host cell.

A further aspect of the invention is the use of an agent increasing expression of TRT in the manufacture of a medicament for the treatment of a condition addressed by increasing proliferative capacity of a vertebrate cell, optionally the medicament being for  
20 inhibiting the effects of ageing.

Yet a further aspect of the invention is the use of an inhibitor of telomerase enzyme activity in the manufacture of a medicament for the treatment of a condition associated with an elevated level of telomerase activity within a human cell.

The proteins, variants and fragments of the invention, and the encoding  
25 polynucleotides or fragments, are also each provided in a further aspect of this invention for use as a pharmaceutical.

The invention further includes the use of a protein, variant or fragment, or of a polynucleotide or fragment, in each case as defined herein, in the manufacture of a medicament, for example in the manufacture of a medicament for inhibiting an effect of  
30 aging or cancer.

In certain embodiments of the present invention, the TRT polynucleotides are other than the 389 nucleotide polynucleotide of AA281296 (SEQ ID NO:62) and/or other than clone 712562, the plasmid containing an insert, the sequence of which insert is shown in Figure 58, SEQ ID NO:122.

5           The invention further includes the use of a protein, variant or fragment, or of a polynucleotide or fragment, in each case as defined herein, in the manufacture of a medicament, for example in the manufacture of a medicament for inhibiting an effect of aging or cancer. Another aspect of the invention is a polynucleotide selected from:  
10       (a) a DNA encoding a polypeptide having a sequence as set forth in SEQ ID NOS:2, 152-222, 52, 58, 63, 64, 65, 67, 69, or 117; (b) a polynucleotide of at least 10 nucleotides which hybridizes to the foregoing DNA and which codes for an hTRT protein or variant or which hybridizes to a coding sequence for such a variant; and, (c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which code for an hTRT polypeptide or variant.

15           The invention further provides for expression vectors comprising nucleic acids encoding the TRT of the invention and cells comprising a the TRT-encoding polynucleotides. The invention further provides for transfected cells having a heterologous gene coding for at least 10 nucleotides of a telomerase reverse transcriptase-encoding nucleic acid and a transfected cell into which has been introduced an exogenous nucleic  
20       acid sequence which specifically hybridizes under stringent conditions to a TRT-encoding nucleic acid of the invention, has been introduced, and which expresses the exogenous nucleic acid as a protein or peptide. The transfected cell can be a mortal, karyotypically normal, diploid cell and can be derived from a bacterium, an insect, a plant, a fungus, a yeast or a mammal. The transfected cell can be contained within a non-human animal or  
25       progeny thereof.

          A further embodiment includes a non-human animal, or progeny thereof, into which an exogenous nucleic acid sequence which specifically hybridizes under stringent conditions to a TRT-encoding nucleic acid, has been introduced and the animal expresses the exogenous nucleic acid as a telomerase reverse transcriptase protein or fragment  
30       thereof. The transgenic non-human animal can have a heterologous gene coding for at

least 10 nucleotides of a telomerase reverse transcriptase protein-encoding nucleic acid. The non-human animal can be a mouse. The non-human animal can comprise a recombinant telomerase reverse transcriptase gene that differs from a naturally occurring telomerase reverse transcriptase gene in one or more codons. The non-human animal can  
5 comprise a gene which differs from a naturally occurring telomerase reverse transcriptase gene by having a substitution, missense mutation, a nonsense mutation, an insertion, or a deletion. The non-human animal can be deficient in a telomerase activity, and the deficiency can be a result of a gene encoding a telomerase having a reduced level of a telomerase activity compared to a wild-type telomerase.

10 The invention provides for an antibody, or binding fragment thereof, wherein the antibody or fragment specifically binds to a telomerase reverse transcriptase protein or immunogenic fragment thereof; an antibody which is specifically immunoreactive under immunologically reactive conditions, to a telomerase reverse transcriptase protein, or immunogenic fragment, and an antibody which is specifically immunoreactive under  
15 immunologically reactive conditions, to a telomerase reverse transcriptase protein, or immunogenic fragment thereof.

The invention also provides use of a polynucleotide that is at least ten nucleotides to 10 kb in length and comprises a contiguous sequence of at least ten nucleotides that is identical or exactly complementary to a contiguous sequence in a naturally occurring  
20 telomerase reverse transcriptase gene or telomerase reverse transcriptase mRNA in assaying or screening for a telomerase reverse transcriptase gene sequence or telomerase reverse transcriptase mRNA. Another embodiment provides use of a polynucleotide that is at least ten nucleotides to 10 kb in length and comprises a contiguous sequence of at least ten nucleotides that is identical or exactly complementary to a contiguous sequence  
25 in a naturally occurring telomerase reverse transcriptase gene or telomerase reverse transcriptase mRNA in preparing a recombinant host cell.

The invention provides for a method of determining whether a compound or treatment is a modulator of a telomerase reverse transcriptase activity or expression comprising detecting a change in activity or expression in a cell, animal or composition

comprising a telomerase reverse transcriptase recombinant protein or polynucleotide following administration of the compound or treatment.

In another embodiment, the invention provides for method of determining whether a test compound is a modulator of a telomerase reverse transcriptase activity, said method comprising the steps of: contacting a telomerase reverse transcriptase of the invention with the test compound; and measuring the activity of the telomerase reverse transcriptase, wherein a change in the telomerase reverse transcriptase activity measured in the presence of the test compound compared to the activity in the absence of the test compound provides a determination that the test compound modulates the telomerase reverse transcriptase activity.

A further embodiment provides for a method of preparing recombinant telomerase, said method comprising contacting a recombinant telomerase reverse transcriptase of the invention with a telomerase RNA component under conditions such that said recombinant protein and said telomerase RNA component associate to form a telomerase enzyme capable of catalyzing the addition of nucleotides to a telomerase substrate.

An additional embodiment provides for a method of detecting a telomerase reverse transcriptase gene product in a sample comprising: contacting the sample with a probe that specifically binds the gene product, wherein the probe and the gene product form a complex, and detecting the complex; or specifically amplifying the gene product in the biological sample, wherein said gene product is a nucleic acid, and detecting the amplification product; wherein the presence of the complex or amplification product is correlated with the presence of the telomerase reverse transcriptase gene product in the biological sample.

The invention also provides for a method of detecting the presence of at least one telomerase positive human cell in a biological sample comprising human cells, said method comprising the steps: measuring the amount of a telomerase reverse transcriptase gene product in said sample, and, comparing the amount measured with a control correlating to a sample lacking telomerase positive cells, wherein the presence of a higher level of the telomerase reverse transcriptase gene product in said sample as compared to

said control is correlated with the presence of telomerase positive cells in the biological sample.

Another embodiment provides for a method for diagnosing a telomerase-related condition in a mammal, comprising: obtaining a cell or tissue sample from the mammal; 5 determining the amount of a telomerase reverse transcriptase gene product in the cell or tissue; and comparing the amount of telomerase reverse transcriptase gene product in the cell or tissue with the amount in a healthy cell or tissue of the same type; wherein a different amount of telomerase reverse transcriptase gene product in the sample from the mammal and the healthy cell or tissue is diagnostic of a telomerase-related condition.

10 A further embodiment provides for a method for increasing the proliferative capacity of a vertebrate cell *in vitro* by increasing expression of telomerase reverse transcriptase in the cell. Another embodiment provides for use of an agent which increases the expression or activity of a telomerase reverse transcriptase in the manufacture of a medicament for the treatment of a condition addressed by increasing proliferative capacity 15 of a vertebrate cell. The use can be for a medicament to inhibiting an effect of ageing.

Another embodiment provides for a pharmaceutical composition comprising an acceptable carrier and a telomerase reverse transcriptase protein, variant or fragment of the invention, a reverse transcriptase antibody or binding fragment of the invention, a 20 polynucleotide encoding a telomerase reverse transcriptase protein, variant or fragment of the invention, or a nucleic acid that encodes a telomerase reverse transcriptase protein or subsequence thereof.

One embodiment provides for use of an inhibitor of telomerase expression or activity in the manufacture of a medicament for the treatment of a condition associated with an elevated level of telomerase activity within a mammalian cell, said inhibitor being 25 a polynucleotide of the invention, or a polypeptide of the invention, or a compound discovered using any of the forgoing.

Additional embodiments provide for a protein, variant or fragment of any one of polypeptides of the invention for use as a pharmaceutical or in the manufacture of a medicament.

The invention provides for use of a TRT protein, variant or fragment of the invention in the manufacture of a medicament for inhibiting an effect of ageing or cancer and the use of a TRT polynucleotide or fragment of the invention in the manufacture of a medicament for inhibiting an effect of ageing or cancer. The medicament's inhibitory effect on ageing can increase the lifespan of a cell or an animal to which the medicament is administered.

The invention further provides for a method for detecting the presence of a polynucleotide sequence encoding at least a portion of a telomerase reverse transcriptase in a biological sample, comprising the steps of: providing a biological sample suspected of containing a nucleic acid corresponding to the polynucleotide sequence of a telomerase reverse transcriptase; a probe comprising a nucleotide sequence of a telomerase reverse transcriptase, or a fragment thereof capable of hybridizing to a telomerase reverse transcriptase from a biological sample; combining said nucleic acid-containing biological sample with said probe under conditions such that a hybridization complex is formed between said nucleic acid and said probe; and detecting said hybridization complex. The nucleic acid in the biological sample can be a ribonucleic acid or a deoxyribonucleic acid. In one embodiment, the detected hybridization complex correlates with the expression of a telomerase reverse transcriptase in the biological sample. In another embodiment the detecting of the hybridization complex comprises the detection of alterations in the nucleotide sequence of a telomerase reverse transcriptase in said biological sample.

The invention also provides for use of a polynucleotide or fragment comprising a purified antisense nucleotide having a nucleic acid sequence complementary to at least a portion of the telomerase reverse transcriptase polynucleotide of the invention in the manufacture of a medicament.

The invention further provides for a method for producing a polypeptide comprising an amino acid sequence encoded by a TRT nucleotide sequence of the invention, the method comprising culturing a host cell comprising a TRT nucleotide sequence of the invention, under conditions suitable for the expression of the polypeptide encoded therein. In one embodiment the polypeptide is isolated or purified.

## PATENT

The invention also provides for a method for detecting the expression or presence of a telomerase reverse transcriptase in a biological sample comprising the steps of: providing: a biological sample suspected of expressing telomerase reverse transcriptase protein; and an anti-TRT antibody of the invention; combining the biological sample and the antibody under conditions such that an antibody:telomerase reverse transcriptase  
5 protein complex is formed; and detecting said complex wherein the presence of the complex correlates with the expression or presence of said telomerase reverse transcriptase in said biological sample.

The invention further provides recombinant, synthetic and isolated proteins and  
10 nucleic acids that include TRT "motifs," as shown in Figures 48, 55, 56 and 57. These motifs effect common telomerase structure and function and define members of the TRT genus of the invention. Novel reagents of the invention corresponding to these motif regions can be used in methods of the invention to generate unique peptides, antibodies, and nucleic acids, including complementary and antisense hybridization probes and  
15 primers, to identify additional members of the TRT genus, including TRT isoforms, homologues, alleles and TRT species from other organisms.

Two TRT proteins are considered to have a statistically significant sequence identity, *i.e.*, having significant homology, at the amino acid level *in a conserved region* of the TRT protein, such as the motifs described above and in the Figures, if, after  
20 adjusting for deletions, additions and the like, the conserved regions have about 20% to 30% sequence identity, as can be deduced or derived from Figures 48, 55, 56 and 57. However, this sequence identity can be higher, for example, as high as about 40% to 50% or higher, if, *e.g.* the conserved region of comparison is shorter, *i.e.*, a region of 10 consecutive amino acids. Furthermore, the skilled artisan can deduce or derive additional  
25 TRT motifs, modifications of these TRT motifs, variations in the amount of sequence identity in a particular TRT motif to determine whether a polypeptide or nucleic acid is a member of the TRT genus of the invention, and the like, by reference the teachings and sequences of the invention, particularly including Figures 48, 55, 56 and 57.

Thus, in one embodiment, the invention provides for an isolated or recombinant  
30 TRT polypeptide, said polypeptide characterized by having a statistically significant

sequence identity to an amino acid sequence comprising: Trp-R<sub>1</sub>-X<sub>7</sub>-R<sub>1</sub>-R<sub>1</sub>-R<sub>2</sub>-X-Phe-Phe-Tyr-X-Thr-Glu-X<sub>8,9</sub>-R<sub>3</sub>-R<sub>3</sub>-Arg-R<sub>4</sub>-X<sub>2</sub>-Trp (SEQ ID NOS:16 and 17), where X is any amino acid and a subscript refers to the number of consecutive residues, R<sub>1</sub> is leucine or isoleucine, R<sub>2</sub> is glutamine or arginine, R<sub>3</sub> is phenylalanine or tyrosine, and R<sub>4</sub> is lysine or histidine.

One embodiment provides for an isolated or recombinant nucleic acid that encodes a TRT polypeptide, said polypeptide characterized by having a statistically significant sequence identity to an amino acid sequence comprising: Trp-R<sub>1</sub>-X<sub>7</sub>-R<sub>1</sub>-R<sub>1</sub>-R<sub>2</sub>-X-Phe-Phe-Tyr-X-Thr-Glu-X<sub>8,9</sub>-R<sub>3</sub>-R<sub>3</sub>-Arg-R<sub>4</sub>-X<sub>2</sub>-Trp (SEQ ID NOS:16 and 17) where X is any amino acid and a subscript refers to the number of consecutive residues, R<sub>1</sub> is leucine or isoleucine, R<sub>2</sub> is glutamine or arginine, R<sub>3</sub> is phenylalanine or tyrosine, and R<sub>4</sub> is lysine or histidine.

The invention also provides for an isolated or recombinant TRT polypeptide having a statistically significant sequence identity to an amino acid sequence comprising a motif of contiguous amino acids selected from the group consisting of: Motif T of Figures 55 or 57, Motif 1 of Figures 55 or 57, Motif 2 of Figures 55 or 57, Motif A of Figures 55 or 57, Motif B of Figures 55 or 57, Motif C of Figures 55 or 57, Motif D of Figures 55 or 57, and Motif E of Figures 55 or 57.

Another embodiment provides for an isolated or recombinant TRT polypeptide having a statistically significant sequence identity to an amino acid sequence comprising a motif of contiguous amino acids selected from the group consisting of:

Motif T, comprising the sequence W-X<sub>12</sub>-F-F-Y-X-T-E-X<sub>10-11</sub>-R-X<sub>3</sub>-W-X<sub>7</sub>-I (SEQ ID NOS:119 and 120), or, alternatively  
W-L-X-Y-X-X-h-h-X-h-h-X-p-F-F-Y-X-T-E-X-p-X-X-X-p-X-X-X-Y-X-R-K-X-X-W  
(SEQ ID NO:116);

Motif T' comprising the sequence E-X<sub>2</sub>-V-X (SEQ ID NO:121);

Motif 1, comprising the sequence h-R-h-X-P-K (SEQ ID NO:473), or X<sub>3</sub>-R-X<sub>2</sub>-P-K-X<sub>3</sub> (SEQ ID NO:139);

Motif 2, comprising the sequence (F/L)-R-h-I-X<sub>2</sub>-h (SEQ ID NO:474);

PATENT

Motif A, comprising the sequence  $X_4$ -F- $X_3$ -D- $X_4$ -Y-D- $X_2$  (SEQ ID NO:144), or,  
P-X-L-Y-F-h-X-h-D-h- $X_2$ - C-Y-D-X-I (SEQ ID NO:475);  
Motif B', comprising the sequence Y- $X_4$ -G- $X_2$ -Q-G- $X_3$ -S- $X_8$  (SEQ ID NO:146),  
or, K-X-Y-X-Q- $X_2$ -G-I-P-Q-G-S-X-L-S-X-h-L (SEQ ID NO:115); and,  
5 Motif C, comprising the sequence  $X_6$ -D-D-X-L- $X_3$  (SEQ ID NO:147), or  
wherein X is any amino acid,  $X_2$  is any two amino acids,  $X_3$  is any three amino acids, an the like.

An embodiment provides for an isolated or recombinant TRT polypeptide having a statistically significant sequence identity to an amino acid sequence motif comprising the  
10 sequence W(L/I)XXXXhhXhh(Q/R)  
XFFYXTEXXXXXXXXXX(F/Y)(F/Y)RXXXWXX(L/I)XXHXIXXXX(K/M) (SEQ ID NO:471), wherein X is any amino acid and wherein h is a hydrophobic amino acid.

One embodiment provides for an isolated or recombinant TRT polypeptide having a statistically significant sequence identity to an amino acid sequence motif  
15 comprising the sequence FFYXTE (SEQ ID NO:71), wherein X is any amino acid.

The invention also provides for an isolated or recombinant TRT polypeptide having a statistically significant sequence identity to an amino acid sequence motif comprising the sequence hRhIPK (SEQ ID NO:367), wherein h is a hydrophobic amino acid.

20 Another embodiment provides for an isolated or recombinant TRT polypeptide having a statistically significant sequence identity to an amino acid sequence motif comprising the sequence hXXXXhRhIPK (SEQ ID NO:472), wherein h is a hydrophobic amino acid and wherein X is any amino acid.

The invention also provides for an isolated or recombinant TRT polypeptide  
25 having a statistically significant sequence identity to an amino acid sequence motif comprising the sequence KXYXQXXGIPQGSXLSXhLXXhXYXDL (SEQ ID NO:115), wherein h is a hydrophobic amino acid and wherein X is any amino acid.

One embodiment provides for an isolated or recombinant TRT polypeptide comprising an amino acid sequence motif comprising the sequence

(L/I)(L/M)(R/K)(L/V)XDD(F/Y)Lh(I/V)(T/S) (SEQ ID NO:114), wherein h is a hydrophobic amino acid and wherein X is any amino acid.

Another embodiment provides for an isolated or recombinant TRT polypeptide comprising an amino acid sequence motif comprising the sequence (NH<sub>2</sub>)-  
 5 X<sub>300-600</sub>-W-X<sub>12</sub>-FFY-X-TE-X<sub>10-11</sub>-R-X<sub>3</sub>-W-X<sub>7</sub>-I-X<sub>5-20</sub>-E-X<sub>2</sub>-V-X-X<sub>5-20</sub>-X<sub>3</sub>-R-X<sub>2</sub>-PK-X<sub>4-10</sub>-R-  
 X-I-X-X<sub>60-80</sub>-X<sub>4</sub>-F-X<sub>3</sub>-D-X<sub>4</sub>-YD-X<sub>2</sub>-X<sub>80-130</sub>-Y-X<sub>4</sub>-G-X<sub>2</sub>-QG-X<sub>3</sub>-S-X<sub>8</sub>-X<sub>5-35</sub>-X<sub>6</sub>-DD-X-L-X<sub>3</sub>-  
 X<sub>10-20</sub>-X<sub>12</sub>-K (SEQ ID NO:4), wherein h is a hydrophobic amino acid and wherein X is any amino acid.

Furthermore, other embodiments provide for an isolated or recombinant  
 10 TRT polypeptides selected from the group of organisms consisting of *Euplotes*, *Tetrahymena*, *Schizosaccharomyces*, *Oxytricha*, mouse and mammals.

## DESCRIPTION OF THE FIGURES

Figure 1 is a schematic diagram of the affinity purification of telomerase showing  
 15 the binding and displacement elution steps.

Figure 2 is a photograph of a Northern blot of telomerase preparations obtained during purification of *Euplotes* telomerase.

Figure 3 shows telomerase activity through the *Euplotes* telomerase purification protocol.

20 Figure 4 is a photograph of a SDS-PAGE gel of *Euplotes* telomerase, showing the presence of an approximately 123 kDa polypeptide and an approximately 43 kDa doublet.

Figure 5 is a graph showing the sedimentation coefficient of *Euplotes* telomerase.

Figure 6 is a photograph of a polyacrylamide/urea gel with 36% formamide containing *Euplotes* telomerase (TTTTGGGG=SEQ ID NO:44; GGGGTTTT=SEQ ID  
 25 NO:45).

Figure 7 shows the putative alignments of a telomerase RNA template, with SEQ ID NOS:43 and 44 in Panel A, and SEQ ID NOS:43 and 45 in Panel B.

Figure 8 is a photograph of lanes 25-30 of the gel shown in Figure 6, shown at a lighter exposure level (G<sub>4</sub>T<sub>4</sub>G<sub>4</sub>T<sub>4</sub>=(SEQ ID NO:61).

Figure 9 shows the DNA sequence of the *Euplotes* telomerase gene encoding the 123 kDa telomerase protein subunit (SEQ ID NO:1).

Figure 10 shows the amino acid sequence of the *Euplotes* 123 kDa telomerase protein subunit (SEQ ID NO:2).

5        Figure 11 shows the DNA sequence of the gene encoding the *Euplotes* 43 kDa telomerase protein subunit (SEQ ID NO:3).

Figure 12 shows the DNA sequence (SEQ ID NO:3), as well as the amino acid sequences of all three open reading frames of the *Euplotes* 43 kDa telomerase protein subunit (SEQ ID NOS:4-6) (individual peptides = SEQ ID NOS:152-222).

10        Figure 13 shows a sequence comparison between the 123 kDa telomerase protein subunit of *E. aediculatus* (SEQ ID NO:223) and the 80 kDa polypeptide of *T. thermophila* (SEQ ID NO:224).

Figure 14 shows a sequence comparison between the 123 kDa telomerase protein subunit of *E. aediculatus* (SEQ ID NO:225) and the 95 kDa polypeptide of *T. thermophila* (SEQ ID NO:226).

15        Figure 15 shows the best-fit alignment between a portion of the "La-domain" of the 43 kDa telomerase protein subunit of *E. aediculatus* (SEQ ID NO:9) and a portion of the 95 kDa polypeptide of *T. thermophila* (SEQ ID NO:10).

Figure 16 shows the best-fit alignment between a portion of the "La-domain" of the 43 kDa telomerase protein subunit of *E. aediculatus* (SEQ ID NO:11) and a portion of the 80 kDa polypeptide of *T. thermophila* (SEQ ID NO:12).

20        Figure 17 shows the alignment and motifs of the polymerase domain of the 123 kDa telomerase protein subunit of *E. aediculatus* (SEQ ID NOS:227-230) and the polymerase domains of various reverse transcriptases (RT). (Dong (Line) = SEQ ID NOS:231-234; al s.c. (group II) = SEQ ID NOS:235-239; HIV- RT = SEQ ID NOS:240-243; L8543.12 yeast = SEQ ID NOS:244-247; consensus Motif A = SEQ ID NO:248; consensus Motif B = SEQ ID NO:249; consensus Motif C = SEQ ID NO:250; consensus Motif D = SEQ ID NO:251; consensus Motif E = SEQ ID NO:252).

30        Figure 18 shows the alignment of a domain of the 43 kDa telomerase protein subunit (SEQ ID NO:23) with various La proteins (SEQ ID NOS:24-27).

Figure 19 shows the nucleotide sequence encoding the *T. thermophila* 80 kDa polypeptide (SEQ ID NO:51).

Figure 20 shows the amino acid sequence of the *T. thermophila* 80 kDa polypeptide (SEQ ID NO:52).

5        Figure 21 shows the nucleotide sequence encoding the *T. thermophila* 95 kDa polypeptide (SEQ ID NO:53).

Figure 22 shows the amino acid sequence of the *T. thermophila* 95 kDa polypeptide (SEQ ID NO:54).

10       Figure 23 shows the amino acid sequence of L8543.12 ("Est2p") (*Saccharomyces cerevisiae*) (SEQ ID NO:55).

Figure 24 shows the alignment of the amino acid sequence encoded by an *Oxytricha* PCR product (SEQ ID NO:58) with the *Euplotes* TRT sequence (SEQ ID NO:59).

15       Figure 25 shows the alignment of the hTRT amino acid motifs (SEQ ID NO:67), with portions of the *tez1* *Schizosaccharomyces pombe* (*S. pombe*) sequence (SEQ ID NO:63), *S. cerevisiae* Est2p (SEQ ID NO:64), and the *Euplotes* p123 (SEQ ID NO:65) amino acid sequences.

Figure 26 shows the DNA sequence of *S. cerevisiae* Est2 (SEQ ID NO:66).

20       Figure 27 shows the amino acid sequence (SEQ ID NO:67) encoded by the nucleic acid sequence of Figure 28 (SEQ ID NO:62).

Figure 28 shows the DNA sequence (SEQ ID NO:62) encoding the amino acid sequence of SEQ ID NO:67 of Figure 27, as shown in Figure 25 (human).

Figure 29 shows the amino acid sequence of *Schizosaccharomyces tez1* (SEQ ID NO:69).

25       Figure 30 shows the DNA sequence of *Schizosaccharomyces tez1* ("Sp\_Trt1p") (SEQ ID NO:68).

Figure 31 shows the alignment of *S. cerevisiae* EST2p (SEQ ID NO:83), *Euplotes* (SEQ ID NO:84), and *Tetrahymena* (SEQ ID NO:85) amino acid sequences, as well as consensus sequences (SEQ ID NOS:243-255).

Figure 32 shows sequences of peptides useful for production of anti-TRT antibodies (SEQ ID NOS:256-261).

Figure 33 is a schematic summary of the *S. pombe* *tez1*<sup>+</sup> sequencing experiments.

Figure 34 shows two degenerate PCR primers (SEQ ID NOS:262 and 263) used  
5 to identify the *S. pombe* homolog of the *E. aediculatus* p123 (SEQ ID NOS:264 and 265) sequences.

Figure 35 shows the four major bands produced in PCR using the degenerate primers shown in Figure 34 (peptides QTKGIPQG and DDYLLIT are SEQ ID NOS:264 and 265, respectively).

10 Figure 36 shows the alignment of the amino acid sequence encoded by the M2 PCR product (SEQ ID NO:267) with *E. aediculatus* p123 (SEQ ID NO:266), *S. cerevisiae* (SEQ ID NO:268), and *Oxytricha* (SEQ ID NO:58) TRT protein sequences. Also shown in Figure 36 are the actual genomic sequences (SEQ ID NOS: 270 and 273) and the peptides encoded therefrom (SEQ ID NOS:269 and 274), degenerate primers *Poly 4* (SEQ ID  
15 NO:262) and *Poly 1* (SEQ ID NO:263), homologous regions of the M2 PCR product (SEQ ID NO:271), and its encoded peptide region (SEQ ID NO:272).

Figure 37 is a schematic showing the 3' RT PCR strategy for obtaining *S. pombe* TRT sequences.

Figure 38 shows the libraries and the results of screening libraries for *S. pombe*  
20 telomerase protein sequences.

Figure 39 shows the results obtained with the *Hind*III-digested positive genomic clones containing *S. pombe* telomerase sequence.

Figure 40 is a schematic showing the 5' RT PCR strategy for obtaining *S. pombe* TRT sequences.

25 Figure 41 shows the alignment of RT domains from telomerase catalytic subunit motifs from *S. pombe* *tez1* (SEQ ID NOS:275-279), *S. cerevisiae* Est2 (SEQ ID NOS:280-284), and *E. aediculatus* p123 (SEQ ID NOS:285-289); and, consensus sequence regions (SEQ ID NOS:290-291).

Figures 42a and 42b show the alignment of three telomerase sequences. *S. pombe*  
30 *tez1* (SEQ ID NO:69), *S. cerevisiae* Est2 (SEQ ID NO:55) and *E. aediculatus* p123 (SEQ

ID NO:2). Conservative substitutions and identical amino acid residues are shaded in Figure 42A; identical amino acid residues are shaded in Figure 42B.

Figure 43 shows the disruption strategy used to disrupt the telomerase genes in *S. pombe*.

5        Figure 44 shows the experimental results confirming disruption of *Schizosaccharomyces pombe tez1*.

Figure 45 shows the progressive shortening of telomeres in *S. pombe* due to *tez1* disruption.

10       Figure 46 shows the DNA (SEQ ID NO:68) and amino acid (SEQ ID NO:69) sequence of *tez1*, with the coding regions indicated.

Figure 47 shows the DNA (SEQ ID NO:100) and encoded amino acid (SEQ ID NO:101) of the open reading frame (ORF) for the approximately 63 kDa telomerase protein or fragment thereof, from the EcoRI-NotI insert of clone 712562 (SEQ ID NO:122), which includes the Genbank #AA281296 EST (SEQ ID NO:62).

15       Figure 48 shows an alignment of reverse transcriptase motifs from *E. aediculatus* p123 (SEQ ID NOS:292-297), *S. pombe tez1* (SEQ ID NOS:298-303), *S. cerevisiae* Est2 (SEQ ID NOS:304-309), and human TCPI (SEQ ID NOS:310-315), with various RT motifs and consensus sequences (SEQ ID NOS:290 and 291) indicated in the Figure.

20       Figure 49 provides a restriction and function map of plasmid pGRN121 (ATCC accession # 209016).

Figure 50 provides the results of preliminary nucleic acid sequencing analysis of hTRT (SEQ ID NO:113).

Figure 51 provides a preliminary nucleic acid (SEQ ID NO:113) and deduced ORF sequence (SEQ ID NOS:114-116) of hTRT.

25       Figure 52 provides a refined restriction and function map of plasmid pGRN121.

Figure 53 provides the nucleic acid (SEQ ID NO:117) and deduced ORF sequence (SEQ ID NO:118) of hTRT.

Figure 54 provides a restriction map of lambda clone 25-1.1 (ATCC accession #209024).

Figure 55 shows a multiple sequence alignment of TRT consensus sequences, *i.e.*, motifs ("TRT con") (SEQ ID NOS:366-372) with TRT sequences from several species of the TRT genus, including: *S. pombe* Trt1 ("Sp\_Tr1p") (SEQ ID NOS:373-378); human TRT ("hTRT") (SEQ ID NOS:379-384); *Euplotes* p123 ("Ea\_p123") (SEQ ID NOS:385-390); and *Saccharomyces cerevisiae* Est2p ("Sc\_Est2p") (SEQ ID NOS:391-393, 244, 245, 394 and 395). Figure 55 also shows a multiple sequence alignment of reverse transcriptase consensus sequences, *i.e.*, RT motifs ("RT con") (SEQ ID NOS:290 and 291) and consensus sequences from other RT motif-containing proteins including: "Sc\_a1", cytochrome oxidase group II intron 1-encoded protein from *S. cerevisiae* mitochondria (SEQ ID NOS:396-398, 237, 399 and 239); "Bm\_R1", reverse transcriptase from *Bombyx mori* R1 non-LTR retrotransposable element (SEQ ID NOS:400-406); and reverse transcriptase from HIV-1 (SEQ ID NOS:407-411).

Figures 56A and 56B show the alignment of mouse telomerase reverse transcriptase protein (mTRT) with hTRT. Figure 56A shows alignment of mTRT protein (SEQ ID NO:413) and hTRT protein (SEQ ID NO:412). Consensus peptides are given in SEQ ID NOS:414-416. Figure 56B shows alignment of mTRT DNA (SEQ ID NO:419) and hTRT cDNA (SEQ ID NO: 417). Consensus nucleotides are given in SEQ ID NO:418.

Figure 57 shows a comparison and alignment of hTRT (SEQ ID NOS:420-427); *S. pombe* Trt1 ("spTRT") (SEQ ID NOS:428-435); *Euplotes* p123 ("eaTRT") (SEQ ID NOS:436-443); and *S. cerevisiae* EST2p TRT sequence ("scTRT") (SEQ ID NOS:444-452). The figure also shows a comparison of TRT consensus sequences, *i.e.*, conserved TRT motif sequences ("TRT con"), with SEQ ID NOS:453, 370, 454 and 455, and conserved RT motif sequences ("RT con") SEQ ID NOS:290 and 291 comparing in Figure 57A motifs designated "Telomerase Specific Motifs"; in Figure 57B "Telomerase RT Motifs (Fingers)"; and in Figure 57C "Telomerase RT Motifs (Palm, Primer Grip)."

Figure 58 shows a preliminary nucleic acid and amino acid sequence analysis of hTRT (SEQ ID NOS:117 and 118).

Figure 59 shows the complete sequencing of the TRT cDNA of clone #712562 (SEQ ID NO:122), and the deduced translation product (SEQ ID NO:123).

Figure 60 shows a nucleic acid sequence of the mTRT cDNA (SEQ ID NO:124.)

### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides isolated telomerase enzyme, TRT, and telomerase  
5 protein and nucleic acid associated subunits. These proteins and nucleic acids of the  
invention are further useful for investigations of the full and partial activities of TRT and  
telomerase enzymes, including, *e.g.*, potential nuclease activities. In particular, the present  
invention is directed to the telomerase enzyme, TRT and co-purifying polypeptides and  
nucleic acids obtained from *Euplotes*, as well as other organisms, *e.g.*,  
10 *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals,  
including human.

*Euplotes*, a hypotrichous ciliate, was chosen for use in this invention as it contains  
an unusually large number of chromosomal ends (Prescott (1994) *Microbiol. Rev.* 58:233),  
because a very large number of gene-sized DNA molecules are present in its polyploid  
15 macronucleus. *Tetrahymena*, a holotrichous ciliate commonly used in previous studies of  
telomerase and telomeres, is as evolutionarily distant from *Euplotes* as plants are from  
mammals (Greenwood (1991) *J. Mol. Evol.* 3:163).

The homology found between the 123 kDa *Euplotes aediculatus* telomerase TRT  
subunit and the L8543.12 sequence (SEQ ID NO:55) (*i.e.*, Est2 of *Saccharomyces*  
20 *cerevisiae*; see, Lendvay (1996) *Genetics* 144:1399-1412), *Schizosaccharomyces*, and  
human TRT motifs, provided a strong basis for predicting that full human TRT molecule  
would comprise a protein that is large, basic, and includes such reverse transcriptase (RT)  
motifs. Thus, the compositions and methods of the present invention are useful for the  
identification of other telomerases from a wide variety of species. The present invention  
25 describes the use of the 123 kDa RT motifs in a method to identify similar motifs in  
organisms that are distantly related to *Euplotes* (*e.g.*, *Oxytricha*), as well as other  
organisms, *e.g.*, *Schizosaccharomyces*, *Saccharomyces*, other yeast, *Tetrahymena*, other  
fungi, mouse and other mammals, including human.

The present invention also provides additional methods for the study of the  
30 structure and function of distinct forms of telomerase. It is contemplated that the

telomerase proteins of the present invention will be useful in diagnostic applications, evolutionary (*e.g.*, phylogenetic) investigations, as well as development of compositions and methods for cancer therapy or anti-aging regimens. Although the telomerase protein subunits of the present invention themselves have utility, it further contemplated that the polypeptides of the present invention will be useful in conjunction with the RNA moiety of the telomerase enzyme (*i.e.*, a complete telomerase).

It is also contemplated that methods and compositions of this invention will lead to the discovery of additional unique telomerase structures and/or functions. In addition, the present invention provides novel methods for purification of functional telomerase, as well as telomerase proteins. This affinity based method described in Example 3, is an important aspect in the purification of functionally active telomerase, as are the two anti-TRT antibodies provided for by the invention. A key advantage of this procedure is the ability to use mild elution conditions, during which proteins that bind non-specifically to the column matrix are not eluted.

Telomerase is a ribonucleoprotein complex (RNP) comprising an RNA component and a catalytic protein component. The present invention relates to the cloning and characterization of the catalytic protein component of telomerase, referred to as "TRT" (telomerase reverse transcriptase). TRT is so named because this protein acts as an RNA-dependent DNA polymerase (reverse transcriptase), using the telomerase RNA component ("TR") to direct synthesis of telomere DNA repeat sequences. Moreover, TRT is evolutionarily related to other RTs.

In one aspect, the present invention provides TRT genes and proteins from ciliates, fungi, yeast, and vertebrates, especially mammals, such as humans, human telomerase reverse transcriptase, referred to as "hTRT." TRT is of extraordinary interest and value because telomerase activity in human (and other mammalian cells) correlates with cell proliferative capacity, a state of indefinite cell proliferation, cell immortality, and the development of a neoplastic phenotype. For example, telomerase activity and levels of hTRT gene products are elevated in indefinitely growing and immortal human cells (such as malignant tumor cells and immortal cell lines) relative to mortal cells (such as most human somatic cells).

## PATENT

The present invention is, in one aspect, directed to the nucleic and amino acid sequences of the protein subunits of *Euplotes* (*E. aediculatus*), *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals, including human. In addition, the present invention is directed to the purification of functional telomerase enzyme and enzyme subunits, as TRT. As described below the present invention also  
5 comprises various forms of telomerase enzyme and TRT, including recombinant telomerase and telomerase protein subunits, as TRT, obtained from various organisms.

TRT was initially characterized following purification of telomerase from the ciliate *Euplotes aediculatus*. Extensive purification of *E. aediculatus* telomerase, using  
10 RNA-affinity chromatography and other methods, yielded the protein "p123". Surprisingly, p123 is unrelated to proteins previously believed to constitute the protein subunits of the telomerase holoenzyme (i.e., the p80 and p95 proteins of *Tetrahymena thermophila*). Analysis of the p123 DNA and protein sequences (Genbank Accession No. U95964; Figures 9 and 10) (SEQ ID NO:1 and SEQ ID NO:2) revealed RT motifs  
15 consistent with the role of p123 as the catalytic subunit of telomerase (see, e.g., Figures 17, 25, 55, 57). Moreover, p123 is related to a *S. cerevisiae* (yeast) protein, Est2p, which was known to play a role in maintenance of telomeres in *S. cerevisiae* (Genbank Accession No. S5396), but not recognized as encoding a telomerase catalytic subunit protein (see, e.g., Lendvay et al., 1996, *Genetics*, 144:1399).

20 In one aspect, the present invention provides reagents and methods for identifying and cloning novel TRTs using: nucleic acid probes and primers generated or derived from the TRT polynucleotides disclosed herein (e.g., for cloning TRT genes and cDNAs); antibodies that specifically recognize the motifs or motif sequences or other TRT epitopes (e.g., for expression cloning TRT genes or purification of TRT proteins); by screening  
25 computer databases; or other means. For example, as described in Example 16, PCR (polymerase chain reaction) amplification of *S. pombe* DNA was carried out with degenerate-sequence primers designed from the *Euplotes* p123 RT motifs B' and C. Of four prominent products generated, one encoded a peptide sequence homologous to *Euplotes* p123 and *S. cerevisiae* Est2p. Using this PCR product as a probe, the complete  
30 sequence of the *S. pombe* TRT homologue was obtained by screening of *S. pombe* cDNA

and genomic libraries and amplifying *S. pombe* RNA by reverse transcription and PCR (RT-PCR). The complete sequence of the *S. pombe* gene ("tez1" or "Sp\_Trt1p" or "trt1"; GenBank Accession No. AF015783; Figure 69, Figure 46) revealed that homology with p123 and Est2p was especially high in the RT motifs (see Figures 56, 58). Amplification  
5 using degenerate primers derived from the telomerase RT motifs was also used to obtain TRT gene sequences in *Oxytricha trifallax* and *Tetrahymena thermophila*, as described in Examples 13 and 15, respectively.

The *Euplotes* p123, *S. pombe* trt1, and *S. cerevisiae* Est2p sequences of the invention were used in a search of a computerized database of human expressed sequence  
10 tags (ESTs) using the program BLAST (Altschul et al, 1990, *J. Mol. Biol.* 215:403). Searching this database with the Est2p sequence did not indicate a match, but searching with p123 and trt1 sequences identified a human EST (Genbank accession no. AA281296) (SEQ ID NO:62), as described in Example 17, encoding a homologous protein. Complete  
15 sequencing of the cDNA clone containing the EST (hereinafter, "clone 712562"; see Figure 59, SEQ ID NO:122) showed that seven RT motifs were present. However, this clone could not encode a contiguous human TRT, because motifs B', C, D, and E were contained in a different ORF than the more NH<sub>2</sub>-terminal motifs. In addition, the distance between motifs A and B' was substantially shorter than that of the three previously  
20 characterized TRTs.

A cDNA clone, pGRN121 (ATCC accession # 209016), encoding a functional hTRT (SEQ. ID. NO: 1) was isolated from a cDNA library derived from the human 293  
cell line as described in Example 17. Comparing clone 712562 with pGRN121 showed that clone 712562 has a 182 base pair deletion between motifs A and B'. The additional  
25 182 base pairs present in pGRN121 places all of the TRT motifs in a single open reading frame, and increases the spacing between the motif A and motif B' regions to a distance consistent with the other known TRTs. SEQ. ID. NO: 117 encodes a catalytically active telomerase protein having the sequence of SEQ ID NO: 118. The polypeptide of SEQ ID  
NO: 118 has 1132 residues and a calculated molecular weight of about 127 kilodaltons (kD).

TRT cDNAs possessing the 182 basepair deletion characteristic of the clone 712562 are detected following reverse transcription of RNA from telomerase-positive cells (e.g., testis and 293 cells). hTRT RNAs lacking this 182 base pair sequence are referred to generally as "182 variants" and may represent one, two, or several species. Although  
 5 the hTRT variants lacking the 182 basepair sequence found in the pGRN121 cDNA (SEQ ID NO. 117) are unlikely to encode a fully active telomerase catalytic enzyme, they may play a role in telomerase regulation and/or have partial telomerase activity, such as telomere binding or hTR binding activity.

10 **The 123 kDa and 43 kDa Telomerase Subunit Protein Sequences of *Euplotes***

The nucleic acid and deduced amino acid sequences of the *Euplotes* 123 and 43 kDa protein subunits are shown in Figures 1-6. In accordance with the invention, any nucleic acid sequence which encodes *E. aediculatus* telomerase or its subunits can be used to generate recombinant molecules which express the *Euplotes* telomerase or its subunits.

15 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of telomerase subunit protein sequences, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. The invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon  
 20 choices, taking into account the use of the codon "UGA" as encoding cysteine in *E. aediculatus*. Other than the exception of the "UGA" codon, these combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence encoding naturally occurring *E. aediculatus* telomerase, and all such variations are to be considered as being specifically disclosed. For example, the amino acid sequences  
 25 encoded by each of the three open reading frames of the 43 kDa nucleotide sequence are specifically included (SEQ ID NOS:152-222). It is contemplated that any variant forms of telomerase subunit protein be encompassed by the present invention, as long as the proteins are functional in assays such as those described in the Examples or elsewhere herein.

Although nucleotide sequences which encode *E. aediculatus* telomerase protein subunits and their variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring sequence under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding *E. aediculatus* telomerase protein subunits or their derivatives possessing a substantially different codon usage, including the "standard" codon usage employed by human and other systems. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding telomerase subunits and their derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater or a shorter half-life, than transcripts produced from the naturally occurring sequence.

It is now possible to produce a DNA sequence, or portions thereof, encoding telomerase protein subunits and their derivatives entirely by synthetic chemistry, after which the synthetic gene may be inserted into any of the many available DNA vectors and cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding *Euplotes* (*E. aediculatus*), *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals, including human, proteins, subunits, or any portion thereof.

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of any member of the telomerase genus, including the sequences of Figures 9 (DNA sequence of the gene encoding the 123 kDa telomerase protein subunit), 11 (DNA sequence of the gene encoding the 43 kDa telomerase protein subunit), 12 (open reading frames of the 43 kDa telomerase protein subunit), and 26 (DNA sequence of *S. cerevisiae* Est2), under various conditions of stringency. Thus, in one embodiment, the novel compositions of the invention, including TRT encoding nucleic acids and anti-TRT antibodies, can also be used to identify and purify a genus of TRTs, including TRT isoforms and telomerase or telomerase components from any other organisms.

One embodiment of the invention includes isoforms and homologues of the *Euplotes* 43 kDa telomerase, including the human p43 homologue, which can also be identified and isolated using the unique reagents provided by the invention and the methods described herein.

5 In an additional embodiment, TRT and telomerase enzyme complex components are used to identify telomerase-associated components.

Hybridization conditions used to identify and isolate members of the TRT genus are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex or probe, as taught in Berger and Kimmel (Berger (1987) *Guide to Molecular Cloning Techniques*,  
10 *Meth.Enzymol.*, vol. 152, Academic Press, San Diego CA) incorporated herein by reference, and may be used at a defined "stringency".

Altered nucleic acid sequences encoding telomerase protein subunits which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally  
15 equivalent telomerase subunit. The protein may also show deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent telomerase subunit, or a subunit that lacks one or more TRT partial activities or has another peptide fused thereto. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity,  
20 hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of the telomerase subunit is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine,  
25 threonine; and phenylalanine, tyrosine.

Methods for DNA sequencing are well known in the art and employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland OH), *Taq* DNA polymerase (Perkin Elmer, Norwalk CT), thermostable T7 polymerase (Amersham, Chicago IL), or combinations of recombinant polymerases and  
30 proofreading exonucleases such as the ELONGASE Amplification System marketed by

Gibco BRL (Gaithersburg MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the ABI 377 DNA sequencers (Perkin Elmer).

Also included within the scope of the present invention are alleles encoding  
5 *Euplotes*, *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals, including human telomerase enzyme and TRT proteins and subunits. As used herein, the term "allele" or "allelic sequence" is an alternative form of the nucleic acid sequence encoding telomerase and TRT proteins or subunits. Alleles result from mutations (*i.e.*, changes in the nucleic acid sequence), and generally produce altered mRNAs or  
10 polypeptides whose structure and/or function may or may not be altered. Any given gene may have no, one or many allelic forms. Common mutational changes that give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times within a given sequence.

15

### **Telomerase Reverse Transcriptase Genus and Characterizing Motifs**

The present invention provides isolated and/or recombinant genes and proteins having a sequence of a telomerase catalytic subunit protein (*i.e.*, telomerase reverse transcriptase) that typically are large, basic, proteins having *reverse transcriptase*  
20 (RT) and *telomerase-specific* amino acid motifs. Because these motifs are conserved across diverse organisms, a genus of TRT genes from numerous organisms is provided by the invention and can be identified, isolated or synthesized using primers, nucleic acid probes, and antibodies of the invention, *i.e.*, such as those specific for one or more of the motif sequences.

25

The invention provides telomerase species, alleles and homologues of the genus of TRT, including *Euplotes*, *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals, including human. TRT itself a member of the genus of reverse transcriptase (RT) proteins. The TRT species of the invention described herein illustrates structural features common to the members of the TRT genus in the form of  
30 structural motifs. These motifs can effect common telomerase functions. Sequence

analysis of TRT species show that these species contain amino acid regions common to other RT proteins, as illustrated in Figures 17, 18, 25, 48, 55 and 57. For example, this region is in the approximately the middle third of the hTRT mRNA (cDNA, SEQ ID NO:117); the most structurally conserved region of hTRT compared to RTs from other organisms. Novel reagents of the invention corresponding to such motif regions can be used in methods of the invention to generate antibodies and nucleic acid probes and to identify additional isoforms and telomerase species from other organisms. The invention provides oligonucleotides corresponding to these motif regions, including the RT region, including restriction enzyme fragments and amplification products generated from a known telomerase. Oligonucleotides corresponding to motifs can also be synthesized *in vitro*. PCR primer pairs useful for amplifying RT motifs of TRT are described below. These oligonucleotide can also be used as PCR amplification primers or hybridization probes to identify and isolate additional TRT isoforms, homologues and species from *Euplotes*, *Schizosaccharomyces*, other yeast, *Tetrahymena*, other fungi, mouse and other mammals, including human, and other organisms. These oligonucleotides can also be used as primers to amplify additional TRT species, using techniques such as RACE, as described below.

The seven RT motifs found in TRTs, while similar to those found in other RTs, have particular hallmarks unique to the TRT genus. For example, as shown in Figure 55 and Figure 57C, within the TRT RT motifs there are a number of amino acid substitutions (marked with arrows) in residues highly conserved among the other RTs. For example, in motif C the two aspartic acid residues (DD) that coordinate active site metal ions (see, Kohlstaedt et al., 1992, *Science* 256:1783; Jacobo-Molina (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6320; Patel (1995) *Biochemistry* 34:5351) occur in the context hxDD(F/Y) (SEQ ID NO:13), more specifically, as (L/V)xDD(F/Y) (SEQ ID NO:14), in the telomerase RTs compared to (F/Y)xDDh (SEQ ID NO:15) in the other RTs (where h is a hydrophobic amino acid, and "x" is any amino acid; see Xiong (1990) *EMBO J.* 9:3353; Eickbush, in *The Evolutionary Biology of Viruses*, (S. Morse, Ed., Raven Press, NY, p. 121, 1994).

Another systematic change characteristic of the telomerase subgroup occurs in motif E, where WxGxSx (SEQ ID NO:7) is a consensus sequence or is conserved among the telomerase proteins, whereas hLGxxh (SEQ ID NO:8) is characteristic of other RTs (see Figures 55 and 57C; Xiong (1990), *supra*; Eickbush (1994) *supra*). This motif E is called the "primer grip", and mutations in this region have been reported to affect RNA priming but not DNA priming (Powell (1997) *J. Biol. Chem.* 272:13262). Figures 55 and 57C give sequence alignments of several telomerase RT primer grip regions (motif E), including hTRT. Because telomerase requires a DNA primer (*e.g.*, the chromosome 3' end) it is not unexpected that TRT should differ from other RTs in the primer grip region.

In addition, the distance between motifs A and B' is longer in the TRTs than is typical for other RTs, which may represent an insertion within the "fingers" region of the structure which resembles a right hand (See Figure 57B; see Kohlstaedt (1992) *supra*; Jacobo-Molina (1993) *supra*; and Patel (1995) *supra*).

The T motif ("motif T") is an additional hallmark of TRT proteins. The T motif, shown, *e.g.*, in Figure 55 and Figure 57A, comprises a sequence that can be described using the formula:

W-X<sub>12</sub>-FFY-X-T-E-X<sub>10-11</sub>-R-X<sub>3</sub>-W-X<sub>7</sub>-I (SEQ ID NOS:119 and 120); or, alternatively W-L-X-Y-X-X-h-h-X-h-h-X-p-F-F-Y-X-T-E-X-p-X-X-X-p-X-X-X-Y-X-R-K-X-X-W (SEQ ID NO:116),

where X is any amino acid, h is hydrophobic, p is polar; which comprises a sequence that can also be described using the formula:

Trp-R<sub>1</sub>-X<sub>7</sub>-R<sub>1</sub>-R<sub>1</sub>-R<sub>2</sub>-X-Phe-Phe-Tyr-X-Thr-Glu-X<sub>8,9</sub>-R<sub>3</sub>-R<sub>3</sub>-Arg-R<sub>4</sub>-X<sub>2</sub>-Trp (SEQ ID NOS:16 and 17)

where X is any amino acid and the subscript refers to the number of consecutive residues, R<sub>1</sub> is leucine or isoleucine, R<sub>2</sub> is glutamine or arginine, R<sub>3</sub> is phenylalanine or tyrosine, and R<sub>4</sub> is lysine or histidine.

The T motif can also be described using the formula:

Trp-R<sub>1</sub>-X<sub>4</sub>-h-h-X-h-h-R<sub>2</sub>-p-Phe-Phe-Tyr-X-Thr-Glu-X-p-X<sub>3</sub>-p-X<sub>2,3</sub>-R<sub>3</sub>-R<sub>3</sub>-Arg-R<sub>4</sub>-X<sub>2</sub>-Trp (SEQ ID NOS:18 and 19)

where X is any amino acid, a subscript refers to the number of consecutive residues, R<sub>1</sub> is leucine or isoleucine, R<sub>2</sub> is glutamine or arginine, R<sub>3</sub> is phenylalanine or tyrosine, R<sub>4</sub> is lysine or histidine, h is a hydrophobic amino acid selected from Ala, Leu, Ile, Val, Pro, Phe, Trp, and Met, and p is a polar amino acid selected from Gly, Ser, Thr, Tyr, Cys, Asn and Gln.

In one embodiment, the present invention provides isolated naturally occurring and recombinant TRT proteins comprising one or more of the motifs illustrated in Figures 55 and 57, *e.g.*:

- 10 Motif T W-X<sub>12</sub>-F-F-Y-X-T-E-X<sub>10-11</sub>-R-X<sub>3</sub>-W-X<sub>7</sub>-I (SEQ ID NOS:119 and 120), or, alternatively  
W-L-X-Y-X-X-h-h-X-h-h-X-p-F-F-Y-X-T-E-X-p-X-X-X-p-X-X-X-Y-X-R-K-X-X-W (SEQ ID NO:116)
- 15 Motif T' E-X<sub>2</sub>-V-X (SEQ ID NO:121)
- Motif 1 X<sub>3</sub>-R-X<sub>2</sub>-P-K-X<sub>3</sub> (SEQ ID NO:139), or, alternatively, h-R-h-X-P-K (SEQ ID NO:473)
- Motif 2 X-R-X-I-X (SEQ ID NO:143), or, alternatively (F/L)-R-h-I-X<sub>2</sub>-h (SEQ ID NO:474)
- 20 Motif A X<sub>4</sub>-F-X<sub>3</sub>-D-X<sub>4</sub> -Y-D-X<sub>2</sub> (SEQ ID NO:144), P(K/E)(K/L)(Y/F)FhXhDh (SEQ ID NO:477), or, alternatively P-X-L-Y-F-h-X-h-D-h-X<sub>2</sub>-C-Y-D-X-I (SEQ ID NO:475)
- Motif B' Y-X<sub>4</sub>-G-X<sub>2</sub>-Q-G-X<sub>3</sub>-S-X<sub>8</sub> (SEQ ID NO:146), or, alternatively K-X-Y-X-Q-X<sub>2</sub>-G-I-P-Q-G-S-X-L-S-X-h-L (SEQ ID NO:115)
- Motif C X<sub>6</sub>-D-D-X-L-X<sub>3</sub> (SEQ ID NO:147), or, alternatively, L-L-R-L-X-D-D-X-L-h-I-T (SEQ ID NO:476).

25 When the TRT protein contains more than one TRT motif, the order (from amino terminal to carboxy terminal, NH<sub>2</sub> ->COOH) is as shown in Figure 55.

In one embodiment, the present invention provides isolated naturally occurring TRT proteins comprising the following supermotif:

(NH<sub>2</sub>)-X<sub>300-600</sub>-W-X<sub>12</sub>-FFY-X-TE-X<sub>10-11</sub>-R-X<sub>3</sub>-W-X<sub>7</sub>-I-X<sub>5-20</sub>-E-X<sub>2</sub>-V-X-X<sub>5-20</sub>-X<sub>3</sub>-R-X<sub>2</sub>-PK-X<sub>4-10</sub>-R-X-I-X-X<sub>60-80</sub>-X<sub>4</sub>-F-X<sub>3</sub>-D-X<sub>4</sub>-YD-X<sub>2</sub>-X<sub>80-130</sub>-Y-X<sub>4</sub>-G-X<sub>2</sub>-QG-X<sub>3</sub>-S-X<sub>8</sub>-X<sub>5-35</sub>-X<sub>6</sub>-DD-X-L-X<sub>3</sub>-X<sub>10-20</sub>-X<sub>12</sub>-K (SEQ ID NO:4).

It will be apparent to one of skill that, provided with the reagents, and the

5 TRT sequences disclosed herein for those reagents, and the methods and guidance provided herein (including specific methodologies described *infra*), TRT genes and proteins can be obtained, isolated and produced in recombinant form by one of ordinary skill. For example, primers (e.g., degenerate amplification primers) are provided that hybridize to gene sequences encoding RT and T motifs characteristic of TRT. One or more

10 primers or degenerate primers that hybridize to sequences encoding the FFYXTE (SEQ ID NO:71) region of the T motif, other TRT motifs (as discussed *infra*), or combinations of motifs or consensus sequences, can be prepared based on the codon usage of the target organism, and used to amplify the TRT gene sequence from genomic DNA or cDNA prepared from the target organism. Use of degenerate primers is well known in the art and

15 entails sets of primers that hybridize to the set of nucleic acid sequences that can potentially encode the amino acids of the target motif, taking into account codon preferences and usage of the target organism, and by using amplification (e.g., PCR) conditions appropriate for allowing base mismatches in the annealing steps. Typically two primers are used; however, single primer (or, in this case, a single degenerate primer set)

20 amplification systems are well known and may be used to obtain TRT genes.

Table 1 provides illustrative primers of the invention that may be used to amplify novel TRT nucleic acids, particularly those from vertebrates (e.g., mammals). "N" is an equimolar mixture of all four nucleotides and sequences within parentheses are equimolar mixtures of the specified nucleotides.

TABLE 1  
ILLUSTRATIVE DEGENERATE PRIMERS FOR AMPLIFICATION  
OF TRT NUCLEIC ACIDS

		motif	SEQ ID				
		<u>motif</u>	<u>No:</u>	<u>direction</u>	<u>5'- sequence -3'</u>	<u>primer SEQ ID No:</u>	
5							
	a	<u>FFYVTE</u>	112	Forward	TT(CT)TT(CT)TA(CT)GTNACNGA	148	
10	b	<u>FFYVTE</u>	112	Reverse	TCNGTNAC(GA)TA(GA)AA(GA)AA	149	
	c	<u>RFIPKP</u>	46	Forward	(CA)GNTT(CT)AT(ACT)CCNAA(AG)CC	150	
	d	<u>RFIPKP</u>	46	Reverse	GG(TC)TTNGG(TGA)AT(GA)AANC	456	
15	e	<u>AYDTI</u>	82	Forward	GCNTA(CT)GA(CT)ACNAT	457	
	f	<u>AYDTI</u>	82	Reverse	TANGT(GA)TC(GA)TANGC	458	
	g	<u>GIPOG</u>	86	Forward	GGNAT(ACT)CCNCA(AG)GG	459	
	h	<u>GIPOGS</u>	370	Reverse	(GC)(AT)NCC(TC)TGNGG(TGA)ATNCC	460	
20	i	<u>LVDDFL</u>	6	Forward	(CT)TNGTNGA(CT)GA(CT)TT(CT)(CT)T	461	
	j	<u>DDFLLVT</u>	463	Reverse	GTNACNA(GA)NA(GA)(GA)AA(GA)TC(GA)TC	462	

Allowed primer combinations (y = yes, n = no)

		<u>Reverse</u>				
	<u>Forward</u>	<u>b</u>	<u>d</u>	<u>f</u>	<u>h</u>	<u>i</u>
25	a -	n	y	y	y	y
	c -	n	n	y	y	y
	e -	n	n	n	y	y
30	g -	n	n	n	n	y
	i -	n	n	n	n	n

In one embodiment, an amplified TRT nucleic acid is used as a hybridization probe for colony hybridization to a library (e.g., cDNA library) made from the target organism, such that a nucleic acid having the entire TRT protein coding sequence, or a substantial portion thereof, is identified and isolated or cloned. In this

manner, the invention provides the methods and reagents to identify, isolate and clone all species of the TRT genus. As illustrative examples, reagents and methods such as those just described were used in accordance with the methods described herein to obtain many species of the TRT genus of gene sequences, including human, mouse, 5 *Euplotes aediculatus* 123 kDa and 43 kDa species, *S. cerevisiae*, *Schizosaccharomyces pombe*, *Oxytricha trifallax* and *Tetrahymena thermophila*. It will be recognized that following cloning of a previously uncharacterized TRT specie gene, the sequence can be determined by routine methods and the encoded polypeptide synthesized and assayed for a TRT activity, such as telomerase catalytic activity (as described herein 10 and/or by telomerase assays known in the art).

It will also be apparent to those of skill that all TRT genes and polypeptides are within the scope of the claimed genus because they can be cloned using the unique reagents provided for by the invention and can be identified, isolated and cloned using any of a variety of cloning methods. Use of the TRT motif-containing 15 nucleic acids and polypeptides of the invention can be used in a wide variety of such methods. For example, hybridization using a probe based on the sequence of a known TRT to DNA or other nucleic acid libraries from the target organism can be used as described in the Examples below. It will be appreciated that degenerate PCR primers or their amplification products may themselves be labeled and used as hybridization 20 probes. In another embodiment, expression cloning methods are used.

In a further embodiment, the peptides and proteins provided for by the invention can be produced by synthetic or by recombinant means to generate antibodies, that in turn can react specifically with a TRT from any species, such as human TRTs, including, for example, hTRT isoforms and human p43 homologues. For 25 example, one or more antibodies that specifically bind peptides that span a TRT motif or other TRT epitope, such as the FFYXTE (SEQ ID No:71) motif (where X is any of the twenty standard amino acids) can be employed to isolate a ribosomal complex comprising a TRT protein and the mRNA that encodes it.

For generating such antibodies of the invention, the peptide immunogens are 30 typically between 6 and 30 amino acids in length, more often about 10 to 20 amino

acids in length. The antibodies may also be used to probe a cDNA expression library derived from the organism of interest to identify a clone encoding a TRT sequence. In another embodiment, computer searches of DNA databases for DNAs containing sequences conserved with known TRTs can also be used to identify a clone encoding a TRT sequence.

### **Human Telomerase Motifs**

The present invention also provides nucleic and amino acid sequence information for human telomerase motifs. These sequences were first identified in a BLAST search conducted using the *Euplotes* 123 kDa peptide, and a homologous sequence from *Schizosaccharomyces pombe*, designated as "tez1" (SEQ ID NO:69).

Figure 25 shows the sequence alignment of the *Euplotes* ("p123")(SEQ ID NO:65); *Schizosaccharomyces* ("tez1") (SEQ ID NO:63); yeast Est2p (SEQ ID NO:64) (*i.e.*, the *S. cerevisiae* protein encoded by the *Est2* nucleic acid sequence (SEQ ID NO:55), and also referred to herein as "L8543.12"); and the human homolog (SEQ ID NO:67) identified in this comparison search. The human amino acid sequence of this aligned portion is SEQ ID NO:67 (Figures 25 and 27) (the corresponding cDNA coding sequence is provided in SEQ ID NO:62, Figure 28). The portion of tez1 shown in Figure 25 is SEQ ID NO:63, the portion of yeast Est2 shown is SEQ ID NO:64, and the portion of *Euplotes* p123 shown is SEQ ID NO:65.

As shown in Figure 25, there are regions that are highly conserved among these proteins. For example, as shown in this Figure, there are regions of identity in "Motif 0," "Motif 1," "Motif 2," and "Motif 3." The identical amino acids are indicated with an asterisk (\*), while the similar amino acid residues are indicated by a circle (●). This indicates that there are regions within the telomerase motifs that are conserved among a wide variety of eukaryotes, ranging from yeast to ciliates, to humans. It is contemplated that additional organisms will likewise contain such conserved regions of sequence.

Figure 27 shows the amino acid sequence (SEQ ID NO:67, see also Figure 25, of a cDNA clone encoding human telomerase motifs. Figure 28 shows the DNA

sequence encoding the amino acid sequence of Figure 27 (SEQ ID NO:62), which includes human telomerase peptide motifs. This human amino acid sequence as aligned with other TRT species is provided in SEQ ID NO:67, Figure 25. Figure 29 shows the amino acid sequence of *S. pombe* tez1 (SEQ ID NO:69), while Figure 30 shows the DNA sequence of tez1 (SEQ ID NO:68). In Figure 30, the introns and other non-coding regions are shown in lower case, while the exons (*i.e.*, coding regions are shown in upper case.

The present invention provides oligonucleotide primers and probes that can hybridize specifically to nucleic acids having the TRT protein-encoding or cDNA nucleic acid sequence (*i.e.*, SEQ ID NO:117) or encoding the protein sequence of a TRT (*i.e.*, SEQ ID NO:118) and such reagents can be used to identify and amplify a wide variety of species of the genus of telomerase protein-encoding sequences. Intronic and genomic (non-transcribed) sequences can also be amplified using the PCR primers of the invention to identify new TRT species. For illustrative purposes, PCR primers and amplification methods are described.

Amplification of TRT sequences which are conserved among the different members of the genus, *i.e.*, consensus TRT sequences, such as TRT and RT motifs, can be used to generate oligonucleotide reagents of the invention for use as hybridization probes to identify and isolate additional isoforms and TRT species from other organisms. These oligonucleotides can also be used as primers to amplify additional TRT species or sequences, using techniques such as RACE, as described below.

Oligonucleotides can be used to identify and detect additional telomerase species using a variety of hybridization techniques and conditions. One of skill in the art will appreciate that, whatever amplification or hybridization method is used, if a quantitative result is desired, care must be taken to use a method that maintains or controls for the relative frequencies of the amplified or other target nucleic acids. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, *ed.* Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), *ed.* Innis, Academic Press, Inc., N.Y. (Innis )), ligase chain reaction (LCR) (Wu (1989) *Genomics* 4:560;

Landegren (1988) *Science* 241:1077; Barringer (1990) *Gene* 89:117; transcription  
amplification (Kwoh (1989) *Proc. Natl. Acad. Sci. USA* 86:1173); self-sustained  
sequence replication (Guatelli (1990) *Proc. Natl. Acad. Sci. USA* 87:1874); Q Beta  
replicase amplification and other RNA polymerase mediated techniques (e.g., NASBA,  
5 Cangene, Mississauga, Ontario); see Berger (1987) *Methods Enzymol.* 152:307-316;  
Sambrook, MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold  
Spring Harbor Laboratory, 1989 ("Sambrook"); and, CURRENT PROTOCOLS IN  
MOLECULAR BIOLOGY, Ausubel, ed. John Wiley & Sons, Inc., New York, 1997  
("Ausubel"); as well as Mullis (1987) U.S. Patent Nos. 4,683,195 and 4,683,202;  
10 Arnheim (1990) *C&EN* 36:47; Lomell *J. Clin. Chem.*, 35:1826 (1989); Van Brunt,  
*Biotechnology*, 8:291-294 (1990); Wu (1989) *Gene* 4:560; Sooknanan (1995)  
*Biotechnology* 13:563-564. Methods for cloning *in vitro* amplified nucleic acids are  
described in Wallace, U.S. Pat. No. 5,426,039.

The invention provides for amplification and manipulation or detection of the  
15 products from each of the above methods to prepare DNA encoding TRT protein. In  
PCR techniques, oligonucleotide primers complementary to the two borders of the  
DNA region to be amplified are synthesized and used (see, Innis). PCR can be used in  
a variety of protocols to amplify, identify, isolate and manipulate nucleic acids  
encoding human telomerase. In these protocols, standard methods for selecting  
20 appropriate primers and probes are described. The present invention provides primers  
and probes for identifying and amplifying DNA encoding human telomerase protein  
and can be generated to comprise all or a portion of any of the nucleic acid sequences  
listed herein.

PCR-amplified sequences can also be labeled and used as detectable  
25 oligonucleotide probes, but such nucleic acid probes can be generated using any  
synthetic or other technique well known in the art, as described above. The labeled  
amplified DNA or other oligonucleotide or nucleic acid of the invention can be used as  
probes to further identify and isolate TRT protein species or isoforms from various  
cDNA or genomic libraries.

The present invention provides RACE-based methods for isolating TRT nucleic acids from any organism (RACE is another PCR-based approach for DNA amplification). Briefly, this technique involves using PCR to amplify a DNA sequence using a random 5' primer and a defined 3' primer (5' RACE) or a random 3' primer and a defined 5' primer (3' RACE). The amplified sequence is then subcloned into a vector where can be sequenced and manipulated using standard techniques. The RACE method is well known to those of skill in the art and kits to perform RACE are commercially available (e.g. Gibco BRL #18374-058 (5' RACE) or #18373-019 (3' RACE)(Gaithersburg, MD)), see also Lankiewicz (1997) *Nucleic Acids Res* 25:2037-2038; Frohman (1988) *Proc. Natl. Acad. Sci. USA* 85:8998.

For 5' RACE, a primer, the gene-specific primer, is selected near the 5' end of the known sequence oriented to extend towards the 5' end. The primer is used in a primer extension reaction using a RT and mRNA. After the RNA is optionally removed, the specifically-primed cDNA is either: 1) "tailed" with deoxynucleotide triphosphates (dNTP) and dideoxyterminal transferase, then a primer that is complementary to the tail with a 5' end that provides a unique PCR site and the first gene-specific primer is used to PCR amplify the cDNA; or, 2) an oligonucleotide that provides a unique PCR site is ligated to an end of the cDNA using RNA ligase; then a primer complementary to the added site and the first gene-specific primer is used to PCR amplify the cDNA. Subsequent amplifications are usually performed with a gene-specific primer nested with respect to the first primer. Amplified products are then isolated, usually by gel electrophoresis, then sequenced and examined to see if they contain the additional cDNA sequences desired.

For 3' RACE, an oligo dT-primer is annealed to the poly-A tails of an mRNA and then extended by a reverse transcriptase. Usually the oligo dT primer has a 5' end that provides a unique PCR site. The RNA is then removed, optionally, or dissociated, and the cDNA is amplified with a primer to the oligo dT tail and a gene-specific primer near the 3' end of the known sequence (oriented towards the 3' end). Subsequent amplifications are performed and amplified products isolated, as described for 5' RACE.

Another useful means of obtaining nucleic acids of the invention, such as large genomic clones, is to screen BAC or P1 genomic libraries. BACs, bacterial artificial chromosomes, are vectors that can contain 120+ Kb inserts. BACs are based on the *E. coli* F factor plasmid system and are simple to manipulate and purify in microgram quantities. Because BAC plasmids are kept at one to two copies per cell, the problems of rearrangement observed with YACs, which can also be employed in the present methods, are eliminated. BAC vectors can include marker genes for luciferase and green fluorescent protein (GFP) (Baker (1997) *Nucleic Acids Res* 25:1950-1956). P1 is a bacteriophage that infects *E. coli* that can contain 75-100 Kb DNA inserts (Mejia (1997) *Genome Res* 7:179-186; Ioannou (1994) *Nat Genet* 6:84-89), and screened in much the same way as lambda libraries.

The polynucleotide sequence encoding telomerase, or telomerase protein subunits, or their functional equivalents, may be extended utilizing partial nucleotide sequence and various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, Gobinda (1993) *PCR Meth. Applic.* 2:318-22, describes "restriction-site" polymerase chain reaction (PCR) as a direct method which uses universal primers to retrieve unknown sequence adjacent to a known locus. First, genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia (1988) *Nucleic Acids Res.* 16:8186). The primers may be designed using OLIGO® 4.06 Primer Analysis Software (National Biosciences Inc, Plymouth MN, 1992), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Capture PCR (Lagerstrom (1991) *PCR Methods Applic.* 1:111-19), a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA, may also be used. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before PCR.

Another method which may be used to retrieve unknown sequence is walking PCR (Parker (1991) *Nucleic Acids Res.* 19:3055-60), a method for targeted gene walking. Alternatively, PCR, nested primers, PromoterFinder™ (Clontech, Palo Alto CA) and PromoterFinder libraries can be used to walk in genomic DNA. This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes. A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension into the 5' nontranslated regulatory region.

Capillary electrophoresis may be used to analyze either the size or confirm the nucleotide sequence in sequencing or PCR products. Systems for rapid sequencing are available from Perkin Elmer, Beckman Instruments (Fullerton CA), and other companies. Capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity is converted to electrical signal using appropriate software (e.g., Genotyper™ and Sequence Navigator™ from Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display is computer controlled. Capillary electrophoresis is particularly suited to the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample. The reproducible sequencing of up to 350 bp of M13 phage DNA in 30 min has been reported (Ruiz-Martinez (1993) *Anal. Chem.* 65:2851-8).

### **Expression of the Nucleotide Sequence**

In accordance with the present invention, polynucleotide sequences which encode telomerase, telomerase protein subunits, or their functional equivalents, may be used in recombinant DNA molecules that direct the expression of telomerase or telomerase subunits by appropriate host cells.

5 The nucleotide sequences of the present invention can be engineered in order to alter either or both telomerase subunits for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression and/or activity of the gene product. For example, mutations may be introduced using techniques which are well known in the art, *e.g.*, site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns, to change codon preference, to produce splice variants, to alter activity, etc.

Thus, the invention also provides for a TRT and telomerase enzyme that has been modified in a site-specific manner to modify or delete any or all functions of the telomerase enzyme or the TRT protein. Such a modified telomerase provides for means to alter, especially inhibit, telomerase activity in cells and animals and so to control the unlimited proliferative capacity of cells, such as cancer cells. Such telomerases and TRT proteins can also be employed in the screens of the invention to discover therapeutic agents. For example, the TRT can be engineered to lose its ability to bind substrate DNA, to bind its RNA moiety (as hTR), to catalyze the addition of telomeric DNA, to bind deoxynucleotide substrate, to have nucleolytic activity, to bind telomere-associated proteins or chromosomal structures, and the like. The resulting "mutant proteins" or "muteens" can be used to identify compounds that specifically modulate one, several, or all functions or activities of the TRT protein or telomerase enzyme.

25 Site-specific mutations can be introduced into TRT-encoding nucleic acid by a variety of conventional techniques, well described in the scientific and patent literature. For example, one rapid method to perform site-directed mutagenesis efficiently is the overlap extension polymerase chain reaction (OE-PCR) (Urban (1997) *Nucleic Acids Res.* 25:2227-2228). Other illustrative examples include: site-directed mutagenesis by overlap extension polymerase chain reaction (OE-PCR), as in Urban (1997) *Nucleic*

30

*Acids Res.* 25:2227-2228; Ke (1997) *Nucleic Acids Res* 25:3371-3372, and Chattopadhyay (1997) *Biotechniques* 22:1054-1056, describing PCR-based site-directed mutagenesis "megaprimer" method; Bohnsack (1997) *Mol. Biotechnol.* 7:181-188; Ailenberg (1997) *Biotechniques* 22:624-626, describing site-directed  
5 mutagenesis using a PCR-based staggered re-annealing method without restriction enzymes; Nicolas (1997) *Biotechniques* 22:430-434, site-directed mutagenesis using long primer-unique site elimination and exonuclease III.

In another system, a correctly folded, complete protein and its mutagenized encoding mRNA both remain attached to a ribosome and can be assessed for alterations  
10 in ligand-binding properties of the native protein. Libraries of native folded proteins with engineered site-specific mutations can now be screened while "evolving" in a cell-free system without the transformation or other constraints imposed when using a host cell (Hanes (1997) *Proc. Natl. Acad. Sci. USA* 94:4937-4942). Modified  
15 telomerase enzyme and TRT proteins of the invention can be produced by site-directed mutagenesis and/or chemical modification methods to introduce unnatural amino acid side chains (see Paetzel (1997) *J. Biol. Chem.* 272:9994-10003 for general methodology).

### **Expression Systems**

In order to express a biologically active telomerase protein subunit, the  
20 nucleotide sequence encoding the subunit or the functional equivalent, is inserted into an appropriate expression vector (*i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence). In order to express a biologically active telomerase enzyme, the nucleotide sequence encoding the  
telomerase protein subunits are inserted into appropriate expression vectors and the  
25 nucleotide sequence encoding the telomerase RNA subunit is inserted into the same or another vector for RNA expression. The protein and RNA subunits are then either expressed in the same cell or expressed separately, and then mixed to achieve a reconstituted telomerase.

Methods which are well known to those skilled in the art can be used to  
30 construct expression vectors containing a telomerase protein subunit sequence and

appropriate transcriptional or translational controls. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination or genetic recombination. Such techniques are described in Sambrook and Ausubel. These same methods may be used to convert the UGA codons, which encode cysteine  
5 in *Euplotes*, to the UGU or UGC codon for cysteine recognized by the host expression system.

A variety of expression vector/host systems may be utilized to contain and express a telomerase subunit-encoding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid  
10 or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (*e.g.*, baculovirus); plant cell systems transfected with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmid); or animal cell systems.

15 The “control elements” or “regulatory sequences” of these systems vary in their strength and specificities and are those non-translated regions of the vector, enhancers, promoters, and 3’ untranslated regions, which interact with host cellular proteins to carry out transcription and translation. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including  
20 constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid *lacZ* promoter of the Bluescript® phagemid (Stratagene, La Jolla CA) or pSport1 (Gibco BRL) and *ptrp-lac* hybrids and the like may be used. The baculovirus polyhedron promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (*e.g.*,  
25 heat shock, RUBISCO; and storage protein genes) or from plant viruses (*e.g.*, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from the mammalian genes or from mammalian viruses are most appropriate. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding telomerase or telomerase protein subunits, vectors based on SV40 or  
30 EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the telomerase protein or subunit. For example, when large quantities of telomerase protein, subunit, or peptides, are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily isolated may be desirable. Such vectors include, but are not limited to, the multi functional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding the telomerase or protein subunit may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced (*e.g.*, pin vectors; Van Heeke (1989) *J. Biol. Chem.* 264:5503-5509) and the like. pGEX vectors (Promega, Madison WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be isolated from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin, thrombin or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For reviews, see Ausubel and Grant (1987) *Meth. Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of a sequence encoding telomerase or a telomerase protein subunit, can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV (Brisson (1984) *Nature* 310:511-514) can be used alone or in combination with the omega leader sequence from TMV (Takamatsu (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi (1984) *EMBO J.* 3:1671-1680; Broglie (1984) *Science* 224:838-843) or heat shock promoters (Winter (1991) *Results Probl. Cell Differ.* 17:85-105) can be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection (for reviews of such techniques, see Hobbs or Murry, in *McGraw Hill Yearbook of Science and Technology* McGraw Hill New York NY, pp. 191-196, 1992;

or Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, New York NY, pp. 421-463, 1988).

An alternative expression system which can be used to express telomerase or telomerase protein subunit is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequence encoding the telomerase subunit of interest can be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the sequence encoding the telomerase protein or telomerase protein subunit will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which the telomerase subunit sequence is expressed (Smith (1983) *J. Virol.* 46:584; Engelhard (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-7).

In mammalian host cells, a number of viral-based expression systems can be utilized. In cases where an adenovirus is used as an expression vector, a sequence encoding a telomerase protein or telomerase protein subunit, can be ligated into an adenovirus transcription/ translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing in infected host cells (Logan (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-59). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of a sequence encoding telomerase protein subunits. These signals include the ATG initiation codon and adjacent sequences. In cases where the sequence encoding a telomerase protein subunit will be expressed by the host cell, its initiation codon and upstream sequences can be inserted into the most appropriate expression vector, and no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, or the cell's regulatory environment

will inhibit transcription, exogenous transcriptional control signals including the ATG initiation codon can be provided. The initiation codon should be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf (1994) *Results Probl. Cell Differ.* 20:125; Bittner (1987) *Meth. Enzymol.*).

In addition, a host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or function. Different mammalian host cells, such as CHO (ATCC CCL 61 and CRL 9618), HeLa (ATCC CCL 2), MDCK (ATCC CCL 34 and CRL 6253), HEK 293 (ATCC CRL 1573), WI-38 (ATCC CCL 75) (ATCC: American Type Culture Collection, Rockville, MD), have specific cellular machinery and characteristic mechanisms for such post-translational activities and can be chosen to ensure the correct modification and processing of the introduced, recombinant protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express telomerase or a telomerase subunit protein may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 or more days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Mineishi (1997) *Gene Ther* 4:570-576; Wigler (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Waldman (1996) *Biochim. Biophys. Acta* 1308:241-250; 5 Lowy (1980) *Cell* 22:817) genes which can be employed in tk- or aprt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, *dhfr* confers resistance to methotrexate (Wigler (1980) *Proc. Natl. Acad. Sci. USA* 77:3567); *npt*, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin (1981) *J. Mol. Biol.* 150:1) 10 and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *In McGraw Hill Yearbook of Science and Technology*, McGraw Hill, New York NY, pp 191-196, 1992). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine 15 (Hartman (1988) *Proc. Natl. Acad. Sci. USA* 85:8047). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate, GUS, and luciferase and its substrate, luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes (1995) *Meth. Mol.* 20 *Biol.* 55:121).

### **Cloning of TRT-Encoding Sequences**

There are several well-known methods of introducing nucleic acids into bacterial and other cells, a process often called "transforming," any of which may be used in the methods of the present invention (see Sambrook). Techniques for 25 transforming a wide variety of animal and plant cells are well known and described in the technical and scientific literature. See, for example, Weising, *Ann. Rev. Genet.* 22:421-477 (1988) for plant cells and Sambrook for animal and bacterial cells. Specific examples of methods of expressing the novel telomerase proteins of the invention are described below. For example, these can include fusion of the recipient cells with

bacterial protoplasts containing the DNA, DEAE dextran, infection with viral vectors, and the like.

Bacterial strains which can be used to express telomerase nucleic acid include *Escherichia coli*, *Bacillus subtilis*, *Streptococcus cremoris*, *Streptococcus*  
 5 *lactis*, *Streptococcus thermophilus*, *Leuconostoc citrovorum*, *Leuconostoc mesenteroides*, *Lactobacillus acidophilus*, *Lactobacillus lactis*, *Bifidobacterium bifidum*, *Bifidobacteriu breve*, and *Bifidobacterium longum*.

Yeast strains which can be used to express exogenous nucleic acids include *Pichia pastoris*, *Hansenula polymorpha*, *Torulopsis holmil*, *Saccharomyces fragilis*,  
 10 *Saccharomyces cerevisiae*, *Saccharomyces lactis*, and *Candida pseudotropicalis*. A large number of vectors are available for *S. cerevisiae*. *Kluyveromyces lactis*, and the methylotrophs *Hansenula polymorpha s* and *Pichia pastoris* offer certain advantages over baker's yeast *S. cerevisiae* for the production of certain proteins, see Gellissen (1997) *Gene* 190:87-97; Wegner (1990) *FEMS Microbiol. Rev.* 87:279.

15 The present invention also provides insect expression systems to express large amounts of recombinant TRT and telomerase enzyme of the invention. A commonly used insect system utilizes *Spodoptera frugiperda* infected with a baculovirus, such as *Autographa californica* nuclear polyhedrosis virus. This virus can be used to infect Sf21 (Deutschmann (1994) *Enzyme Microb Technol* 16:506-512) or  
 20 Sf9 cells (MaxBac 2.0, Invitrogen, San Diego, CA) (Zhu (1996) *J Virol Methods* 62(1), 71-79) derived from *Spodoptera frugiperda*, High Five cells derived from *Trichoplusia ni* insect cells (Parrington (1997) *Virus Genes* 14(1), 63-72), and *Lymantria dispar* (Vaughn (1997) *In Vitro Cell Dev Biol Anim* 33:479-482); see also Grabherr (1997) *Biotechniques* 22: 730-735). Baculovirus transfer vectors can be used to replace the  
 25 wild-type AcMNPV polyhedron gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following cotransfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter.  
 30 Baculovirus expression vectors are publicly available, such as pAC360 (Invitrogen, San

Diego, CA). In addition to manufacturer s instructions accompanying the commercially available baculovirus systems, see "Current Protocols in Molecular Biology," Ausubel, Chapter 16.

5 The present invention also provides methods and reagents for recombinant TRT and telomerase enzyme expression in plant cell systems. Constitutive promoters of plants include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, the promoter of the tobacco mosaic virus and transcription initiation regions from various plant genes known to those of skill in the art. The promoter may direct expression of  
10 the polynucleotide of the invention in only a specific tissue (tissue-specific promoters) or may be under environmental control (inducible promoters). Examples of tissue-specific plant promoters under developmental control include promoters that initiate transcription only in certain tissues, such as fruit, seeds, or flowers. The tissue specific E8 promoter from tomato is particularly useful for directing gene expression so that a  
15 desired gene product is located in fruits. Other suitable promoters include those from genes encoding embryonic storage proteins. Examples of environmental conditions that may affect transcription by inducible promoters include anaerobic conditions, elevated temperature, or the presence of light.

Plants can be transformed using viral vectors, such as, for example, tobacco  
20 mosaic virus derived vectors, to express telomerase or TRT of the invention. Selection and construction of vectors and techniques for transforming a wide variety of plant cells are well known, for example, see Hamamoto, U.S. Patent No. 5,618,699. For example, TRT constructs can be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of  
25 the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria. *Agrobacterium tumefaciens*-mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See, for example Horsch, *Science* (1984) 233:496, and Fraley (1983) *Proc. Natl Acad. Sci USA*  
30 80:4803. Plant regeneration from cultured protoplasts is described in Evans,

PROTOPLASTS ISOLATION AND CULTURE, HANDBOOK OF PLANT CELL CULTURE, pp. 124-176, Macmillian Publishing Company, New York, 1983; and Binding, REGENERATION OF PLANTS, PLANT PROTOPLASTS, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee, *Ann. Rev. of Plant Phys.* 38:467 (1987).

Suitable host cells for expressing the nucleic acids of the invention include, for example, but are not limited to: monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293) (Graham (1977) *J. Gen. Virol.* 36:59); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary-cells-DHFR (CHO, Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA* 77:4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.* 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL 1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); and, TRI cells (Mather, et al., *Annals N.Y. Acad. Sci.* 383:44-46 (1982)). The use of mammalian tissue cell culture to express polypeptides is discussed generally in Winnacker, *From Genes to Clones* (VCH Publishers, N.Y., N.Y., 1987).

#### **Nucleic Acid Hybridization Techniques**

The hybridization techniques disclosed herein can be utilized to identify, isolate and characterize genes and gene products (*i.e.*, mRNA) encoding the TRT proteins of the invention, including TRTs from different species and allelic variations of TRT in a specie. A variety of methods for specific DNA and RNA detection and measurement using nucleic acid hybridization techniques are known to those of skill in the art. See NUCLEIC ACID HYBRIDIZATION, A PRACTICAL APPROACH, Ed. Hames, B.D. and Higgins, S.J., IRL Press, 1985; Gall (1989) *Proc. Natl. Acad. Sci. USA* 63:378; and Sambrook. Depending on an application, the selection of a DNA hybridization format is often optional. For example, one method for evaluating the presence or absence of

DNA encoding a telomerase protein in a sample involves a Southern transfer. Briefly, the nucleic acid sample, such as digested DNA or mRNA, is run on agarose slab or polyacrylamide gels in buffer and transferred to membranes. Hybridization is carried out using nucleic acid probes. For the TRT nucleic acids of this invention, the nucleic acid probes may comprise nucleic acid sequences conserved amongst the genus of TRT nucleic acids. Preferably nucleic acid probes are 10 to 20 to 30 or more bases or longer in length (see Sambrook for methods of selecting nucleic acid probe sequences for use in nucleic acid hybridization). Both quantitative and qualitative determination of the presence or absence of DNA or RNA encoding TRT protein can be performed in accordance with the present methods.

Similarly, and as but one of many examples, a Northern transfer can be used for the detection of mRNA encoding telomerase protein, such as TRT. For example, mRNA is isolated from a given cell sample using an acid guanidinium-phenol-chloroform extraction method. The mRNA is then electrophoresed to separate the mRNA species and the mRNA is transferred from the gel to a nitrocellulose membrane. As with the Southern transfers, probes, such as labeled probes or PCR amplification products can be used to identify the presence or absence of telomerase protein-encoding nucleic acid. TRT mRNA of the invention is often expressed in cells at such low levels that it can be extremely difficult to detect by Northern blotting, even using the most sensitive assays. This can be true even with cells that express relatively high levels of TRT mRNA, such as indefinitely proliferating, immortal and cancer cells. Because of the typically very low level of expression of TRT mRNA, an optimized Northern blot protocol is described below.

The low level of TRT mRNA, even in TRT-positive cells, *i.e.*, cells that express telomerase activity, such as cancer cells, is reflected by the low levels of TRT protein that may be seen in such cells. Such protein can be detected by the detection methods of the invention, including immunoblotting (Western blots). TRT protein in the human cancer cell line 293 can be detected using a sensitive Western blot system employing anti-telomerase polyclonal antisera of the invention, although the TRT signal on the

Western blot was weak, in part showing that hTRT is present in low or very low abundance even in immortal cells.

Sandwich assays are commercially useful hybridization assays for detecting or isolating protein or nucleic acid. Such assays utilize a "capture" nucleic acid or protein that is often covalently immobilized to a solid support and a labeled "signal" nucleic acid, typically in solution. A clinical or other sample provides the target nucleic acid or protein. The "capture" nucleic acid or protein and "signal" nucleic acid or protein hybridize with or bind to the target nucleic acid or protein to form a "sandwich" hybridization complex. To be effective, the signal nucleic acid or protein cannot hybridize or bind substantially with the capture nucleic acid or protein.

Typically, oligonucleotide probes are labeled signal nucleic acids that are used to detect hybridization. Complementary probe nucleic acids or signal nucleic acids may be labeled for use in any one of several methods typically used to detect the presence of hybridized polynucleotides. Methods of detection can use labels for autoradiography or autofluorography, such as  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ -labeled probes or the like (see definition of label, above). Other labels include ligands which bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand.

Detection of a hybridization complex may require the binding of a signal generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and anti-ligand interactions as between a ligand-conjugated probe and an anti-ligand conjugated with a signal, i.e., antibody-antigen or complementary nucleic acid binding. The label may also allow indirect detection of the hybridization complex. For example, where the label is a hapten or antigen, the sample can be detected by using antibodies. In these systems, a signal is generated by attaching fluorescent or enzymatic molecules to the antibodies or, in some cases, by attachment of a radioactive label. The sensitivity of the hybridization assays may be enhanced through use of a target nucleic acid or signal amplification system which multiplies the target nucleic acid or signal being detected. *In vitro* amplification techniques suitable for amplifying sequences for use as molecular probes or for

generating nucleic acid fragments for subsequent subcloning are known, as described above. These systems can be used to directly identify allelic variations or mutated sequences where the PCR or LCR primers or other reagents are designed to be extended or ligated only when a specific sequence is present. Alternatively, the specific sequences can be generally amplified using, for example, more generic PCR primers and the amplified target region later probed or sequenced to identify a specific sequence indicative of the allele or mutation.

It will be appreciated that nucleic acid hybridization assays can also be performed in an array-based format. Arrays are a multiplicity of different "probe" or "target" nucleic acids (or other compounds) are hybridized against a target nucleic acid. In this manner a large number of different hybridization reactions can be run essentially "in parallel". This provides rapid, essentially simultaneous, evaluation of a wide number of reactants. Methods of performing hybridization reactions in array based formats are well known to those of skill in the art, *e.g.*, Jackson (1996) *Nature Biotechnology* 14:1685; Chee, *Science* 274:610 (1995).

An alternative means for determining the level of expression of a gene encoding a protein is *in situ* hybridization. *In situ* hybridization assays are well known and are generally described in Angerer (1987) *Methods Enzymol* 152:649. In an *in situ* hybridization assay, cells are fixed to a solid support, typically a glass slide or analyzed by a fluorescence activated cell sorter (FACS). If DNA is to be probed, the cells are typically denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of labeled probes specific to the nucleic acid sequence encoding the protein. The probes are typically labeled, *i.e.*, with radioisotopes or fluorescent reporters. See also U.S. Patent No. 5,583,016, and USSNs 08/770,564 and 08/770,565, both filed 20 December 1996; Soder (1997) *Oncogene* 14:1013-1021, which describe, *e.g.*, *in situ* hybridization of hTR. Another well-known *in situ* hybridization technique is the so-called FISH fluorescence *in situ* hybridization, as described by Macechko (1997) *J Histochem Cytochem* 45:359-363; and, Raap (1995) *Hum Mol Genet* 4(4), 529-534.

### **Identification of Transformants Containing the Polynucleotide Sequence**

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression can be confirmed. For example, if the sequence encoding a telomerase protein subunit is inserted within a marker gene sequence, recombinant cells containing the sequence encoding the telomerase protein subunit can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with the sequence encoding telomerase protein subunit under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem sequence as well.

Alternatively, host cells which contain the coding sequence for telomerase or a telomerase protein subunit and express the telomerase or protein subunit be identified by a variety of standard procedures known to those of skill in the art using methods and reagents of the invention. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the polynucleotide sequence encoding telomerase protein subunits can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions, or fragments of the sequence encoding the subunit. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the nucleic acid sequence to detect transformants containing DNA or RNA encoding the telomerase subunit. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of approximately 10 nucleotides or greater and as many as approximately 100 nucleotides, preferably between 15 to 30 nucleotides, and more preferably between 20-25 nucleotides which can be used as a probe or amplimer.

A variety of standard protocols for detecting and measuring the expression of proteins using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). These and

other assays are described, among other places, in Hampton *et al.*, *Serological Methods a Laboratory Manual*, APS Press, St Paul MN, 1990) and Maddox (1983) *J. Exp. Med.* 158:1211).

5 A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting related sequences include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide or primer. Alternatively, a telomerase protein subunit sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such  
10 vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides.

A number of companies such as Pharmacia Biotech (Piscataway NJ), Promega (Madison WI), and US Biochemical Corp (Cleveland OH) supply commercial kits and  
15 protocols for these procedures. Suitable reporter molecules or labels include those radio nuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include U.S. Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241, herein incorporated by reference. Also,  
20 recombinant immunoglobulins may be produced as shown in U.S. Patent No. 4,816,567 incorporated herein by reference.

### **Purification of Telomerase and Telomerase Subunit Proteins**

In addition to the illustrative method of purification of a TRT species described  
25 in Example 3 below, it is contemplated that additional methods of purifying (recovering) TRT from naturally sources or recombinantly produced telomerase or telomerase protein subunits will be used in accordance with the methods of the invention. Examples of methods for purifying telomerase and compositions used in the methods of the invention are described below.

*Solubility Fractionation*

If the protein mixture is complex, an initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. The preferred salt is ammonium sulfate.

5 Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol is to add saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This  
10 will precipitate the most hydrophobic of proteins. The precipitate is discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such  
15 as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.

*Size Differential Filtration*

If the size of the protein of interest is known or can be estimated from the cDNA sequence, as is the case with the genus of TRT proteins and the illustrative species  
20 herein, proteins of greater and lesser size can be removed by ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration is then ultrafiltered against a membrane with  
25 a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed.

*Column Chromatography*

Proteins can be separated on the basis of their size, net surface charge,  
30 hydrophobicity and affinity for ligands. In addition, antibodies raised against proteins

can be conjugated to column matrices and the proteins immunopurified. All of these general methods are well known in the art. See Scopes, R. K., Protein Purification: Principles and Practice, 2nd ed., Springer Verlag, (1987). Chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech). Protein concentrations can be determined using any  
5 technique, e.g., as in Bradford (1976) *Anal. Biochem.* 72:248-257.

*Purification of TRT*

Telomerase can be isolated by any of a variety of means provided by the invention, as described above. In one embodiment of the invention, telomerase can be  
10 purified to over 60,000-fold purity over cytoplasmic crude cell preparations. Human TRT can be isolated from crude extracts of "293" cells, cells of human embryonic kidney origin that have been transformed with fragments of adenovirus type 5 DNA (Graham (1977) *J. Gen. Virol.* 36:59-77; Stillman (1985) *Mol. and Cell. Biol.* 5:2051-2060). 293 cells are available from the American Type Culture Collection, Accession  
15 No. ATCC CRL 1573.

The steps to be included in a purification method depend on the level of purification one desires. A method to purify telomerase enzyme or TRT protein from an impure composition containing organic biomolecules, for example, a crude extract of telomerase positive cells, to at least 60,000-fold compared to crude extract (about 4%  
20 relative purity) can, for example, involve: (1) contacting the telomerase or TRT protein with a first matrix that binds molecules bearing a negative charge, for example, POROS 50 HQ, separating telomerase or TRT protein from other organic biomolecules that do not bind to the matrix and collecting the telomerase; (2) contacting the telomerase or TRT protein with a matrix that binds molecules bearing a positive charge, for example  
25 POROS Heparin 20 HE-1, and separating telomerase or TRT protein from other organic biomolecules that do not bind to the matrix and collecting the telomerase; (3) contacting the telomerase or TRT protein with a second matrix that binds molecules bearing a negative charge, for example, SOURCE 15Q, separating telomerase or TRT protein from other organic biomolecules that do not bind to the matrix and collecting  
30 the telomerase; (4) contacting the telomerase or TRT protein with an affinity agent

having specific affinity for telomerase or a TRT protein or RNA subunit, for example an oligonucleotide complementary to hTR or an anti-TRT or anti-telomerase antibody or other protein, separating telomerase or TRT protein from other organic biomolecules that do not bind to the affinity agent and collecting the telomerase or TRT protein; and  
5 (5) separating the telomerase or TRT protein from other organic biomolecules according to molecular size, shape, or buoyant density, for example separating molecules according to size on a TosohHaas TSK-gel\*G5000PW<sub>XL</sub> sizing column and collecting the telomerase or TRT protein. The present invention encompasses protocols comprising fewer or additional steps.

10 The purification protocol also can include the step of contacting the telomerase or TRT protein with an intermediate-selectivity matrix, separating telomerase from other organic biomolecules that do not bind to the intermediate-selectivity matrix and collecting the telomerase, preferably before the affinity step. Telomerase can be isolated to different levels of purity by altering, changing the sequence of, or  
15 eliminating any of the steps in the purification protocol. However, any preferred protocol will typically include contacting the telomerase with an affinity agent, such as the antibodies of the invention. Contacting the telomerase with at least one matrix that binds molecules bearing a negative charge or a positive charge is typically a preferred step or steps to include in the protocol as well.

20 *Amino Acid Sequence Determination*

Illustrative amino acid sequences of the telomerase, TRT protein and telomerase-associated proteins of this invention can be determined by, for example, Edman degradation, a technique which is well known in the art. In addition to the internal sequencing (see also Hwang (1996) *J. Chromatogr. B. Biomed. Appl.*  
25 686:165-175), N-terminal sequencing can be performed by techniques known in the art. For C-terminal sequence determination, a chemical procedure for the degradation of peptides and analysis by matrix- assisted- laser- desorption ionization mass spectrometry (MALDI-MS) can be used, as described in Thiede (1997) *Eur. J. Biochem.* 244:750-754.

*Molecular Weight/Isoelectric Point Determination*

The molecular weight of a protein can be determined by many different methods, all known to one of skill in the art. Some methods of determination include: SDS gel electrophoresis, native gel electrophoresis, molecular exclusion chromatography, zonal centrifugation, mass spectroscopy, and calculation from sequencing. Disparity between results of different techniques can be due to factors inherent in the technique. For example, native gel electrophoresis, molecular exclusion chromatography and zonal centrifugation depend on the size of the protein. The proteins that are cysteine rich can form many disulfide bonds, both intra- and intermolecular. SDS gel electrophoresis depends on the binding of SDS to amino acids present in the protein. Some amino acids bind SDS more tightly than others, therefore, proteins will migrate differently depending on their amino acid composition. Mass spectroscopy and calculated molecular weight from the sequence in part depend upon the frequency that particular amino acids are present in the protein and the molecular weight of the particular amino acid. If a protein is glycosylated, mass spectroscopy results will reflect the glycosylation but a calculated molecular weight may not.

The calculated molecular weight of hTRT (SEQ ID NO:118) was estimated to be about 127 kD. However, additional human or non-human TRT proteins, hTRT, hTRT isoforms and other TRT species within the scope of the invention are not limited to this molecular weight range.

The isoelectric point of a protein can be determined by native gel (or disc) electrophoresis, isoelectric focussing or in a preferred method, by calculation given the amino acid content of the protein. The isoelectric point (pI) of hTRT (SEQ ID NO:118) has been calculated to be about 11.3. However, TRT species or isoforms within the scope of the invention are not necessarily limited to this range of isoelectric points.

The cDNA clone pGRN121 encodes a functional hTRT (cDNA is SEQ ID NO:117) and was isolated from a library of the human 293 cell line as described in Example 17. SEQ ID NO:117 encodes a catalytically active telomerase protein having the sequence of SEQ ID NO:118. The polypeptide of SEQ ID NO:118 has 1132

residues and a calculated molecular weight of about 127 kilodaltons (kD). Comparing clone #712562 (SEQ ID NO:122) with pGRN121 showed that clone #712562 has a 182 base pair deletion between motifs A and B'. The additional 182 basepairs present in pGRN121 places all of the TRT motifs in a single open reading frame, and increases the spacing between the motif A and motif B' regions to a distance consistent with the other known TRTs.

TRT can be produced and isolated from recombinant sources. For example, host cells transformed with a nucleotide sequence encoding telomerase or telomerase subunit protein(s) may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing the telomerase or subunit protein encoding sequence can be designed with signal sequences which direct secretion of the telomerase or telomerase subunit protein through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join the sequence encoding the telomerase or subunit protein to a nucleotide sequence encoding a polypeptide domain.

Telomerase or telomerase subunit protein(s) may also be expressed as recombinant proteins with one or more additional polypeptide domains added to facilitate protein purification or other purposes or intended applications. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between the purification domain and telomerase or telomerase protein subunits is useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding telomerase or telomerase protein subunits and nucleic acid sequence encoding 6 histidine residues followed by thioredoxin and an enterokinase cleavage

site. The histidine residues facilitate purification while the enterokinase cleavage site provides a means for purifying the telomerase or telomerase protein subunit from the fusion protein. Literature pertaining to vectors containing fusion proteins is available in the art (*See e.g.*, Kroll (1993) *DNA Cell. Biol.* 12:441-53).

## 5           **Chemical Synthesis of TRT Sequences**

In an alternate embodiment of the invention, in addition to recombinant production, the sequence encoding the telomerase subunit(s) may be synthesized, whole or in part, using chemical methods well known in the art (*See e.g.*, Caruthers (1980) *Nucleic Acids Res. Symp. Ser.* 215-223; and Horn (1980) *Nucleic Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself could be produced using chemical methods to synthesize a telomerase subunit amino acid sequence, in whole or in part. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge (1995) *Science* 269:202; Merrifield (1963) *J. Am. Chem. Soc.* 85:2149) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer. Various fragments of a telomerase protein subunit can be chemically synthesized separately and combined using chemical methods to produce a full length or larger molecule.

The newly synthesized peptide can be isolated and substantially purified by preparative high performance liquid chromatography, as described above (*e.g.*, Creighton, *Proteins, Structures and Molecular Principles*, WH Freeman and Co, New York NY, 1983). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure; Creighton, *supra*). Additionally the amino acid sequences of telomerase subunit proteins, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

Nucleic acids can also be synthetically produced, including oligonucleotide probes and primers, TRT coding sequences, antisense, ribozymes and the like, by a variety of solution or solid phase methods. Detailed descriptions of the procedures for

solid phase synthesis of nucleic acids by phosphite-triester, phosphotriester, and H-phosphonate chemistries are widely available. For example, the solid phase phosphoramidite triester method of Beaucage and Carruthers using an automated synthesizer is described in Itakura, U.S. Pat. No. 4,401,796; Carruthers, U.S. Pat. Nos. 5 4,458,066 and 4,500,707; Carruthers (1982) *Genetic Engineering* 4:1-17; see also Needham-VanDevanter (1984) *Nucleic Acids Res.* 12:6159-6168; Beigelman (1995) *Nucleic Acids Res* 23: 3989-3994; Jones, chapt 2, Atkinson, chapt 3, and Sproat, chapt 4, in OLIGONUCLEOTIDE SYNTHESIS: A PRACTICAL APPROACH, Gait (ed.), IRL Press, Washington D.C. (1984); Froehler (1986) *Tetrahedron Lett.* 27:469-472; Froehler, 10 *Nucleic Acids Res.* 14:5399-5407 (1986); Sinha, *Tetrahedron Lett.* 24:5843-5846 (1983); and Sinha, *Nucl. Acids Res.* 12:4539-4557 (1984). Methods to purify oligonucleotides include native acrylamide gel electrophoresis, anion-exchange HPLC, as described in Pearson (1983) *J. Chrom.* 255:137-149. The sequence of the synthetic oligonucleotide can be verified using any chemical degradation method, for example, 15 see Maxam (1980) *Methods in Enzymology* 65:499-560, Xiao (1996) *Antisense Nucleic Acid Drug Dev* 6:247-258, or for solid-phase chemical degradation procedures, Rosenthal (1987) *Nucleic Acids Symp Ser* 18:249-252.

#### **Methods Relating to Telomerase and Telomerase Subunit Proteins**

20 The nucleotide and peptide sequences disclosed herein are based in part on the homology between the *E. aediculatus* telomerase 123 kDa protein subunit, the yeast protein L8543.12 (Est2), *Schizosaccharomyces*, and the human motifs observed during the development and implementation of and generated by the present invention. In particular, the yeast and 123 kDa protein contain the RT motif in their C-terminal 25 regions, they share similarity in regions outside the RT motif, they are similarly basic (with a pI of 10.1 for the 123 kDa protein, and of 10.0 for the yeast), and they are both large (123 kDa and 103 kDa). Furthermore, in view of the RT motifs, these subunits are believed to comprise the catalytic core of their respective telomerases. Indeed, the RT motifs of the 123 kDa *E. aediculatus* telomerase protein subunit is shown in the

present invention to be useful for the identification of similar sequences in other organisms.

As *E. aediculatus* and *S. cerevisiae* are so phylogenetically distant, it was contemplated that this homology provided a strong basis for predicting that human and other telomerases will contain a protein that is large, basic, and includes such RT motifs. Indeed, motifs have been identified within clones encoding the human homolog of the TRT protein. It is further contemplated that this protein is essential for human telomerase catalytic activity. This observation proved valuable for amplification of the human telomerase gene by PCR and other methods. The methods and reagents of the invention have application for screening for telomerase sequences in human and other animals, as well as for prioritizing candidate telomerase proteins or genes identified by genetic, biochemical, or nucleic acid hybridization methods. It is also contemplated that the telomerase proteins of the present invention will find use in "tailing" or extending chromosomal or other DNA 3' ends *in vitro*.

It is contemplated that expression of telomerase and/or telomerase subunit proteins in cell lines will find use in the development of diagnostics for tumors and aging factors. The nucleotide sequence may be used in hybridization or PCR technologies to diagnose the induced expression of messenger RNA sequences early in the disease process. Likewise the protein can be used to produce antibodies useful in ELISA assays or a derivative or other diagnostic format. Such diagnostic tests allow different classes of human tumors or other cell-proliferative diseases to be distinguished and thereby facilitate the selection of appropriate treatment regimens.

It is contemplated that the finding of the RT motifs in the telomerase proteins of the present invention will be used to develop methods to test known and yet to be described reverse transcriptase inhibitors, including nucleosides, and non-nucleosides for anti-telomerase activity.

It is contemplated that the amino acid sequence motifs disclosed herein will lead to the development of drugs (*e.g.*, telomerase inhibitors) useful in humans and/or other animals, that will arrest cell division in cancers or other disorders characterized by proliferation of cells. It is also contemplated that the telomerase proteins will find use

in methods for targeting and directing RNA or RNA-tethered drugs to specific sub-cellular compartments such as the nucleus or sub-nuclear organelles, or to telomeres.

5 In one embodiment of the diagnostic method of the present invention, normal or standard values for telomerase mRNA expression are established as a baseline. This can be accomplished by a number of assays such as quantitating the amount of telomerase mRNA in tissues taken from normal subjects, either animal or human, with nucleic probes derived from the telomerase or telomerase protein subunit sequences provided herein (either DNA or RNA forms) using techniques which are well known in the art (*e.g.*, Southern blots, Northern blots, dot or slot blots). The standard values  
10 obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease (*e.g.*, tumors or disorders related to aging). Deviation between standard and subject values can establish the presence of a disease state. In addition, the deviation can indicate, within a disease state, a particular clinical outcome (*e.g.*, metastatic or non-metastatic).

15 The nucleotide sequence encoding telomerase or telomerase protein subunits is useful when placed in an expression vector for making quantities of protein for therapeutic use. The antisense nucleotide sequence of the telomerase gene is potentially useful in vectors designed for gene therapy directed at neoplasia including metastases. Additionally, the inhibition of telomerase expression can be useful in  
20 detecting the development of disturbances in the aging process or problems occurring during chemotherapy. Alternatively, the telomerase or telomerase protein subunit encoding nucleotide sequences can be used to direct the expression of telomerase or subunits in situations where it is desirable to increase the amount of telomerase activity.

## 25 **Telomerase Subunit Protein Antibodies**

The invention also provides methods and reagents for detecting or quantitating telomerase and/or TRT or other telomerase subunit protein, such as the *Euplotes* p43 (43 kDa) protein and its human homologue, by a variety of methods. For example, telomerase can be detected and quantified by incorporating functional activity assays of  
30 the invention, by immunological assays utilizing a variety of anti-telomerase antibodies

provided by the invention, and by nucleic acid-based methodologies, examples of which are also described in detail below.

In one embodiment, the invention provides antibodies that bind hTRT specifically or TRTs generally, and so can be used to identify and isolate any member of the genus of TRTs provided for in the invention or to identify a single specie of telomerase, or hTRT. Antibodies which can identify any member of the genus can be generated by using as antigens peptides containing structural features common to all members of the genus or other TRT-specific epitopes. These common structural features of telomerase are also described above. In general, the antibodies of the invention can be used to identify, purify, or inhibit any or all activity of telomerase enzyme and TRT protein. Antibodies can act as antagonists of telomerase activity in a variety of way, for example, by preventing the telomerase complex or nucleotide from binding to its DNA substrates, by preventing the components of telomerase from forming an active complex, by maintaining a functional (telomerase complex) quaternary structure or by binding to one of the enzyme's active sites or other sites that have allosteric effects on activity (the different partial activities of telomerase are described in detail elsewhere in this specification). General methods for producing the antibodies of the invention are described below.

It is further contemplated that antibodies directed against the telomerase subunit proteins, including those directed towards TRT motifs, will find use in the diagnosis and treatment of conditions and diseases associated with expression of telomerase (including the over-expression and the absence of expression).

Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library.

Given the phylogenetic conservation of the RT motif in the 123 kDa subunit of the *Euplotes* telomerase, it is contemplated that antibodies directed against this subunit will be useful for the identification of homologous subunits in other organisms, including humans, for example, hTRT and the human homologue of the *Euplotes* 43 kDa (p43) TRT polypeptide. It is further contemplated that antibodies directed against

the motifs provided in the present invention will find use in treatment and/or diagnostic areas of application.

Telomerase subunit proteins used for antibody induction need not retain biological activity; however, the protein fragment, or oligopeptide must be immunogenic, and preferably antigenic. Peptides used to induce specific antibodies can have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids. Preferably, they should mimic a portion of the amino acid sequence of the natural protein and can contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of telomerase subunit protein amino acids can be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. Complete telomerase used for antibody induction can be produced by co-expression of protein and RNA components in cells, or by reconstitution *in vitro* from components separately expressed or synthesized.

Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art and described in the scientific and patent literature, see, e.g., Coligan, CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley/Greene, NY (1991); Stites (eds.) BASIC AND CLINICAL IMMUNOLOGY (7th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein ( Stites ); Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE (2d ed.) Academic Press, New York, NY (1986); Kohler (1975) *Nature* 256:495; Harlow and Lane, *supra*. Such techniques include selection of antibodies from libraries of recombinant antibodies displayed in phage or similar on cells. See, Huse (1989) *Science* 246:1275 and Ward (1989) *Nature* 341:544. Recombinant antibodies can be expressed by transient or stable expression vectors in mammalian cells, as in Norderhaug (1997) *J. Immunol. Methods* 204:77-87.

To produce large amounts of antibodies for use in, for example, immunoaffinity purification or diagnostics, a number of immunogens provided by the invention may be used. Telomerase isolated from a natural source or more preferably from a recombinant protein isolated from transformed cells provided by the present invention can be used as immunogen for the production of monoclonal or polyclonal antibodies. Naturally occurring telomerase or TRT protein from any organism or recombinant telomerase or

TRT protein can be used either in pure or impure form. Synthetic peptides are made using any portion of the TRT amino acid sequence for use as immunogens. The peptides can be used alone or conjugated to another composition as immunogens.

Furthermore, telomere structures can be used as immunogens to create telomerase-specific antibodies. For example, under certain conditions, telomeres can form higher order superstructures, called G-quartets (Sen (1992) *Biochemistry* 31:65-70; Fang (1993) *Biochemistry* 32:11646-11657) which can be used as immunogens. Other novel tertiary structures which potentially can be immunogenic include stable hairpins or G-quadruplexes by the telomerase product (Salazar (1996) *Biochemistry* 35:16110-16115). These novel structures can act as an immunogens for the formation of antibodies which can, for example, monitor the formation of telomerase product, inhibit telomerase activity or identify telomerase in a sample. These novel structures can also be the hybridization target for nucleotides, which can also be used to measure formation of telomere product, inhibit activity, and the like.

Methods for the production of polyclonal and monoclonal antibodies are known to those of skill in the art. In brief, an immunogen is mixed with an adjuvant, as described above, and animals are immunized. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the immunogen. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done (Harlow and Lane, *supra*). Various illustrative peptides, proteins and fusion proteins of the invention have been used to generate such polyclonal antibodies.

Monoclonal antibodies to telomerase or telomerase protein subunits be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein, *Nature* 256:495-497 (1975), the human B-cell hybridoma technique (Kosbor (1983) *Immunol. Today* 4:72; Cote (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R Liss Inc, New York

NY, pp 77-96, 1985). Large amounts of monoclonal antibodies for use in immunoaffinity purification or immunoassays may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired telomerase protein are immortalized, commonly by fusion with a myeloma cell. Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for telomerase and TRT protein. The yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from appropriate human B cells, *i.e.*, immunized according to the general protocol outlined in Huse (1989) *Science, supra*.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with telomerase protein, protein subunit, or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants are commercially available, and include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (*Bacillus Calmette-Guerin*) and *Corynebacterium parvum* are potentially useful adjuvants.

Animals (*e.g.*, inbred strain of mice or rabbits) can be immunized with a TRT or a fragment thereof, such as the polypeptide or peptide comprising SEQ ID NO:118, or with isoforms or immunogenic fragments thereof, alone or using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen. Polyclonal sera are collected and titered against the telomerase in an immunoassay, for example, a solid phase immunoassay with the telomerase immobilized on a solid support. Polyclonal

antisera with a titer of, for example,  $10^4$  or greater are selected and tested for their cross reactivity against homologous proteins from other organisms and/or non-telomerase protein, using, for example, a competitive binding immunoassay. Specific monoclonal and polyclonal antibodies and antisera will usually bind with a  $K_D$  of at least about 1  $\mu\text{M}$ , preferably at least about 0.1  $\mu\text{M}$  or better, and most preferably, 0.01  $\mu\text{M}$  or better.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents (Orlandi (1989) *Proc. Natl. Acad. Sci. USA* 86: 3833; and Winter (1991) *Nature* 349:293).

Antibody fragments which contain specific binding sites for telomerase or telomerase protein subunits may also be generated. For example, such fragments include, but are not limited to, the  $\text{F(ab')}_2$  fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the  $\text{F(ab')}_2$  fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse (1989) *Science* 256:1275).

A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between telomerase or telomerase protein subunit and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific telomerase protein subunit is preferred in some situations, but a competitive binding assay may also be employed (*See e.g.*, Maddox (1983) *J. Exp. Med.* 158:1211).

Peptides selected from the group comprising the sequences shown in Figure 32 can be used to generate polyclonal and monoclonal antibodies specifically directed against human and other telomerase proteins. The peptides are useful for inhibition of protein-RNA, protein-protein interaction within the telomerase complex, and protein-DNA interaction at telomeres. Antibodies produced against these peptides are then used in various settings, including but not limited to anti-cancer therapeutics capable of

inhibiting telomerase activity, for purification of native telomerase for therapeutics, for purification and cloning other components of human telomerase and other proteins associated with human telomerase, and diagnostic reagents.

5 The concentration of telomerase or TRT protein can be measured by a variety of immunoassay methods of the invention. Generally, immunoassays are described in Stites, *supra*. The immunoassays of the present invention can be performed in any of several configurations, for background information see ENZYME IMMUNOASSAY, E.T. Maggio, ed., CRC Press, Boca Raton, Florida (1980); Tijssen, and Harlow and Lane, *supra*.

10 *Immunological Binding Assays.*

Immunological binding assays (e.g., U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168) are known in the art. For a review, see also METHODS IN CELL BIOLOGY Vol. 37: *Antibodies in Cell Biology*, Asai, ed. Academic Press, Inc. New York (1993); and Stites, *supra*. Immunological binding assays (or immunoassays) typically utilize a capture agent to bind specifically to and often immobilize the  
15 analyte. The capture agent is a moiety that specifically binds to the analyte. In one embodiment of the present invention, the capture agent is an antibody that specifically binds to telomerase or TRT, such antibody (anti-telomerase or anti-TRT) produced by the methods of the present invention.

20 Immunoassays also often utilize a labeling agent to specifically bind to and label the binding complex formed by the capture agent and the analyte, as described above. The labeling agent may itself be, for example, one of the moieties comprising the antibody/analyte complex: the labeling agent can be a labeled telomerase or a labeled anti-telomerase antibody. Alternatively, the labeling agent may be a third  
25 moiety, such as another antibody, that specifically binds to the antibody-telomerase complex. The labeling agent can be, for example, a second anti-telomerase antibody bearing a label. The second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second can be modified with a detectable moiety, such as  
30 biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled

streptavidin. Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins are normal constituents of the cell walls of streptococcal bacteria and exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (*see, generally Akerstrom (1985) J. Immunol.*135:2589-2542; 5 *Chaubert (1997)Mod Pathol*10:585-591 (1997)).

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the 10 incubation time will depend upon the assay format, analyte, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

(1) *Non-Competitive Assay Formats*

15 Immunoassays for detecting telomerase and TRT protein may be, for example, either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of captured analyte (as telomerase, TRT or hTRT) is directly measured. In one preferred "sandwich" assay, for example, the capture agent (anti-telomerase antibodies) can be bound directly to a solid substrate where they are 20 immobilized. These immobilized antibodies then capture protein present in the test sample. The telomerase or TRT protein thus immobilized is then bound by a labeling agent, such as a second anti-telomerase antibody bearing a label. Alternatively, the second anti-telomerase or anti-TRT antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the 25 second antibody is derived. The second can be modified with a detectable moiety, such as biotin, to which a third labeled molecule can specifically bind, such as enzyme-labeled streptavidin.

(2) *Competitive Assay Formats*

In competitive assays, the amount of analyte (telomerase) present in the sample 30 is measured indirectly by measuring the amount of an added (exogenous) analyte

(telomerase or TRT) displaced (or competed away) from a capture agent (anti-telomerase or anti-TRT antibody) by the analyte present in the sample. In one competitive assay, a known amount of, in this case telomerase or TRT, usually labeled, is added to the sample and the sample is then contacted with a capture agent, in this case an antibody that specifically binds telomerase or TRT. The amount of labeled telomerase or TRT bound to the antibody is inversely proportional to the concentration of telomerase or TRT present in the sample.

In another embodiment, the antibody is immobilized on a solid substrate. The amount of telomerase or TRT bound to the antibody may be determined either by measuring the amount of telomerase or TRT present in an telomerase/antibody or TRT/antibody complex, or alternatively by measuring the amount of remaining uncomplexed telomerase or TRT. The amount of telomerase or TRT may be detected by providing a labeled telomerase or TRT molecule.

A hapten inhibition assay is another competitive assay. In this assay a known analyte, in this invention telomerase or TRT, is immobilized on a solid substrate. A known amount of anti-telomerase or anti-TRT antibody is added to the sample, and the sample is then contacted with the immobilized telomerase or TRT. In this case, the amount of anti-telomerase or anti-TRT antibody bound to the immobilized telomerase or TRT is inversely proportional to the amount of telomerase or TRT present in the sample. Again the amount of immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

Immunoassays in the competitive binding format can be used for crossreactivity determinations to permit one of skill to determine if a protein or enzyme complex is a TRT or telomerase enzyme of the invention. For example, a TRT can be immobilized to a solid support. Proteins are added to the assay which compete with the binding of the antisera to the immobilized antigen. The ability of the proteins to

compete with the binding of the antisera to the immobilized TRT is compared to the binding by the same TRT as was used to coat the solid support.

(3) *Other Assay Formats*

The present invention also provides methods for Western blot (immunoblot) analysis to detect and/or quantify the presence of telomerase protein in a sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind telomerase. The anti-telomerase protein antibodies specifically bind to telomerase on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (*e.g.*, labeled sheep anti-mouse antibodies) that specifically bind to the anti-telomerase protein.

Antibodies can also be used to probe expression libraries, see Young (1982) *Proc. Natl. Acad. Sci. USA* 80:1194. In general, a cDNA expression library may be prepared from commercially available kits or using readily available components. Phage (Hurst (1997) *Methods Mol Biol* 69:155-159), bacteria (Davis (1997) *Proc. Natl. Acad. Sci. USA* 94:2128-2132), insect (Granziero (1997) *J. Immunol. Methods* 203:131-139), yeast, and animal cell libraries (*Xenopus* oocytes) can be used. One selects mRNA from a source that is optionally enriched with the target mRNA or in which the protein is abundant and creates cDNA which is then ligated into a vector and the vector is transformed into the library host cells for immunoscreening. Screening involves binding and identification of antibodies bound to specific proteins on cells or immobilized on a solid support such as nitrocellulose or nylon membranes. Positive clones are selected for purification to homogeneity and the isolated cDNA then prepared for expression in the desired host cells. See also *METHODS OF CELL BIOLOGY, VOL. 37, Antibodies in Cell Biology*, Assai (ed.) 1993.

The methods of the invention are also compatible with other assay formats, including liposome immunoassays (LIA) (Rongen (1997) *J. Immunol. Methods* 204:105-133), in which liposomes designed to bind specific molecules (*e.g.*, antibodies)

and release encapsulated reagents or markers are employed. The released chemicals can be detected using standard techniques (*see, e.g.* Monroe (1986) *Amer. Clin. Prod. Rev.* 5:34 ).

## 5     **Diagnostic Assays Using Telomerase Specific Antibodies**

Particular telomerase and telomerase protein subunit antibodies are useful for the diagnosis of conditions or diseases characterized by expression of telomerase or telomerase protein subunits, or in assays to monitor patients being treated with telomerase, its fragments, agonists or inhibitors (including antisense transcripts capable  
10 of reducing expression of telomerase). Diagnostic assays for telomerase include methods utilizing the antibody and a label to detect telomerase in human body fluids or extracts of cells or tissues. The polypeptides and antibodies of the present invention can be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter  
15 molecule. A wide variety of reporter molecules are known, several of which were described above. In particular, the present invention is useful for diagnosis of human disease, although it is contemplated that the present invention will find use in the veterinary arena.

A variety of protocols for measuring telomerase protein(s) using either  
20 polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on the telomerase proteins or a subunit is preferred, but a  
25 competitive binding assay can be employed. These assays are described, among other places, in Maddox (1983) *supra*.

In order to provide a basis for diagnosis, normal or standard values for human telomerase expression are usually established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with  
30 antibody to telomerase or telomerase subunit(s) under conditions suitable for complex

formation which are well known in the art. The amount of standard complex formation is quantified by comparing various artificial membranes containing known quantities of telomerase protein, with both control and disease samples from biopsied tissues. Then, standard values obtained from normal samples are compared with values obtained from  
5 samples from subjects potentially affected by disease (*e.g.*, metastases). Deviation between standard and subject values establishes the presence of a disease state.

### **Drug Screening**

The invention contemplates screening for compositions capable of modifying the DNA replicative capacity of telomerase, or a partial activity of telomerase or TRT,  
10 by any means. In various embodiments, the invention includes: screening for antagonists that bind to TRT protein's active site or interfere with reverse transcription of its RNA moiety; screening for compositions that inhibit the association of nucleic acid and/or telomerase-associated compositions with TRT, such as the association of TR with TRT or the association of TRT with a telomerase associated protein, or  
15 association of TRT with a telomere or a nucleotide; screening for compositions that promote the disassociation or promote the association of the enzyme complex, such as an antibody directed to TR or TRT; screening for agents that effect the processivity of the enzyme; and, screening for nucleic acids and other compositions that bind to TRT, such as a nucleic acid identical to, complementary to, or comprises TR. The invention  
20 further contemplates screening for compositions that increase or decrease the transcription of the TRT gene and/or translation of the TRT gene product.

Screening for antagonist activity provides for compositions that decrease telomerase replicative capacity, thereby mortalizing otherwise indefinitely replicating (proliferating) cells or immortal cells, such as cancer cells. Telomerase activity has  
25 been identified as an important cancer marker, one whose levels can detect, diagnose and prognose the outcome or seriousness of disease, as described in U.S. Patent Nos. 5,489,508; 5,648,125; and 5,639,613. The present invention provides useful reagents for diagnosing and prognosing cancer by analyzing a telomerase activity and hTRT gene expression.

Screening for agonist activity or transcriptional or translational activators provides for compositions that increase the telomerase's telomere replicative capacity, or a partial activity of a telomerase enzyme or a TRT. Such agonist compositions provide for methods of increasing the proliferative capacity of cells, creating a state of indefinite proliferation, including immortalization, of otherwise normal untransformed cells, including cells which can express useful proteins. Such agonists can also provide for methods of controlling cellular senescence.

Telomerase or telomerase subunit proteins or their catalytic or immunogenic fragments or oligopeptides thereof can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between telomerase or the subunit protein and the agent being tested, may be measured.

Another technique for drug screening which may be used for high throughput screening of compounds having suitable binding affinity to the telomerase or telomerase protein subunit is described in detail in "Determination of Amino Acid Sequence Antigenicity" (Geysen, WO Application 84/03564, published on September 13, 1984, incorporated herein by reference). In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with fragments of telomerase or telomerase protein subunits and washed. Bound telomerase or telomerase protein subunit is then detected by standard methods developed for other applications well known in the art. Isolated or substantially purified telomerase or telomerase protein subunit can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding telomerase or subunit protein(s) specifically compete with a test compound for binding telomerase or the subunit protein. In this manner, the antibodies can be used to detect the presence of any peptide

which shares with the antibody the ability to bind one or more antigenic determinants with the telomerase or subunit protein.

### **Polynucleotides Encoding Telomerase Subunit Proteins and Their Applications**

5           A polynucleotide sequence encoding telomerase subunit proteins or any part thereof may be used for diagnostic and/or therapeutic purposes. For diagnostic purposes, the sequence encoding a telomerase subunit protein of this invention can be used to detect and quantitate gene expression of the telomerase or subunit protein. The diagnostic assay is useful to distinguish between absence, presence, and excess  
10   expression of telomerase, and to monitor regulation of telomerase levels during therapeutic intervention. Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules, and synthetic and non-naturally occurring analogues thereof, including, for example, nucleotides with non-ionic backbones, such as peptide nucleic acids (PNAs).

15           Another aspect of the subject invention is to provide hybridization or PCR probes or primers that are capable of detecting polynucleotide sequences, including genomic sequences, encoding telomerase subunit proteins or closely related molecules. The specificity of the probe, whether it is made from a highly specific region (*e.g.*, 10 unique nucleotides in the 5' regulatory region), or a less specific region (*e.g.*, especially  
20   in the 3' region), and the stringency of the hybridization or amplification (maximal, high, intermediate or low) will determine whether the probe identifies only naturally occurring telomerase, telomerase subunit proteins or related sequences of a particular telomerase or TRT species or all or some of the members of the genus of TRT polynucleotides.

25           Probes may also be used for the detection of related sequences and should preferably contain at least 50% of the nucleotides (identical or complementary) from any of these telomerase subunit protein-encoding sequences. The hybridization probes of the subject invention may be derived from the nucleotide sequence provided by the present invention (*e.g.*, SEQ ID NO:1, 3, 62, 66, 68, or 117), or from genomic  
30   sequences including promoter, enhancer elements and introns of the naturally occurring

sequences encoding telomerase subunit proteins. Hybridization probes may be labeled by a variety of reporter groups, including commercially available radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

5 Other means for producing specific hybridization probes for DNAs include the cloning of nucleic acid sequences encoding telomerase subunit proteins or derivatives into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA  
10 polymerase and the appropriate radioactively labeled nucleotides.

### **Diagnostic Applications**

Polynucleotide sequences encoding telomerase may be used for the diagnosis of conditions or diseases with which the abnormal expression of telomerase is associated.  
15 For example, polynucleotide sequences encoding human telomerase may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect telomerase expression. The form of such qualitative or quantitative methods may include Southern or northern analysis, dot blot or other membrane-based technologies; PCR technologies; dip stick, pin, chip and ELISA technologies. All of these techniques are  
20 well known in the art and are the basis of many commercially available diagnostic kits.

The telomerase-encoding nucleotide sequences disclosed herein provide the basis for assays that detect activation or induction associated with disease (including metastasis); in addition, the lack of expression of telomerase may be detected using the telomerase-encoding nucleotide sequences disclosed herein. The nucleotide sequence  
25 may be labeled by methods known in the art and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After an incubation period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off, the dye is quantitated and  
30 compared with a standard. If the amount of dye in the biopsied or extracted sample is

significantly elevated over that of a comparable control sample, the nucleotide sequence has hybridized with nucleotide sequences in the sample, and the presence of elevated levels of nucleotide sequences encoding telomerase in the sample indicates the presence of the associated disease. Alternatively, the loss of expression of human telomerase sequences in a tissue which normally expresses telomerase sequences indicates the presence of an abnormal or disease state.

Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an individual patient. In order to provide a basis for the diagnosis of disease, a normal or standard profile for human telomerase expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with human telomerase or a portion thereof, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained for normal subjects with a dilution series of human telomerase run in the same experiment where a known amount of isolated or substantially purified human telomerase is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients affected by telomerase-associated diseases. Deviation between standard and subject values establishes the presence of disease.

Once disease is established, a therapeutic agent is administered and a treatment profile is generated. Such assays may be repeated on a regular basis to evaluate whether the values in the profile progress toward or return to the normal or standard pattern. Successive treatment profiles may be used to show the efficacy of treatment over a period of several days or several months.

PCR, which may be used as described in US Patent Nos. 4,683,195, 4,683,202, and 4,965,188 (herein incorporated by reference) provides additional uses for oligonucleotides based upon the sequence encoding telomerase subunit proteins. Such oligomers are generally chemically synthesized, but they may be generated enzymatically or produced from a recombinant source. Double-stranded nucleic acids comprise two separate strands of nucleotide sequences, one with sense orientation (5' to

3') and one with antisense (3' to 5'), and can also be employed under optimized conditions for identification of a specific gene or condition. Oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Additionally, methods which may be used to quantitate the expression of a particular molecule include radiolabeling (Melby (1993) *J. Immunol. Meth.* 159:235-44) or biotinylating [Duplaa (1993) *Anal. Biochem.* 229-36) nucleotides, co-amplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation. A definitive diagnosis of this type may allow health professionals to begin aggressive treatment and prevent further worsening of the condition. Similarly, further assays can be used to monitor the progress of a patient during treatment. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known such as the triplet genetic code, specific base pair interactions, and the like.

### **Therapeutic Application**

Based upon its homology to other telomerase sequences, the polynucleotides encoding telomerase protein subunits disclosed herein can be useful in the treatment of metastasis; in particular, inhibition of telomerase expression may be therapeutic.

Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences (sense or antisense) to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense of a sequence encoding a telomerase subunit. See, for example, the techniques described in Sambrook and Ausubel.

The polynucleotides comprising full length cDNA sequence and/or its regulatory elements enable researchers to use the sequence encoding a telomerase subunit, including the various motifs as an investigative tool in sense (Yousoufian (1993) *Mol. Cell. Biol.* 13:98-104) or antisense (Eguchi (1991) *Ann. Rev. Biochem.* 60:631-652) regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers, or larger fragments, can be designed from various locations along the coding or control regions.

Genes encoding a telomerase subunit can be turned off by transfecting a cell or tissue with expression vectors which express high levels of a desired telomerase fragment. Such constructs can flood cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA, PNA, or the like, to the control regions of the sequence encoding human telomerase (*i.e.*, the promoters, enhancers, and introns). Oligonucleotides derived from the transcription initiation site, (e.g., between -10 and +10 regions of the leader sequence) are preferred for some applications. The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules (for a review of recent therapeutic advances using triplex DNA, see Gee *et al.*, in Huber and Carr, *Molecular and Immunologic Approaches*, Futura Publishing Co, Mt Kisco NY, 1994).

### **Inhibitory Oligonucleotides**

One particularly useful set of inhibitors provided by the present invention includes oligonucleotides which are able to either bind mRNA encoding TRT protein or

to the TRT gene, in either case preventing or inhibiting the production of functional TRT protein. Other oligonucleotides of the invention interact with telomerase's RNA moiety, such as hTR, or are able to prevent binding of telomerase or TRT to its DNA target, or one telomerase component to another, or to a substrate. Such

5 oligonucleotides can also bind the telomerase enzyme or TRT protein and inhibit a partial activity as described herein (such as its processive activity, its RT activity, its nucleolytic activity, and the like). The association can be through sequence specific hybridization to another nucleic acid or by general binding, as in an aptamer.

Another useful class of inhibitors includes oligonucleotides which cause  
10 inactivation or cleavage of hTRT mRNA or hTR. That is, the oligonucleotide is chemically modified or has enzyme activity which causes such cleavage, such as ribozymes. As noted above, one may screen a pool of many different such oligonucleotides for those with the desired activity.

Another useful class of inhibitors includes oligonucleotides which bind  
15 polypeptides. Double- or single-stranded DNA or single-stranded RNA molecules that bind to specific polypeptide targets are called "aptamers." The specific oligonucleotide-polypeptide association may be mediated by electrostatic interactions. For example, aptamers specifically bind to anion-binding exosites on thrombin, which physiologically binds to the polyanionic heparin (Bock (1992) *Nature* 355:564-566).  
20 Because TRT protein binds both hTR and its DNA substrate, and because the present invention provides hTRT and other TRT proteins in isolated and substantially purified form in large quantities, those of skill in the art can readily screen for TRT-binding aptamers using the methods of the invention.

Antagonists of telomerase-mediated DNA replication can also be based on  
25 inhibition of TR, such as hTR (Norton (1996) *Nature Biotechnology* 14:615-619) through complementary sequence recognition or cleavage, as through ribozymes. Such agents can be used in combination with those of the invention to enhance the desired effect.

Telomerase activity can be inhibited by targeting the TRT mRNA with  
30 antisense oligonucleotides capable of binding the TRT mRNA. In some situations,

naturally occurring nucleic acids used as antisense oligonucleotides may need to be relatively long (18 to 40 nucleotides) and present at high concentrations. A wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, as discussed above, PNAs containing non-ionic backbones, such as N-(2-aminoethyl) glycine units can be used. Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197; Antisense Therapeutics, ed. Sudhir Agrawal (Humana Press, Totowa, New Jersey, 1996). Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and morpholino carbamate nucleic acids, as described above.

As noted above, combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the TRT proteins of the invention (for general background information, see Gold (1995) *J. of Biol. Chem.* 270:13581-13584).

## **Inhibitory Ribozymes**

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of the sequence encoding human telomerase.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene

containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

5               Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA. Thus, the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in  
10 such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.

              In some circumstances, the enzymatic nature of a ribozyme can be advantageous  
15 over other technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide. This potential advantage reflects the ability of the ribozyme to act enzymatically. Thus, a  
20 single ribozyme molecule is able to cleave many molecules of target RNA. In addition, a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity  
25 is defined as the ratio of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.

The enzymatic ribozyme RNA molecule has complementarity to the target, such as the mRNA encoding TRT. The enzymatic ribozyme RNA molecule is able to cleave RNA and thereby inactivate a target RNA molecule. The complementarity functions to allow sufficient hybridization of the enzymatic ribozyme RNA molecule to the target RNA for cleavage to occur. One hundred percent complementarity is preferred, but complementarity as low as 50-75% may also be employed. The present invention provides ribozymes targeting any portion of the coding region for a TRT gene that cleave the TRT gene mRNA in a manner that will inhibit the translation of the mRNA and thus reduce telomerase activity. In addition, the invention provides ribozymes targeting the nascent RNA transcript of the TRT gene to reduce telomerase activity.

The enzymatic ribozyme RNA molecule can be formed in a hammerhead motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) *Aids Research and Human Retroviruses* 8:183; hairpin motifs by Hampel (1989) *Biochemistry* 28:4929, and Hampel (1990) *Nuc. Acids Res.* 18:299; the hepatitis delta virus motif by Perrotta (1992) *Biochemistry* 31:16; the RNaseP motif by Guerrier-Takada (1983) *Cell* 35:849; and the group I intron by Cech U.S. Pat. No. 4,987,071. The recitation of these specific motifs is not intended to be limiting; those skilled in the art will recognize that an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequences within or surrounding that substrate binding site that impart an RNA cleaving activity to the molecule.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding human telomerase and/or telomerase protein subunits. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively,

antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues.

RNA molecules can be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking  
5 sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine and wybutosine as well as acetyl-, methyl-, thio- and similarly modified forms of adenine,  
10 cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Methods for introducing vectors into cells or tissues include those methods discussed *infra*, and which are equally suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors can be introduced into cells, such as stem cells, taken from  
15 the patient and clonally propagated for autologous transplant back into that same patient, as is presented in a different context in US Patent Nos. 5,399,493 and 5,437,994, the disclosure of which is herein incorporated by reference. Delivery by transfection and by liposome are quite well known in the art and applicable to the present invention.

20

#### **Detection and Mapping of Related Polynucleotide Sequences in Other Genomes**

The nucleic acid sequence encoding *E. aediculatus*, *S. cerevisiae*, *S. pombe*, and mammalian, *e.g.*, human, telomerase subunit proteins and sequence variants thereof,  
25 can also be used to generate hybridization probes for mapping the naturally occurring homologous genomic sequence in human and other genomes. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include *in situ* hybridization to chromosomal spreads, flow-sorted chromosomal preparations, or artificial chromosome constructions such as  
30 yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1

constructions or single chromosome cDNA libraries, as reviewed by Price (1993) *Blood Rev.* 7:127; and Trask (1991) *Trends Genet.* 7:149.

5 The technique of fluorescent *in situ* hybridization (FISH) of chromosome spreads has been described (Verma (1988) *Human Chromosomes: A Manual of Basic Techniques*, Pergamon Press, New York, NY). Fluorescent *in situ* hybridization of chromosomal preparations and other physical chromosome mapping techniques can be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of *Science* (265:1981f). Correlation between the location of the sequence encoding a telomerase unit protein on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with the disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals.

15 *In situ* hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps (*See e.g.*, Hudson (1995) *Science* 270:1945). Often the placement of a gene on the chromosome of another mammalian species such as mouse (Whitehead Institute/MIT Center for Genome Research, Genetic Map of the Mouse, Database Release 10, April 28, 1995) may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques.

## 25 **Optimizing Expression of Telomerase and TRT**

In bacterial and other expression systems, codon usage is known to present a potential impediment to high-level gene expression. "Rare" codons, depending on their frequency and context in an mRNA, can have an adverse effect on levels of protein translated therefrom. The problem, if encountered, can be alleviated by modification of the relevant codons or by coexpression of the cognate tRNA genes or by other means.

30

Use of protease-deficient host strains can also increase yields from bacterial expression systems, see Makrides (1996) *Microbiol Rev* 60:512-538.

One can optimize levels of expression of telomerase and TRT by vector design modifications, such as using exogenous transcriptional regulatory elements. For example, as discussed below, the myeloproliferative sarcoma virus (MPSV) LTR promoter consistently drives higher expression levels in some mammalian cell lines.

Generally, those of skill in the art recognize that nucleic acids having certain specific sequences can be poorly expressed in one cell and expressed well in other cells. As a precaution, one should avoid including extraneous sequences, *i.e.*, non-coding sequences such as 3' untranslated sequences from a cDNA, with the desired coding sequence. Thus, one optimization strategy involves removing all extraneous sequences from the coding sequence insert. This strategy can in some circumstances increase protein expression 5 to 10 fold in bacteria, insect, yeast, mammalian and other cells expression systems.

Gene amplification, whether by higher vector copy number or by replication of a gene in a chromosome, can increase yields of recombinant proteins in mammalian and other cells. One *in vitro* amplification method for heterologous gene expression in mammalian cells is based on the stable transfection of cells with long, linear DNA molecules having several copies of complete expression units, coding for the gene of interest, linked to one terminal unit coding for a selectable marker. As another example, gene amplification of the gene of interest can be achieved by linking it to a dihydrofolate reductase (Dhfr) gene and administering methotrexate to the transfected cells; this method can increase recombinant protein production many fold (see Monaco (1996) *Gene* 180:145-150).

### **Production and Expression of and Screening with Telomerase and TRT**

In one embodiment, the invention provides screening assays to identify modulators of telomerase activity in animals and plants. The screening assay can utilize telomerase or TRT derived by a full or partial reconstitution of telomerase activity, or by an augmentation of existing activity. The assay or screens provided by

the invention can be used to test for the ability of telomerase to synthesize telomere DNA or to test for any one or all or of the “partial activities” of TRT and TRTs generally, as described above. The assay can incorporate *ex vivo* modification of cells which have been manipulated to express telomerase with or without its RNA moiety or associated proteins, and these can be reimplanted into an animal, which can be used for *in vivo* testing. Thus, this invention provides *in vivo* assays and transgenic animals useful therein. These *in vivo* assays systems can employ “knockout” cells, in which one or several units of the endogenous telomerase enzyme complex have been deleted or inhibited, as well as cells in which an exogenous or endogenous telomerase activity is reconstituted or activated.

The invention also contemplates a method of screening for telomerase modulators in animals by reconstituting a telomerase activity, or an anti-telomerase activity, into an animal, such as a transgenic animal. The invention provides for *in vivo* assays systems that include “knockout” models, in which one or several units of the endogenous telomerase, such as TRT, telomerase RNA moiety and/or telomerase-associated proteins have been deleted or inhibited. The endogenous telomerase activity, full or partial, can remain. The “knockout” of such genes includes knocking out of cell lines, tissues, or entire animals, as with transgenic animals.

In one embodiment, an exogenous telomerase activity, full or partial, is reconstituted. The transgenic animals of the invention also provide for methods of expressing large amounts of fully or partially active telomerase compositions of the invention, such as TRT. Such transgenic animals also provide for a means of producing indefinitely proliferating cells and immortalization of otherwise normal cells, which can then be used to express compositions of interest.

In one embodiment of the invention, recombinant telomerase or TRT is expressed in normal, diploid mortal cells to create indefinitely proliferating cells or to immortalize them, or to facilitate long-term culture or replication of the cells. Other telomerase enzyme complex components, such as nucleic acid telomeric sequence template molecules (hTR, for example) or other associated proteins, that are beneficial for expression or act as modulators of activity, can also be co-expressed. This

invention provides methods to obtain diploid indefinitely proliferating or immortal cells with an otherwise normal phenotype and karyotype. This aspect of the invention is of enormous practical and commercial utility; for example, the FDA and public would value the production of recombinant proteins from normal cells to minimize concern regarding viral or other contamination of the products made from such cells. The present invention allows one to produce indefinitely proliferating or immortal hybrids of human B lymphocytes and myeloma cells to obtain human hybridomas for human monoclonal antibody production. Using the methods of this invention, transfection of TRT protein or telomerase activity into human B lymphocytes allows one to generate in definitely proliferating or immortal cells for antibody production. Another embodiment provides for methods for introducing recombinant telomerase and/or telomerase associated RNA and other compounds of the invention into cells to produce a commercially desirable protein. For example, by the methods of the invention an indefinitely proliferating or immortal, yet karyotypically normal, human pituitary cell that makes hormones, such as growth hormone, could be produced for commercial use. In a variation of this embodiment, a normal human cell is removed from the body, and a state of indefinite proliferation or immortalization is created using the methods and reagents of the invention; the cell is then transfected with a gene of interest such that the gene is expressed at appropriate levels; and, the modified cell is introduced back into the individual such that the transfected gene expresses a molecule that impacts the health of the individual.

Another embodiment of the invention involves a similar method, but the cell is a “universal donor cell” which has been modified to delete histocompatibility antigens or modified in some way to prevent or decrease the possibility of immune rejection. A complication arising from the reintroduction of these cells into an individual is the possibility that the cells may lose growth control and change to a state of uncontrolled cell growth, becoming a cancer, tumor or other malignancy. The present invention solves this complication by providing means to express TRT or other telomerase components conditionally and/or by providing means for knocking out the telomerase (or a telomerase enzyme complex component necessary for activity). Moreover, even

“mortal” cells used in transplantation or for other purposes can be mortalized by the methods of the invention. Without an active telomerase, the cells are irreversibly mortal, thus decreasing the probability of cancerous or malignant transformation after transplantation or other reintroduction into a host organism. This would not affect the cell’s function, as telomerase is not normally active in somatic cells.

Means to provide TRT and other telomerase components conditionally, *i.e.*, controllable expression in the host cell, tissue or animal, includes use of antisense constructs which, when signaled to express the antisense nucleotide in the appropriate cell or tissue, inhibits telomerase activity and stops the cell from dividing. Expression of recombinant antibody binding components intracellularly can also be used for this purpose. Inducible and/or tissue-specific cis- and/or trans-acting transcriptional and translational regulatory elements can be used to control expression of TRT and other telomerase components. Examples of cis-acting transcriptional regulatory elements include promoters and enhancers of the telomerase gene. Examples of cis-acting translational regulatory elements include elements that stabilize mRNA or protect the transcript from degradation. The identification and isolation of cis- and trans- acting regulatory agents provide for further methods and reagents for identifying agents that modulate transcription and translation of telomerase.

The invention also provides transgenic animals and methods for expressing the telomerase and TRT compositions of the invention in such animals, as well as otherwise normal cells that can be used to express compositions of interest and can be used in related methods. The invention also provides transgenic animals expressing endogenous or exogenous TRT, either alone or co-expressed with the enzyme’s RNA moiety or other telomerase-associated proteins. The invention provides for transgenic animals and recombinant cells to be used, for example, as bioreactors (Khillan (1997) *Methods Mol. Biol.* 63:327-342) to produce large amounts of telomerase, TRT and other proteins of the invention. To create a living assay system to screen for modulators of TRT, a non-human animal model can be used. In this non-human animal, the endogenous telomerase can be first debilitated, or “knocked out” before introducing a recombinant TRT, TR and/or other telomerase-associated components.

Telomerase-expressing nucleic acid of the invention may be introduced into the genome of an animal or plant host organism by a variety of conventional techniques (Jacenko (1997) *Methods Mol. Biol.* 62, 399-424). For example, recent advances in transgenic and gene-targeting approaches allow a sophisticated manipulation of the mouse genome by gene addition, gene deletion, or gene modifications, making this animal convenient for the methods of the invention (Franz (1997) *J. Mol. Med.* 75:115-129; Peterson (1997) *Genet. Eng. (NY)* 19:235-255). Many cloning vectors for transgene construction are known in the art, for example, as in Yang (1997) *Biotechniques* 22:1032-1034. There are two well-established procedures for simple introduction of DNA into animal genomes, pronuclear DNA injection and transduction using a retrovirus (Wei (1997) *Annu. Rev. Pharmacol. Toxicol.* 37:119-141). Microinjection techniques for use in introducing DNA into animals and plants are known in the art and described in the scientific and patent literature. The introduction of DNA constructs into cells using polyethylene glycol precipitation is described in Paszkowski (1984) *EMBO J.* 3:2717. Electroporation techniques are described in Fromm (1985) *Proc. Natl. Acad. Sci. USA* 82:5824. Ballistic transformation techniques are described in Klein (1987) *Nature* 327:70.

The invention also provides transgenic plants and methods for expressing the telomerase and TRT compositions of the invention and screening assays to identify modulators of telomerase activity in such plants. In plants, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the DNA constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. As discussed above, plant virus vectors such as tobacco mosaic virus containing the telomerase sequences of the invention can be used to inoculate a plant (Rouwendal (1997) *Plant Mol Biol* 33:989-999).

### **Pharmaceutical Compositions**

The present invention also relates to pharmaceutical compositions that comprise telomerase and/or telomerase subunit nucleotides, proteins, antibodies, agonists,

antagonists, or inhibitors, alone or in combination with at least one other agent, such as a stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. Any of these molecules can be administered to a patient alone, or in  
5 combination with other agents, drugs or hormones, in pharmaceutical compositions where it is mixed with suitable excipient(s), adjuvants, and/or pharmaceutically acceptable carriers. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert.

10 **Administration Of Pharmaceutical Compositions**

Administration of pharmaceutical compositions is accomplished orally or parenterally. Methods of parenteral delivery include topical, intra-arterial (*e.g.*, directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. In addition to the active  
15 ingredients, these pharmaceutical compositions can contain suitable pharmaceutically acceptable carriers comprising excipients and other compounds that facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration can be found in the latest edition of "Remington's Pharmaceutical Sciences" (Maack  
20 Publishing Co, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc.,  
25 suitable for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or  
30 protein fillers include, but are not limited to sugars, including lactose, sucrose,

mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound (*i.e.*, dosage).

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations for parenteral administration include aqueous solutions of active compounds. For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension can also contain suitable

stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally  
5 known in the art.

### **Manufacture And Storage**

The pharmaceutical compositions of the present invention can be manufactured in substantial accordance with standard manufacturing procedures known in the art  
10 (*e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes).

The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic  
15 solvents that are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions comprising a compound of the invention formulated in a acceptable carrier have been prepared, they can be placed in an  
20 appropriate container and labeled for treatment of an indicated condition. Such labeling would typically include amount, frequency and method of administration.

### **Therapeutically Effective Dose**

Pharmaceutical compositions suitable for use in the present invention include  
25 compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in an appropriate animal model. The animal model is  
30 also used to achieve a desirable concentration range and route of administration. Such

information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of protein or its antibodies, antagonists, or inhibitors which ameliorate the symptoms or condition.

5 Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals (*e.g.*, ED<sub>50</sub>, the dose therapeutically effective in 50% of the population; and LD<sub>50</sub>, the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD<sub>50</sub>/ED<sub>50</sub>. Pharmaceutical compositions  
10 which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the  
15 route of administration.

The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state (*e.g.*, tumor size and location); age,  
20 weight and gender of the patient; diet; time and frequency of administration; drug combination(s); reaction sensitivities; and tolerance/response to therapy. Long acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks, depending on half-life and clearance rate of the particular formulation. Guidance as to particular dosages and methods of delivery is provided in  
25 the literature (*see*, US Patent Nos. 4,657,760; 5,206,344; and 5,225,212, herein incorporated by reference). Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, and the like.

It is contemplated, for example, that human telomerase can be used as a therapeutic molecule to combat disease (*e.g.*, cancer) and/or other problems associated with aging. It is further contemplated that antisense molecules capable of reducing the expression of human telomerase or telomerase protein subunits can be used as  
5 therapeutic molecules to treat tumors associated with the aberrant expression of human telomerase. Still further, it is contemplated that antibodies directed against human telomerase and capable of neutralizing the biological activity of human telomerase can be used as therapeutic molecules to treat tumors associated with the aberrant expression of human telomerase and/or telomerase protein subunits.

10

### DEFINITIONS

To facilitate understanding the invention, a number of terms are defined below.

"Affinity purification" as used herein refers to the purification of  
ribonucleoprotein particles, through the use of an "affinity oligonucleotide" (*i.e.*, an  
15 antisense oligonucleotide) to bind the particle, followed by the step of eluting the particle from the oligonucleotide by means of a "displacement oligonucleotide." In the present invention, the displacement oligonucleotide has a greater degree of complementarity with the affinity oligonucleotide, and therefore produces a more thermodynamically stable duplex than the particle and the affinity oligonucleotide. For  
20 example, telomerase may be bound to the affinity oligonucleotide and then eluted by use of a displacement oligonucleotide which binds to the affinity oligonucleotide. In essence, the displacement oligonucleotide displaces the telomerase from the affinity oligonucleotide, allowing the elution of the telomerase. Under sufficiently mild conditions, the method results in the enrichment of functional ribonucleoprotein  
25 particles. Thus, the method is useful for the purification of telomerase from a mixture of compounds.

"Alterations in the polynucleotide" as used herein comprise any alteration in the sequence of polynucleotides encoding telomerases, including deletions, insertions, and point mutations, which can be detected using hybridization assays. Included within this  
30 definition is the detection of alterations to the genomic DNA sequence which encodes

telomerase (*e.g.*, by alterations in pattern of restriction enzyme fragments capable of hybridizing to any sequence such as SEQ ID NOS: 1 or 3, *e.g.*, RFLP analysis, the inability of a selected fragment of any sequence to hybridize to a sample of genomic DNA, *e.g.*, using allele-specific oligonucleotide probes, improper or unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the telomere or telomerase genes *e.g.*, using FISH to metaphase chromosomes spreads, etc.).

The term "amino acid sequence" as used herein refers to peptide or protein sequence.

10 "Amplification" is defined as the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) or other technologies well known in the art (*e.g.*, Dieffenbach and Dveksler, *PCR Primer, a Laboratory Manual*, Cold Spring Harbor Press, Plainview NY, 1995). As used herein, the term "polymerase chain reaction" ("PCR") refers to the method of K.B. Mullis (U.S. Patent Nos. 4,683,195 and 4,683,202, hereby incorporated by reference), which describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing and polymerase extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable

15  
20  
25  
30

parameter. By virtue of the repeating aspect of the process, the method is referred to as the "polymerase chain reaction" (hereinafter "PCR"). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified".

5           As used herein, the terms "amplification product" and "PCR product" refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences. With PCR, it is possible to amplify a single copy of a specific target  
10       sequence in genomic DNA to a level detectable by several different methodologies (*e.g.*, hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of <sup>32</sup>P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide sequence can be amplified with the appropriate set  
15       of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications. Amplified target sequences may be used to obtain segments of DNA (*e.g.*, genes) for insertion into recombinant vectors.

          The term "antibody" refers to a polypeptide substantially encoded by an  
20       immunoglobulin gene or immunoglobulin genes, or fragments or synthetic or recombinant analogues thereof which specifically bind and recognize analytes and antigens. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or  
25       lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one  
30       "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily

responsible for antigen recognition. The terms variable light chain ( $V_L$ ) and variable heavy chain ( $V_H$ ) refer to these light and heavy chains respectively. Antibodies exist, *e.g.*, as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases, *see*, FUNDAMENTAL IMMUNOLOGY, 3RD ED., W.E. Paul, ed., Raven Press, N.Y. (1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodologies, for example, recombinant single chain Fv or antibodies or fragments thereof displayed on the surface of a phage, virus or a cell. The term immunologically reactive conditions refers to an environment in which antibodies can bind to antigens, such as a TRT of the invention. As discussed below, this can be an immunological binding assay. The phrase "specifically binds to an antibody" when referring to a protein or peptide, refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies specific for a telomerase TRT protein of this invention or to any portion of a protein defined by a TRT sequence can be selected to immunoreact specifically with all TRT species of the invention or only a single TRT specie of the invention, and not with other non-telomerase proteins. As described below, a variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Publications, New York (Harlow and Lane), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. A specific or selective reaction is one which generates, for example, a signal at least twice (2X) over background signal or "noise."

The term "antigenic determinant" as used herein refers to that portion of an antigen that makes contact with a particular antibody (*i.e.*, an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (*i.e.*, the immunogen used to elicit the immune response) for binding to an antibody.

As used herein, the term "antisense" is used in reference to RNA sequences or other oligonucleotides or nucleic acids, including those containing or composed entirely of synthetic or non-naturally occurring nucleotides or linkages, which are complementary to a specific RNA sequence (*e.g.*, mRNA). Antisense RNA may be produced by any method, including synthesis by splicing the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a coding strand. Once introduced into a cell, this transcribed strand combines with natural mRNA produced by the cell to form duplexes. These duplexes then block either the further transcription of the mRNA or its translation. In this manner, mutant or altered phenotypes may be generated. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. The designation (-) (*i.e.*, "negative") is sometimes used in reference to the antisense strand, with the designation (+) sometimes used in reference to the sense (*i.e.*, "positive") strand.

The term "biologically active" refers to telomerase (or other) molecules or peptides having structural, regulatory, or biochemical functions of a naturally occurring telomerase (or other) molecule or peptide. Likewise, "immunologically active," defines the capability of the natural, recombinant, or synthetic telomerase proteins or any polypeptide or oligopeptide thereof, to induce a specific immune response in appropriate animals or cells, and to bind with specific antibodies.

As used herein, the term "capable of replicating telomeric DNA" refers to the ability of functional telomerase enzymes to perform the function of replicating DNA located in telomeres. It is contemplated that this term encompass the replication of

telomeres, as well as sequences and structures that are commonly found located in telomeric regions of chromosomes. For example, "telomeric DNA" includes, but is not limited to the tandem array of repeat sequences found in the telomeres of most organisms.

5           As used herein, the term "ciliate" refers to any of the protozoans belonging to the phylum Ciliophora.

          As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (*i.e.*, a sequence of nucleotides) related by the base-pairing rules. For example, for the sequence "5'-A-G-T-3'," is complementary to the sequence  
10   "3'-T-C-A-5'." Complementarity may be "partial," in which only some of the nucleotide bases of the double stranded nucleic acid are matched according to the base pairing rules. Or, there may be "complete" or "total" complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid  
15   strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon binding between nucleic acids.

          The term "conservative substitution" refers to a change in the amino acid composition of a protein, such as the TRT of the invention, to a "conservative variant," such that the change(s) do not substantially alter the protein's (the conservative  
20   variant's) activity and corresponding changes in nucleotide sequences of nucleic acids. This includes conservatively modified variations of a particular amino acid sequence, *i.e.*, amino acid substitutions of those amino acids that are not critical for protein activity or substitution of amino acids with other amino acids having similar properties (*e.g.*, acidic, basic, positively or negatively charged, polar or non-polar, *etc.*) such that  
25   the substitutions of even critical amino acids does not substantially alter activity. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine  
30   (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6)

Phenylalanine (F), Tyrosine (Y), Tryptophan (W) (see also, Creighton (1984) *Proteins*, W.H. Freeman and Company). One of skill in the art will appreciate that the above-identified substitutions are not the only possible conservative substitutions. For example, for some purposes, one may regard all charged amino acids as conservative substitutions for each other whether they are positive or negative. In addition, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence can also be considered "conservatively modified variations." The term "conservative substitution" also refers to a change in a nucleic acid sequence to a "conservative variant," such that the substitution does not substantially alter the contemplated activity of the (conservative variant) nucleic acid, for example, as not changing the activity of the protein encoded by the unchanged nucleic acid. A nucleic acid sequence of the invention implicitly encompasses conservative (modified) variants thereof (*e.g.* degenerate codon substitutions) and complementary sequences and as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer (1991) *Nucleic Acid Res.* 19:5081; Ohtsuka (1985) *J. Biol. Chem.* 260:2605-2608; Rossolini (1994) *Mol. Cell. Probes* 8:91-98).

The term "correlates with expression of a polynucleotide," as used herein, indicates that the detection of the presence of ribonucleic acid (RNA) complementary to a telomerase sequence by hybridization assays is indicative of the presence of mRNA encoding eukaryotic telomerases, including human telomerases in a sample. Such correlation can include expression of the telomerase mRNA from the gene encoding the protein.

A "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

The term "derivative" as used herein refers to the chemical structure of a molecule and modifications of such structures, as, for example, a nucleic acid encoding telomerase structures, such as the 123 kDa or 43 kDa protein subunits of the *E.*

*aediculatus* telomerase, or other telomerase proteins or peptides. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative includes a nucleic acid that would encode a polypeptide which retains essential biological characteristics of naturally-occurring telomerase or its subunits.

As used herein, the term "eukaryote" refers to organisms distinguishable from "prokaryotes." It is intended that the term encompass all organisms with cells that exhibit the usual characteristics of eukaryotes such as the presence of a true nucleus bounded by a nuclear membrane, within which lie the chromosomes, the presence of membrane-bound organelles, and other characteristics commonly observed in eukaryotic organisms. Thus, the term includes, but is not limited to such organisms as fungi, protozoa, and animals (*e.g.*, humans).

As used herein, the term "*Euplotes* telomerase polypeptide," refers to a polypeptide which comprises at least a portion of the *Euplotes* telomerase structure. The term encompasses the 123 kDa and 43 kDa polypeptide or protein subunits of the *Euplotes* telomerase. It is also intended that the term encompass variants of these protein subunits. It is further intended to encompass the polypeptides encoded by SEQ ID NOS: 1 and 3. As molecular weight measurements may vary, depending upon the technique used, it is not intended that the present invention be precisely limited to the 123 kDa or 43 kDa molecular masses of the polypeptides encoded by SEQ ID NOS:1 and 3, as determined by any particular method such as SDS-PAGE.

The term "expression vector" or "vector" refers to any recombinant expression system for the purpose of expressing a nucleic acid sequence of the invention *in vitro* or *in vivo*, constitutively or inducibly, in any cell, including a prokaryotic, yeast, fungal, plant, insect or mammalian cell. The expressed nucleic acid sequence is inserted in (spliced into) the vector. The term includes linear or circular nucleic acid expression systems, such as those that remain episomal or integrate into the host cell genome. The expression systems can have the ability to self-replicate or not, *i.e.*, drive only transient expression in a cell. The term includes recombinant expression "cassettes" which

contain only the minimum elements needed for transcription of a recombinant nucleic acid.

The terms "homology," "sequence identity" and "sequence similarity" refers to a degree of complementarity or sequence identity. There may be partial homology or complete homology (*i.e.*, identity). A partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid and can be referred to using the functional term as "substantially homologous" to the completely complementary sequence. The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (*i.e.*, the hybridization) of a completely homologous to a target under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding may be tested by the use of a second target which lacks even a partial degree of complementarity; in the complete absence of non-specific binding the probe will not hybridize to the second non-complementary target. The terms "sequence identity," "sequence similarity" and "homology" refer to when two sequences, such as the nucleic acid and amino acid sequences of the hTRT proteins of the telomerase of the invention, when optimally aligned, as with the programs BLAST, GAP, FASTA or BESTFIT, share at least 40 percent to 50 percent sequence identity, and preferably at least 60 percent or greater sequence identity. "Percentage amino acid sequence identity" refers to a comparison of the sequences of two TRT nucleic acids or polypeptides which, when optimally aligned, have approximately the designated percentage of the same nucleotides or amino acids, respectively. For example, "60% sequence identity" and "60% homology" refer to a comparison of the sequences of two nucleic acids or polypeptides which, when optimally aligned, have 60% identity. An additional algorithm that is suitable for determining sequence similarity is the BLAST

algorithm, which is described in Altschul (1990) *J. Mol. Biol.* 215: 403-410; Shpaer (1996) *Genomics* 38:179-191. Software for performing BLAST analyses is publicly available at National Center for Biotechnology Information

(<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al, supra.*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.

The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The term BLAST refers to the BLAST algorithm which performs a statistical analysis of the similarity between two sequences; see, e.g., Karlin (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.

The term “a TRT polypeptide comprising an amino acid sequence with significant sequence identity to a motif” refers to TRT proteins which are considered to have a statistically significant sequence identity, *i.e.*, have significant homology or significantly identical, at the amino acid sequence level in a conserved region of the TRT protein, such as the motif sequences defined herein. Two TRT proteins are considered to have a statistically significant sequence identity in the conserved region

if, after adjusting for deletions, additions and the like, the conserved regions have about 20% to 30% sequence identity or greater sequence identity. For example, this sequence identity can be higher, for example, about 40% to 50% or higher if the region of comparison is shorter, *i.e.*, a region of about ten consecutive amino acids.

5           The term "hybridization" as used herein includes "any process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs, *Dictionary of Biotechnology*, Stockton Press, New York NY, 1994). As used herein the term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be  
10           further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (*e.g.*,  $C_0t$  or  $R_0t$  analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized to a solid  
15           support, *e.g.*, a nylon membrane or a nitrocellulose filter as employed in Southern and Northern blotting, dot blotting or a glass slide as employed in *in situ* hybridization, including FISH (fluorescent *in situ* hybridization).

          The term "specifically hybridizes" refers to a nucleic acid that hybridizes, duplexes or binds to a particular target DNA or RNA sequence. The target sequences  
20           can be present in a preparation of total cellular DNA or RNA. Proper annealing conditions depend, for example, upon a nucleic acid's, such as a probe's length, base composition, and the number of mismatches and their position on the probe and corresponding target, and can be readily determined empirically providing the appropriate reagents are available. For discussions of nucleic acid probe design and  
25           annealing conditions, see, for example, Sambrook and Ausubel. The terms "stringent hybridization," "stringent hybridization conditions," "stringent conditions," or "specific hybridization conditions" refer to conditions under which an oligonucleotide (when used, for example, as a probe or primer) will hybridize to its target subsequence, such as a TRT recombinant sequence of a nucleic acid in a biological sample but not to a  
30           non-telomerase sequence. Stringent conditions are sequence-dependent. Thus, in one

set of stringent conditions an oligonucleotide probe will hybridize to only one specie of the genus of TRT of the invention. In another set of stringent conditions an oligonucleotide probe will hybridize to all species of the invention's genus of TRT but not to non-telomerase nucleic acids. Longer sequences hybridize specifically at higher temperatures. Stringent conditions are selected to be about 5°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium (if the target sequences are present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, *i.e.*, about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60°C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Often, high stringency wash conditions are preceded by low stringency wash conditions to remove background probe signal. An example of medium stringency wash conditions for a duplex of, *e.g.*, more than 100 nucleotides, is 1x SSC at 45°C for 15 minutes (see Sambrook). An example, low stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 4x to 6x SSC at 40°C for 15 minutes. A signal to noise ratio of 2x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a "specific hybridization." Nucleic acids which do not hybridize to each other under stringent conditions can still be substantially identical if the polypeptides which they encode are substantially identical. This can occur, *e.g.*, when a nucleic acid is created that encodes for conservative substitutions. Stringent hybridization and stringent hybridization wash conditions are different under different environmental parameters, such as for Southern and Northern hybridizations. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993)

LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY-

HYBRIDIZATION WITH NUCLEIC ACID PROBES, part I, chapt. 2, Overview of Principles of Hybridization and the Strategy of Nucleic Acid Probe Assays, Elsevier, NY.

An "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to, naturally occurring sequences.

As used herein, "isolated" or "purified" when referring to a molecule or composition, such as, for example, a TRT polypeptide or nucleic acid or a telomerase-associated polypeptide or nucleic acid, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (*e.g.*, RNAs), or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, for example, a TRT is considered isolated when the TRT has been isolated from any other component with which it is naturally associated, *e.g.*, cell membrane, as in a cell extract. An isolated composition can, however, also be substantially pure.

The term "label" refers to a detectable composition, such as by spectroscopic, photochemical, biochemical, immunochemical, physical or chemical means. For example, useful labels include  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , fluorescent dyes (*e.g.*, FITC, rhodamine, lanthanide phosphors), electron-dense reagents, enzymes, *e.g.*, as commonly used in an ELISA (*e.g.*, horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available. The label can be directly incorporated into a nucleic acid, peptide or other target compound to be detected, or it can be attached to a probe or antibody which hybridizes or binds to the target. A peptide can be made detectable by incorporating predetermined polypeptide epitopes recognized by a secondary reporter (*e.g.*, leucine zipper pair sequences, binding sites for secondary antibodies, transcriptional activator polypeptide, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance or impact on other useful or desired properties. See for example, Mansfield (1995) *Mol Cell Probes* 9:145-156.

As used herein, the term "macronucleus" refers to the larger of the two types of nuclei observed in the ciliates. This structure is also sometimes referred to as the "vegetative" nucleus. Macronuclei contain many copies of each gene and are transcriptionally active.

5           As used herein, the term "micronucleus" refers to the smaller of the two types of nuclei observed in the ciliates. This structure is sometimes referred to as the "reproductive" nucleus, as it participates in meiosis and autogamy. Micronuclei are diploid and are transcriptionally inactive.

          "Nucleic acid sequence" or "oligonucleotide" as used herein refers to a  
10   deoxyribonucleotide or ribonucleotide oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of natural or synthetic origin which may be single- or double-stranded, or contain a sense or antisense strand. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogues of natural nucleotides which have similar or improved binding or other properties, for the  
15   purposes desired, as the reference nucleic acid. The term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved thereover for the purposes desired. The term also encompasses nucleic-acid-like structures with synthetic backbones. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate,  
20   phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and other nucleic acids; see Oligonucleotides and Analogues, A Practical Approach, edited by F. Eckstein, IRL Press at Oxford University Press (1991); Antisense Strategies, Annals of the New York Academy of Sciences, Volume 600, Eds.  
25   Baserga and Denhardt (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; Antisense Research and Applications (1993, CRC Press) in its entirety and specifically Chapter 15, by Sanghvi, entitled "Heterocyclic base modifications in nucleic acids and their applications in antisense oligonucleotides." "Peptide nucleic acid" or "PNA" as used herein refers to an oligomeric molecule in which nucleosides are joined by  
30   peptide, rather than phosphodiester, linkages. These small molecules, also designated

anti-gene agents, stop transcript elongation by binding to their complementary (template) strand of nucleic acid (Nielsen (1993) *Anticancer Drug Des.* 8:53-63).

PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units, as

described in USSN 08/630,019, filed 9 April 1996, and the US CIP USSN 08/838,545

5 and PCT application PCT/US/97/05931, both filed on April 9, 1997. Phosphorothioate linkages are described in WO 97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197. Other synthetic backbones encompasses by the term include methylphosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) *Biochemistry* 36:8692-8698), and benzylphosphonate  
10 linkages which, compared with unmodified oligonucleotides and methylphosphonates, are more stable against nucleases and exhibit a higher lipophilicity (Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product. The term "exogenous nucleic acid" refers to a nucleic acid that  
15 has been isolated, synthesized, cloned, ligated, excised in conjunction with another nucleic acid, in a manner that is not found in nature, and/or introduced into and/or expressed in a cell or cellular environment other than or at levels or forms different than the cell or cellular environment in which said nucleic acid or protein is be found in nature. The term encompasses both nucleic acids originally obtained from a different  
20 organism or cell type than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed.

As used herein, the term "polymerase" refers to any polymerase suitable for use in the amplification of nucleic acids of interest. It is intended that the term encompass such DNA polymerases as *Taq* DNA polymerase obtained from *Thermus aquaticus*,  
25 although other polymerases, both thermostable and thermolabile are also encompassed by this definition.

As used herein, the term "polyploid" refers to cells or organisms which contain more than two sets of chromosomes.

As used herein the term "portion" when in reference to a protein (as in "a  
30 portion of a given protein") refers to fragments of that protein. The fragments may

range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:2" encompasses the full-length 123 kDa telomerase protein subunit and fragments thereof.

5           As used herein, the term "probe" refers to a molecule that can specifically bind to another. For example, a probe can be an oligonucleotide (*i.e.*, a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of hybridizing to another oligonucleotide or polynucleotide of interest. Probes are useful in the detection, identification and  
10   isolation of particular gene sequences or particular gene products, whether nucleic acid or protein. It is contemplated that any probe used in the present invention can be labelled with any "reporter molecule," that is detectable in any detection system, including, but not limited to enzyme (*e.g.*, ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is further  
15   contemplated that the oligonucleotide, antibody, or other protein or nucleic of interest (*i.e.*, to be detected) can be labelled with a reporter molecule. It is also contemplated that both the probe and oligonucleotide of interest can be labelled. It is not intended that the present invention be limited to any particular detection system or label.

          As used herein, the terms "restriction endonucleases" and "restriction enzymes"  
20   refer to bacterial or other enzymes, which cut double-stranded or single-stranded DNA at or near a specific nucleotide sequence.

          The term "recombinant," when used with reference to a cell or nucleic acid, protein, or vector, refers to a material, or a material corresponding to the natural or native form of the material, that has been modified by the introduction of a new moiety  
25   or alteration of an existing moiety, or is identical thereto but produced or derived from synthetic materials. For example, recombinant cells can express genes that are not found within the native (non-recombinant) form of the cell or can express native genes that are otherwise expressed at a different level, typically, under or not expressed. The term "recombinant means" refers to techniques where a recombinant nucleic acid such  
30   as a cDNA coding a protein is inserted into an expression vector, the vector is

introduced into a cell and the cell expresses the protein. "Recombinant means" also encompass the ligation of nucleic acids having coding or promoter sequences from different sources into one vector for expression of a protein fusion, including proteins such as the TRT proteins of the invention, either constitutively or inducibly.

5           As used herein, the term "recombinant DNA molecule" refers to a DNA molecule which is comprised of segments of DNA joined together by means of molecular biological techniques and recombinant means.

          As used herein, the term "ribonucleoprotein" refers to a complex macromolecule containing both RNA and protein.

10           The term "sample" as used herein is used in its broadest sense. A biological sample suspected of containing a nucleic acid encoding a telomerase subunit may comprise a cell, chromosomes isolated from a cell (*e.g.*, a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern blot analysis), RNA (in solution or bound to a solid support such as for  
15 Northern blot analysis), cDNA (in solution or bound to a solid support) and the like. A sample suspected of containing a protein may comprise a cell, a portion of a tissue, an extract containing one or more proteins and the like.

          The terms "specific binding" or "specifically binding" when used in reference to the interaction of an antibody and a protein or peptide means that the interaction is  
20 dependent upon the presence of a particular structure (*i.e.*, the antigenic determinant or epitope) on the protein; in other words the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labelled "A" and the antibody will reduce the  
25 amount of labelled A bound to the antibody.

          "Stringency" when used in reference to nucleic acid hybridization or binding typically occurs in a range from about  $T_m - 5^\circ\text{C}$  ( $5^\circ\text{C}$  below the  $T_m$  of the probe) to about  $20^\circ\text{C}$  to  $25^\circ\text{C}$  below  $T_m$ . As will be understood by those of skill in the art, a stringent hybridization can be used to identify or detect identical polynucleotide sequences or to  
30 identify or detect similar or related polynucleotide sequences. The art knows well that

numerous equivalent conditions may be employed to comprise either low or high stringency conditions; factors such as the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (*e.g.*, the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency hybridization different from, but equivalent to, the above listed conditions.

10 A "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively.

As used herein, the term " $T_m$ " is used in reference to the "melting temperature." The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. The equation for calculating the  $T_m$  of nucleic acids is well known in the art. As indicated by standard references, a simple estimate of the  $T_m$  value may be calculated by the equation:  $T_m = 81.5 + 0.41(\% G + C)$ , when a nucleic acid is in aqueous solution at 1 M NaCl (*see e.g.*, Anderson and Young, Quantitative Filter Hybridisation, *in Nucleic Acid Hybridisation* (1985). Other references include more sophisticated computations which take structural as well as sequence characteristics into account for the calculation of  $T_m$ .

20 As used herein, the term "target" refers to a molecule to be detected or specifically manipulated. For example, in PCR the target refers to the region of nucleic acid bounded by the primers used for polymerase chain reaction. Thus, the "target" is sought to be sorted out from other nucleic acid sequences. A "segment" is defined as a region of nucleic acid within the target sequence.

25 As used herein, the terms "telomerase" and "telomerase complex" refer to functional telomerase enzymes. It is intended that the terms encompass the complex of proteins and nucleic acids found in telomerases. For example, the terms encompass the 123 kDa and 43 kDa telomerase protein subunits and telomerase RNA of *E. aediculatus*. The terms "TRT" and "telomerase reverse transcriptase" refer to a  
30 telomere-specific RNA-dependent DNA polymerase protein, such as, for example, the

123 kDa telomerase protein subunit of *E. aediculatus*. The terms “TRT” and “telomerase reverse transcriptase” refer to a telomerase holoenzyme without an RNA component, unless indicated otherwise. The term “telomerase” and “telomerase enzyme” refers to a TRT with an internal RNA component, *i.e.*, an RNA moiety used as a template for DNA synthesis (“TR”). The telomerase can utilize a portion of its internal RNA moiety as a template to specify the addition of telomeric DNA repeat sequences to chromosomal ends. The TRT protein of the invention is a genus of proteins comprising species with common structural characteristics, *i.e.*, motifs, as discussed in detail below. The TRT of the invention includes species capable of catalyzing the synthesis of telomeres when associated with an RNA moiety (TR), such as hTR, species capable of one or several or all partial activities of telomerase, and species such as TRT isoforms which are considered members of the genus of the invention because they contain requisite common structural characteristics of the genus or sufficient sequence identity with another member of the genus. hTR has been cloned and characterized, and a variety of useful primers, probes, and expression vectors have been described, as well as diagnostic and therapeutic methods that target hTR and are useful for diagnosing and treating cancer and other telomerase related diseases, see PCT Publication Nos. 96/01835 and 96/40868 and U.S. Patent No. 5,583,016; see also USSN 08/478,352, 08/472,802 and 08/482,115, all filed 7 June 1995; 08/521,634, filed 31 August 1995; 08/714,482, filed 16 September 1996; and 08/770,564 and 08/770,565, both filed 20 December 1996. See also Feng (1995) *Science* 269:1236. In addition, the mouse telomerase RNA component (mTR) has been cloned and characterized, see USSN 08/782,787, filed 10 February 1997; 08/670,516, filed 27 June 1996; and 08/485,778, filed 7 June 1995. hTR knockout mice have been constructed, see USSN 08/623,166, filed 28 March 1996.

The terms “telomerase activity” and “telomerase reverse transcriptase activity” can refer to either “full” or any “partial activity” of a telomerase reverse transcriptase or telomerase. Telomerase reverse transcriptase activity includes the ability to synthesize DNA, such as a telomere or telomeric DNA, using a nucleic acid template, such as the telomerase RNA. A telomerase reverse transcriptase “partial activity” can

include, but is not limited to, such functions as the ability of TRT to: bind substrate DNA; to bind the telomerase RNA moiety (TR), *i.e.*, hTR; to catalyze the addition of nucleotides to a DNA substrate; to bind deoxynucleotide substrate; to exhibit “nucleolytic activity” (see Collins (1993) *Genes Dev* 7:1364-1376); to bind telomerase  
 5 or telomere-associated proteins or chromosomal structures; to exhibit the “processive” or “non-processive” activity of telomerase (see Morin (1989) *Cell* 59:521-529); to exhibit “reverse-transcriptase-like activity” of telomerase (see Lingner (1997) *Science* 276(5312):561-567); to bind nucleotides as part of its enzymatic processive DNA polymerization activity; to bind chromosomes *in vivo*; to bind oligonucleotide primers  
 10 *in vitro* (Harrington (1995) *J Biol Chem* 270: 8893-8901) or in reconstituted systems; and, to bind histones, nuclear matrix protein, cell division/ cell cycle control proteins and the like.

A “variant” in regard to amino acid sequences indicates an amino acid sequence that differs by one or more amino acids from another, usually related amino acid  
 15 sequence. The variant may have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties (*e.g.*, replacement of leucine with isoleucine). More rarely, a variant may have “non-conservative” changes, *e.g.*, replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions (*i.e.*, additions), or both. Guidance in determining  
 20 which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTar software. Thus, it is contemplated that this definition will encompass variants of telomerase and/or telomerase protein subunits. For another example, the polypeptides encoded by the  
 25 three open reading frames (ORFs) of the *Euplotes* 43 kDa polypeptide gene may be considered to be variants of each other, as well as variants of the human homologue of the 43 kDa *Euplotes* gene encoding the polypeptide. Such variants can be tested in functional assays, such as telomerase assays, to detect the presence of functional telomerase in a sample.

**EXPERIMENTAL**

The following examples are provided to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

5           In the experimental disclosure which follows, the following abbreviations apply: eq (equivalents); M (Molar);  $\mu$ M (micromolar); N (Normal); mol (moles); mmol (millimoles);  $\mu$ mol (micromoles); nmol (nanomoles); g (grams); mg (milligrams);  $\mu$ g (micrograms); ng (nanograms); l or L (liters); ml (milliliters);  $\mu$ l (microliters); cm (centimeters); mm (millimeters);  $\mu$ m (micrometers); nm (nanometers); °C (degrees  
10 Centigrade); RPN (ribonucleoprotein); MeRN (2'-O-methylribonucleotides); dNTP (deoxyribonucleotide); dH<sub>2</sub>O (distilled water); DDT (dithiothreitol); PMSF (phenylmethylsulfonyl fluoride); TE (10 mM Tris HCl, 1 mM EDTA, approximately pH 7.2); KGlu (potassium glutamate); SSC (salt and sodium citrate buffer); SDS (sodium dodecyl sulfate); PAGE (polyacrylamide gel electrophoresis); Novex (Novex,  
15 San Diego, CA); BioRad (Bio-Rad Laboratories, Hercules, CA); Pharmacia (Pharmacia Biotech, Piscataway, NJ); Boehringer-Mannheim (Boehringer-Mannheim Corp., Concord, CA); Amersham (Amersham, Inc., Chicago, IL); Stratagene (Stratagene Cloning Systems, La Jolla, CA); NEB (New England Biolabs, Beverly, MA); Pierce (Pierce Chemical Co., Rockford, IL); Beckman (Beckman Instruments, Fullerton, CA);  
20 Lab Industries (Lab Industries, Inc., Berkeley, CA); Eppendorf (Eppendorf Scientific, Madison, WI); and Molecular Dynamics (Molecular Dynamics, Sunnyvale, CA).

**EXAMPLE 1: Growth of *Euplotes aediculatus***

25           In this Example, cultures of *E. aediculatus* were obtained from Dr. David Prescott, MCDB, University of Colorado. Dr. Prescott originally isolated this culture from pond water, although this organism is also available from the ATCC (ATCC #30859). Cultures were grown as described (Swanton (1980) *Chromosoma* 77:203), under non-sterile conditions, in 15-liter glass containers containing *Chlorogonium* as a food source. Organisms were harvested from the cultures when the density reached  
30 approximately 10<sup>4</sup> cells/ml.

**EXAMPLE 2: Preparation of Nuclear Extracts**

In this Example, nuclear extracts of *E. aediculatus* were prepared as described in the art (Lingner (1994) *supra*), with minor modifications, as indicated below.

Briefly, cells grown as described in Example 1 were concentrated with 15  $\mu$ m Nytex filters and cooled on ice. The cell pellet was resuspended in a final volume of 110 ml  
5 TMS/PMSF/spermidine phosphate buffer. The stock TMS/ PMSF/ spermidine phosphate buffer was prepared by adding 0.075 g spermidine phosphate (USB) and 0.75 ml PMSF (from 100 mM stock prepared in ethanol) to 150 ml TMS. TMS comprised 10 mM Tris-acetate, 10 mM  $MgCl_2$ , 85.5752 g sucrose/liter, and 0.33297 g  
10  $CaCl_2$ /liter, pH 7.5.

After resuspension in TMS/PMSF/spermidine phosphate buffer, 8.8 ml 10% NP-40 and 94.1 g sucrose were added and the mixture placed in a siliconized glass beaker with a stainless steel stirring rod attached to an overhead motor. The mixture was stirred until the cells were completely lysed (approximately 20 minutes). The  
15 mixture was then centrifuged for 10 minutes at 7500 rpm (8950 x g), at 4°C, using a Beckman JS-13 swing-out rotor. The supernatant was removed and nuclei pellet was resuspended in TMS/PMSF/spermidine phosphate buffer, and centrifuged again, for 5 minutes at 7500 rpm (8950 x g), at 4°C, using a Beckman JS-13 swing-out rotor.

The supernatant was removed and the nuclei pellet was resuspended in a buffer  
20 comprised of 50 mM Tris-acetate, 10 mM  $MgCl_2$ , 10% glycerol, 0.1% NP-40, 0.4 M KGlu, 0.5 mM PMSF, pH 7.5, at a volume of 0.5 ml buffer per 10 g of harvested cells. The resuspended nuclei were then dounced in a glass homogenizer with approximately 50 strokes, and then centrifuged for 25 minutes at 14,000 rpm at 4°C, in an Eppendorf centrifuge. The supernatant containing the nuclear extract was collected, frozen in  
25 liquid nitrogen, and stored at -80°C until used.

**EXAMPLE 3: Purification of Telomerase**

In this Example, nuclear extracts prepared as described in Example 2 were used to purify *E. aediculatus* telomerase. In this purification protocol, telomerase was first  
30 enriched by chromatography on an Affi-Gel-heparin column, and then extensively

purified by affinity purification with an antisense oligonucleotide. As the template region of telomerase RNA is accessible to hybridization in the telomerase RNP particle, an antisense oligonucleotide (*i.e.*, the "affinity oligonucleotide") was synthesized that was complementary to this template region as an affinity bait for the telomerase. A  
5 biotin residue was included at the 5' end of the oligonucleotide to immobilize it to an avidin column.

Following the binding of the telomerase to the oligonucleotide, and extensive washing, the telomerase was eluted by use of a displacement oligonucleotide. The affinity oligonucleotide included DNA bases that were not complementary to the  
10 telomerase RNA 5' to the telomerase-specific sequence. As the displacement oligonucleotide was complementary to the affinity oligonucleotide for its entire length, it was able to form a more thermodynamically stable duplex than the telomerase bound to the affinity oligonucleotide. Thus, addition of the displacement oligonucleotide resulted in the elution of the telomerase from the column.

15 The nuclear extracts prepared from 45 liter cultures were frozen until a total of 34 ml of nuclear extract was collected. This corresponded to 630 liters of culture (*i.e.*, approximately  $4 \times 10^9$  cells). The nuclear extract was diluted with a buffer to 410 ml, to provide final concentrations of 20 mM Tris-acetate, 1 mM  $MgCl_2$ , 0.1 mM EDTA, 33 mM KGlu, 10% (vol/vol) glycerol, 1 mM dithiothreitol (DTT), and 0.5 mM  
20 phenylmethylsulfonyl fluoride (PMSF), at a pH of 7.5.

The diluted nuclear extract was applied to an Affi-Gel-heparin gel column (Bio-Rad), with a 230 ml bed volume and 5 cm diameter, equilibrated in the same buffer and eluted with a 2-liter gradient from 33 to 450 mM KGlu. The column was run at 4°C, at a flow rate of 1 column volume/hour. Fractions of 50 mls each were collected and  
25 assayed for telomerase activity as described in Example 4. Telomerase was eluted from the column at approximately 170 mM KGlu. Fractions containing telomerase (approximately 440 ml) were pooled and adjusted to 20 mM Tris-acetate, 10 mM  $MgCl_2$ , 1 mM EDTA, 300 mM KGlu, 10% glycerol, 1 mM DTT, and 1% Nonidet P-40. This buffer was designated as "WB."

## PATENT

To this preparation, 1.5 nmol of each of two competitor DNA oligonucleotides (5'-TAGACCTGTTAGTGTACATTTGAATTGAAGC-3' (SEQ ID NO:28)) and (5'-TAGACCTGTTAGGTTGGATTGTGGCATCA-3' (SEQ ID NO:29)), 50 µg yeast RNA (Sigma), and 0.3 nmol of biotin-labelled telomerase-specific oligonucleotide (5'-biotin-TAGACCTGTTA-(MeRN G)<sub>2</sub>-(MeRN U)<sub>4</sub>-(MeRN G)<sub>4</sub>-(MeRN U)<sub>4</sub>-MeRN G-3') (SEQ ID NO:60), were added per ml of the pool. The 2-*O*-methyribonucleotides of the telomerase specific oligonucleotides were complementary to the telomerase RNA template region; the deoxyribonucleotides were not complementary. The inclusion of competitor, non-specific DNA oligonucleotides increased the efficiency of the purification, as the effects of nucleic acid binding proteins and other components in the mixture that would either bind to the affinity oligonucleotide or remove the telomerase from the mixture were minimized.

This material was then added to Ultralink immobilized neutravidin plus (Pierce) column material, at a volume of 60 µl of suspension per ml of pool. The column material was pre-blocked twice for 15 minutes each blocking, with a preparation of WB containing 0.01% Nonidet P-40, 0.5 mg BSA, 0.5 mg/ml lysozyme, 0.05 mg/ml glycogen, and 0.1 mg/ml yeast RNA. The blocking was conducted at 4°C, using a rotating wheel to block the column material thoroughly. After the first blocking step, and before the second blocking step, the column material was centrifuged at 200 x g for 2 minutes to pellet the matrix.

The pool-column mixture was incubated for 8 minutes at 30°C, and then for an additional 2 hours at 4°C, on a rotating wheel (approximately 10 rpm; Labindustries) to allow binding. The pool-column mixture was then centrifuged 200 xg for 2 minutes, and the supernatant containing unbound material was removed. The pool-column mixture was then washed. This washing process included the steps of rinsing the pool-column mixture with WB at 4°C, washing the mixture for 15 minutes with WB at 4°C, rinsing with WB, washing for 5 minutes at 30°C, with WB containing 0.6 M KGlu, and no Nonidet P-40, washing 5 minutes at 25°C with WB, and finally, rinsing again with WB. The volume remaining after the final wash was kept small, in order to yield a ratio of buffer to column material of approximately 1:1.

Telomerase was eluted from the column material by adding 1 nmol of displacement deoxyoligonucleotide (5'-CA<sub>4</sub>C<sub>4</sub>A<sub>4</sub>C<sub>2</sub>TA<sub>2</sub>CAG<sub>2</sub>TCTA-3')(SEQ ID NO:30), per ml of column material and incubating at 25°C for 30 minutes. The material was centrifuged for 2 minutes at 14,000 rpm in a microcentrifuge (Eppendorf), and the eluate collected. The elution procedure was repeated twice more, using fresh displacement oligonucleotide each time. As mentioned above, because the displacement oligonucleotide was complementary to the affinity oligonucleotide, it formed a more thermodynamically stable complex with the affinity oligonucleotide than the telomerase. Thus, addition of the displacement oligonucleotide to an affinity-bound telomerase resulted in efficient elution of telomerase under native conditions. The telomerase appeared to be approximately 50% pure at this stage, as judged by analysis on a protein gel. The affinity purification of telomerase and elution with a displacement oligonucleotide is shown in Figure 1 (panels A and B, respectively). In this Figure, the 2'-O-methyl sugars of the affinity oligonucleotide are indicated by the bold line. The black and shaded oval shapes in this Figure are intended to represent the protein subunits of the present invention graphically.

The protein concentrations of the extract and material obtained following Affi-Gel-heparin column chromatography were determined using the method of Bradford (Bradford (1976) *Anal. Biochem.* 72:248), using BSA as the standard. Only a fraction of the telomerase preparation was further purified on a glycerol gradient.

The sedimentation coefficient of telomerase was determined by glycerol gradient centrifugation, as described in Example 8.

Table 1 below is a purification table for telomerase purified according to the methods of this Example. The telomerase was enriched 12-fold in nuclear extracts, as compared to whole cell extracts, with a recovery of 80%; 85% of telomerase was solubilized from nuclei upon extraction.

**Table 1. Purification of Telomerase**

Fraction	Protein (mg)	Telomerase (pmol of RNP)	Telomerase/ Protein/pmol of RNP/mg	Recovery (%)	Purification Factor
Nuclear Extract	2020	1720	0.9	100	1
Heparin	125	1040	8.3	60	10
Affinity	0.3**	680	2270	40	2670
Glycerol Gradient	NA*	NA*	NA*	25	NA*

\*NA=Not available

\*\*This value was calculated from the measured amount of telomerase (680 pmol), by assuming a purity of 50% (based on a protein gel).

#### **EXAMPLE 4: Telomerase Activity**

At each step in the purification of telomerase, the preparation was analyzed by three separate assays, one of which was activity, as described in this Example. In general, telomerase assays were done in 40  $\mu$ l containing 0.003-0.3  $\mu$ l of nuclear extract, 50 mM Tris-Cl (pH 7.5), 50 mM KGlu, 10 mM  $MgCl_2$ , 1 mM DTT, 125  $\mu$ M dTTP, 125  $\mu$ M dGTP, and approximately 0.2 pmoles of 5'- $^{32}P$ -labelled oligonucleotide substrate (*i.e.*, approximately 400,000 cpm). Oligonucleotide primers were heat-denatured prior to their addition to the reaction mixture. Reactions were assembled on ice and incubated for 30 minutes at 25°C. The reactions were stopped by addition of 200  $\mu$ l of 10 mM Tris-Cl (pH 7.5), 15 mM EDTA, 0.6% SDS, and 0.05 mg/ml proteinase K, and incubated for at least 30 minutes at 45°C. After ethanol precipitation, the products were analyzed on denaturing 8% PAGE gels, as known in the art (*See e.g.*, Sambrook).

#### **EXAMPLE 5: Quantitation of Telomerase Activity**

In this Example, quantitation of telomerase activity through the purification procedure is described. Quantitation was accomplished by assaying the elongation of

oligonucleotide primers in the presence of dGTP and [gamma-<sup>32</sup>P]dTTP. Briefly, 1 μM 5'-(G<sub>4</sub>T<sub>4</sub>)<sub>2</sub>-3' (SEQ ID NO:61) oligonucleotide was extended in a 20 μl reaction mixture in the presence of 2 μl of [gamma-<sup>32</sup>P]dTTP (10 mCi/ml, 400 Ci/mmol; 1 Ci=37 GBq), and 125 μM dGTP as described (Lingner (1994) *supra*), and loaded onto an 8% PAGE sequencing gel as is known in the art.

The results of this study are shown in Figure 3. In lane 1, there is no telomerase present (*i.e.*, a negative control); lanes 2, 5, 8, and 11 contained 0.14 fmol telomerase; lanes 3, 6, 9, and 12 contained 0.42 fmol telomerase; and lanes 4, 7, 10, and 13 contained 1.3 fmol telomerase. Activity was quantified using a PhosphorImager (Molecular Dynamics) using the manufacturer's instructions. It was determined that under these conditions, 1 fmol of affinity-purified telomerase incorporated 21 fmol of dTTP in 30 minutes.

As shown in this Figure 3, the specific activity of the telomerase did not change significantly through the purification procedure. Affinity-purified telomerase was fully active. However, it was determined that at high concentrations, an inhibitory activity was detected and the activity of crude extracts was not linear. Thus, in the assay shown in Figure 3, the crude extract was diluted 700-7000-fold. Upon purification, this inhibitory activity was removed and no inhibitory effect was detected in the purified telomerase preparations, even at high enzyme concentrations.

#### **EXAMPLE 6: Gel Electrophoresis and Northern Blots**

As indicated in Example 4, at each step in the purification of telomerase, the preparation was analyzed by three separate assays. This Example describes the gel electrophoresis and blotting procedures used to quantify telomerase RNA present in fractions and analyze the integrity of the telomerase ribonucleoprotein particle.

#### **Denaturing Gels and Northern Blots**

In this Example, synthetic T7-transcribed telomerase RNA of known concentration served as the standard. Throughout this investigation, the RNA component was used as a measure of telomerase.

A construct for phage T7 RNA polymerase transcription of *E. aediculatus* telomerase RNA was produced using PCR. The telomerase RNA gene was amplified with primers that annealed to either end of the gene. The primer that annealed at the 5' end also encoded a hammerhead ribozyme sequence to generate the natural 5' end upon cleavage of the transcribed RNA, a T7-promoter sequence, and an *EcoRI* site for subcloning. The sequence of this 5' primer was 5'-

5 GCGGGAATTCTAATACGACTCACTATAGGGAAGAACTCTGATGAGGCCGA  
AAGGCCGAACTCCACGAAAGTGGAGTAAGTTTCTCGATAATTGATCTGTA  
G-3' (SEQ ID NO:31). The 3' primer included an *EaeI* site for termination of

10 transcription at the natural 3' end, and a *BamHI* site for cloning. The sequence of this 3' primer was 5'-CGGGGATCCTCTTCAAAAGATGAGAGGACAGCAAAC-3' (SEQ ID NO:32). The PCR amplification product was cleaved with *EcoRI* and *BamHI*, and subcloned into the respective sites of pUC19 (NEB), to give "pEaT7." The correctness of this insert was confirmed by DNA sequencing. T7 transcription was performed as

15 described by Zaug *Biochemistry* (1994) 33:14935, with *EaeI*-linearized plasmid. RNA was gel-purified and the concentration was determined (an  $A_{260}$  of 1 = 40  $\mu\text{g/ml}$ ). This RNA was used as a standard to determine the telomerase RNA present in various preparations of telomerase.

The signal of hybridization was proportional to the amount of telomerase RNA, and the derived RNA concentrations were consistent with, but slightly higher than those obtained by native gel electrophoresis. Comparison of the amount of whole telomerase RNA in whole cell RNA to serial dilutions of known T7 RNA transcript concentrations indicated that each *E. aediculatus* cell contained approximately 300,000 telomerase molecules.

25 Visualization of the telomerase was accomplished by Northern blot hybridization to its RNA component, using the methods described (Linger (1994) *Genes Develop.* 8:1984). Briefly, RNA (less than or equal to 0.5  $\mu\text{g/lane}$ ) was resolved on an 8% PAGE and electroblotted onto a Hybond-N membrane (Amersham), as known in the art (*see e.g.*, Sambrook and Ausubel). The blot was hybridized overnight

30 in 10 ml of 4x SSC, 10x Denhardt's solution, 0.1% SDS, and 50  $\mu\text{g/ml}$  denatured

herring sperm DNA. After pre-hybridizing for 3 hours,  $2 \times 10^6$  cpm probe/ml hybridization solution was added. The randomly labelled probe was a PCR-product that covered the entire telomerase RNA gene. The blot was washed with several buffer changes for 30 minutes in 2x SSC, 0.1% SDS, and then washed for 1 hour in 0.1x SSC and 0.1% SDS at 45°C.

### Native Gels and Northern Blots

In this experiment, the purified telomerase preparation was run on native (*i.e.*, non-denaturing) gels of 3.5% polyacrylamide and 0.33% agarose, as known in the art and described (Lamond (1994), *supra*). The telomerase comigrated approximately with the xylene cyanol dye.

The native gel results indicated that telomerase was maintained as an RNP throughout the purification protocol. Figure 2 is a photograph of a Northern blot showing the mobility of the telomerase in different fractions on a non-denaturing gel as well as *in vitro* transcribed telomerase. In this figure, lane 1 contained 1.5 fmol telomerase RNA, lane 2 contained 4.6 fmol telomerase RNA, lane 3 contained 14 fmol telomerase RNA, lane 4 contained 41 fmol telomerase RNA, lane 5 contained nuclear extract (42 fmol telomerase), lane 6 contained Affi-Gel-heparin-purified telomerase (47 fmol telomerase), lane 7 contained affinity-purified telomerase (68 fmol), and lane 8 contained glycerol gradient-purified telomerase (35 fmol).

As shown in Figure 2, in nuclear extracts, the telomerase was assembled into an RNP particle that migrated slower than unassembled telomerase RNA. Less than 1% free RNA was detected by this method. However, a slower migrating telomerase RNP complex was also sometimes detected in extracts. Upon purification on the Affi-Gel-heparin column, the telomerase RNP particle did not change in mobility (Figure 2, lane 6). However, upon affinity purification the mobility of the RNA particle slightly increased (Figure 2, lane 7), perhaps indicating that a protein subunit or fragment had been lost. On glycerol gradients, the affinity-purified telomerase did not change in size, but approximately 2% free telomerase RNA was detectable (Figure 2, lane 8), suggesting that a small amount of disassembly of the RNP particle had occurred.

**EXAMPLE 7: Telomerase Protein Composition**

In this Example, the analysis of the purified telomerase protein composition are described. Glycerol gradient fractions obtained as described in Example 8, were separated on a 4-20% polyacrylamide gel (Novex). Following electrophoresis, the gel was stained with Coomassie brilliant blue. Figure 4 shows a photograph of the gel. Lanes 1 and 2 contained molecular mass markers (Pharmacia) as indicated on the left side of the gel shown in Figure 4. Lanes 3-5 contained glycerol gradient fraction pools as indicated on the top of the gel (*i.e.*, lane 3 contained fractions 9-14, lane 4 contained fractions 15-22, and lane 5 contained fractions 23-32). Lane 4 contained the pool with 1 pmol of telomerase RNA. In lanes 6-9 BSA standards were run at concentrations indicated at the top of the gel in Figure 4 (*i.e.*, lane 6 contained 0.5 pmol BSA, lane 7 contained 1.5 pmol BSA, lane 8 contained 4.5 BSA, and lane 9 contained 15 pmol BSA).

As shown in Figure 4, polypeptides with molecular masses of 120 and 43 kDa co-purified with the telomerase. The 43 kDa polypeptide was observed as a doublet. It was noted that the polypeptide of approximately 43 kDa in lane 3 migrated differently than the doublet in lane 4; it may be an unrelated protein. The 120 kDa and 43 kDa doublet each stained with Coomassie brilliant blue at approximately the level of 1 pmol, when compared with BSA standards. Because this fraction contained 1 pmol of telomerase RNA, all of which was assembled into an RNP particle (*See*, Figure 2, lane 8), there appear to be two polypeptide subunits that are stoichiometric with the telomerase RNA. However, it is also possible that the two proteins around 43 kDa are separate enzyme subunits.

Affinity-purified telomerase that was not subjected to fractionation on a glycerol gradient contained additional polypeptides with apparent molecular masses of 35 and 37 kDa, respectively. This latter fraction was estimated to be at least 50% pure. However, the 35 kDa and 37 kDa polypeptides that were present in the affinity-purified material were not reproducibly separated by glycerol gradient centrifugation. These polypeptides may be contaminants, as they were not visible in all activity-containing preparations.

**EXAMPLE 8: Sedimentation Coefficient**

The sedimentation coefficient for telomerase was determined by glycerol gradient centrifugation. In this Example, nuclear extract and affinity-purified telomerase were fractionated on 15-40% glycerol gradients containing 20 mM Tris-acetate, with 1 mM MgCl<sub>2</sub>, 0.1 mM EDTA, 300 mM KGlu, and 1 mM DTT, at pH 7.5. Glycerol gradients were poured in 5 ml (13 x 51 mm) tubes, and centrifuged using an SW55Ti rotor (Beckman) at 55,000 rpm for 14 hours at 4°C.

Marker proteins were run in a parallel gradient and had a sedimentation coefficient of 7.6 S for alcohol dehydrogenase (ADH), 113 S for catalase, 17.3 S for apoferritin, and 19.3 S for thyroglobulin. The telomerase peak was identified by native gel electrophoresis of gradient fractions followed by blot hybridization to its RNA component.

Figure 5 is a graph showing the sedimentation coefficient for telomerase. As shown in this Figure, affinity-purified telomerase co-sedimented with catalase at 11.5 S, while telomerase in nuclear extracts sedimented slightly faster, peaking around 12.5 S. Therefore, consistent with the mobility of the enzyme in native gels, purified telomerase appears to have lost a proteolytic fragment or a loosely associated subunit.

The calculated molecular mass for telomerase, if it is assumed to consist of one 120 kDa protein subunit, one 43 kDa subunit, and one RNA subunit of 66 kDa, adds up to a total of 229 kDa. This is in close agreement with the 232 kDa molecular mass of catalase. However, the sedimentation coefficient is a function of the molecular mass, as well as the partial specific volume and the frictional coefficient of the molecule, both of which are unknown for the *Euplotes* telomerase RNP.

**EXAMPLE 9: Substrate Utilization**

In this Example, the substrate requirements of *Euplotes* telomerase were investigated. One simple model for DNA end replication predicts that after semi-conservative DNA replication, telomerase extends double-stranded, blunt-ended DNA molecules. In a variation of this model, a single-stranded 3' end is created by a helicase

or nuclease after replication. This 3' end is then used by telomerase for binding and extension.

To determine whether telomerase is capable of elongating blunt-ended molecules, model hairpins were synthesized with telomeric repeats positioned at their 3' ends. These primer substrates were gel-purified, 5'-end labelled with polynucleotide kinase, heated at 0.4  $\mu$ M to 80°C for 5 minutes, and then slowly cooled to room temperature in a heating block, to allow renaturation and helix formation of the hairpins. Substrate mobility on a non-denaturing gel indicated that very efficient hairpin formation was present, as compared to dimerization.

Assays were performed with unlabelled 125  $\mu$ M dGTP, 125  $\mu$ M dTTP, and 0.02  $\mu$ M 5'-end-labelled primer (5'-<sup>32</sup>P-labelled oligonucleotide substrate) in 10  $\mu$ l reaction mixtures that contained 20 mM Tris-acetate, with 10 mM MgCl<sub>2</sub>, 50 mM KGlu, and 1 mM DTT, at pH 7.5. These mixtures were incubated at 25°C for 30 minutes. Reactions were stopped by adding formamide loading buffer (*i.e.*, TBE, formamide, bromthymol blue, and cyanol, see, e.g., Sambrook).

Primers were incubated without telomerase ("-"), with 5.9 fmol of affinity-purified telomerase ("+"), or with 17.6 fmol of affinity-purified telomerase ("+++"). Affinity-purified telomerase used in this assay was dialyzed with a membrane having a molecular cut-off of 100 kDa, in order to remove the displacement oligonucleotide. Reaction products were separated on an 8% PAGE/urea gel containing 36% formamide, to denature the hairpins. The sequences of the primers used in this study, as well as their lane assignments are shown in Table 2.

TABLE 2. Primer Sequences

Lane	Primer Sequence (5' to 3')	SEQ ID NO:
1-3	C <sub>4</sub> (A <sub>4</sub> C <sub>4</sub> ) <sub>3</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub> G <sub>4</sub>	SEQ ID NO:33
4-6	C <sub>2</sub> (A <sub>4</sub> C <sub>4</sub> ) <sub>3</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub> G <sub>4</sub>	SEQ ID NO:34
7-9	(A <sub>4</sub> C <sub>4</sub> ) <sub>3</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub> G <sub>4</sub>	SEQ ID NO:35
10-12	A <sub>2</sub> C <sub>4</sub> (A <sub>4</sub> C <sub>4</sub> ) <sub>2</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub> G <sub>4</sub>	SEQ ID NO:36
13-15	C <sub>4</sub> (A <sub>4</sub> C <sub>4</sub> ) <sub>2</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub>	SEQ ID NO:37
16-18	(A <sub>4</sub> C <sub>4</sub> ) <sub>3</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub>	SEQ ID NO:38
19-21	A <sub>2</sub> C <sub>4</sub> (A <sub>4</sub> C <sub>4</sub> ) <sub>2</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub>	SEQ ID NO:39
22-24	C <sub>4</sub> (A <sub>4</sub> C <sub>4</sub> ) <sub>2</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub>	SEQ ID NO:37
25-27	C <sub>2</sub> (A <sub>4</sub> C <sub>4</sub> ) <sub>2</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub>	SEQ ID NO:41
28-30	(A <sub>4</sub> C <sub>4</sub> ) <sub>2</sub> CACA(G <sub>4</sub> T <sub>4</sub> ) <sub>3</sub>	SEQ ID NO:42

The gel results are shown in Figure 6. Lanes 1-15 contained substrates with telomeric repeats ending with four G residues. Lanes 16-30 contained substrates with telomeric repeats ending with four T residues. The putative alignment on the telomerase RNA template is indicated in Figure 7 (SEQ ID NOS:43-45). It was assumed that the primer sets anneal at two very different positions in the template shown in Figure 7 (*i.e.*, panel A and B, respectively). This may have affected their binding and/or elongation rate.

Figure 8 shows a lighter exposure of lanes 25-30 in Figure 6. The lighter exposure of Figure 8 was taken to permit visualization of the nucleotides that are added and the positions of pausing in elongated products. Percent of substrate elongated for the third lane in each set was quantified on a PhosphorImager, as indicated on the bottom of Figure 6.

The substrate efficiencies for these hairpins were compared with double-stranded telomere-like substrates with overhangs of differing lengths. A model substrate that ended with four G residues (see lanes 1 to 15 of Figure 6) was not elongated when it was blunt ended (see lanes 1-3). However, slight extension was observed with an overhang length of two bases; elongation became efficient when the

overhang was at least 4 bases in length. The telomerase acted in a similar manner with a double-stranded substrate that ended with four T residues, with a 6-base overhang required for highly efficient elongation. In Figure 6, the faint bands below the primers in lanes 10-15 that are independent of telomerase represent shorter oligonucleotides in the primer preparations.

The lighter exposure of lanes 25-30 in Figure 8 shows a ladder of elongated products, with the darkest bands correlating with the putative 5' boundary of the template (as described by Lingner (1994) *supra*). The abundance of products that correspond to other positions in the template suggested that pausing and/or dissociation occurs at sites other than the site of translocation with the purified telomerase.

As shown in Figure 6, double-stranded, blunt-ended oligonucleotides were not substrates for telomerase. To determine whether these molecules would bind to telomerase, a competition experiment was performed. In this experiment, 2 nM of 5'-end labelled substrate with the sequence  $(G_4T_4)_2$  (SEQ ID NO:61), or a hairpin substrate with a six base overhang were extended with 0.125 nM telomerase (Figure 6, lanes 25-27). Although the same unlabeled oligonucleotide substrates competed efficiently with labelled substrate for extension, no reduction of activity was observed when the double-stranded blunt-ended hairpin oligonucleotides were used as competitors, even in the presence of 100-fold excess hairpins.

These results indicated that double-stranded, blunt-ended oligonucleotides cannot bind to telomerase at the concentrations and conditions tested in this Example. Rather, a single-stranded 3' end is required for binding. It is likely that this 3' end is required to base pair with the telomerase RNA template.

#### **EXAMPLE 10: Cloning & Sequencing of the 123 kDa Polypeptide**

In this Example, the cloning of the *Euplotes* 123 kDa polypeptide of telomerase (*i.e.*, the 123 kDa protein subunit) is described. In this study, an internal fragment of the telomerase gene was amplified by PCR, with oligonucleotide primers designed to match peptide sequences that were obtained from the purified polypeptide obtained in Example 3, above. The polypeptide sequence was determined using the Nano

electrospray (ES) tandem mass spectroscopy methods known in the art and described by Calvio (1995) *RNA* 1:724-733. The oligonucleotide primers used in this Example had the following sequences, with positions that were degenerate shown in parentheses: 5'-TCT(G/A)AA(G/A)TA(G/A)TG(T/G/A)GT(G/A/T/C)A(T/G/A)(G/A)TT(G/A)TTCAT-3' (SEQ ID NO:47), and 5'-GCGGATCCATGAA (T/C)CC(A/T)GA(G/A)AA(T/C)CC(A/T)AA(T/C)GT-3' (SEQ ID NO:48).

A 50 µl reaction contained 0.2 mM dNTPs, 0.15 µg *E. aediculatus* chromosomal DNA, 0.5 µl *Taq* (Boehringer-Mannheim), 0.8 µg of each primer, and 1x reaction buffer (Boehringer-Mannheim). The reaction was incubated in a thermocycler (Perkin-Elmer), using the following--5 minutes at 95°C, followed by 30 cycles of 1 minute at 94°C, 1 minute at 52°C, and 2 minutes at 72°C. The reaction was completed by a 10 minute incubation at 72°C.

A genomic DNA library was prepared from the chromosomal *E. aediculatus* DNA by cloning blunt-ended DNA into the *Sma*I site of pCR-Script plasmid vector (Stratagene). This library was screened by colony hybridization, with the radiolabelled, gel-purified PCR product. Plasmid DNA of positive clones was prepared and sequenced by the dideoxy method (Sanger (1977) *Proc. Natl. Acad. Sci. USA* 74:5463) or manually, through use of an automated sequencer (ABI). The DNA sequence of the gene encoding this polypeptide is shown in Figure 9 (SEQ ID NO:1). The start codon in this sequence inferred from the DNA sequence, is located at nucleotide position 101, and the open reading frame ends at position 3193. The genetic code of *Euplotes* differs from other organisms in that the "UGA" codon encodes a cysteine residue. The amino acid sequence of the polypeptide inferred from the DNA sequence is shown in Figure 10 (SEQ ID NO:2), and assumes that no unusual amino acids are inserted during translation and no post-translational modification occurs.

### **EXAMPLE 11: Cloning & Sequencing of the 43 kDa Polypeptide**

The invention provides for isoforms and homologues of the *Euplotes* p43 (43 kDa) telomerase, including the human p43 (kDa) homologue. Such 43 kDa nucleic acids and corresponding proteins, as members of the telomerase subunit genus, can also

be identified and isolated using the reagents provided by the invention and the methods described herein. The identification and cloning of the *Euplotes* 43 kDa polypeptide, described below, provides an illustrative example of a means to isolate further members of the 43 kDa sub-genus.

5 In this Example, the cloning of the 43 kDa polypeptide of *Euplotes* telomerase (*i.e.*, the 43 kDa protein subunit) is described. In this study, an internal fragment of the corresponding telomerase gene was amplified by PCR, with oligonucleotide primers designed to match peptide sequences that were obtained from the purified polypeptide obtained in Example 3, above. The polypeptide sequence was determined using the  
10 nanoES tandem mass spectroscopy methods known in the art and described by Calvio, *supra*). The oligonucleotide primers used in this Example had the following sequences-  
-5'-NNNGTNAC(C/T/A)GG(C/T/A)AT(C/T/A)AA(C/T)AA-3' (SEQ ID NO:49), and  
5'-(T/G/A)GC(T/G/A)GT(C/T)TC(T/C)TG(G/A)TC(G/A)TT(G/A)TA-3' (SEQ ID  
NO:50). In this sequence, "N" indicates the presence of any of the four nucleotides  
15 (*i.e.*, A, T, G, or C).

The PCR was performed as described above in Example 10. A genomic DNA library was prepared and sequenced as described above in Example 10. The DNA sequence of the gene encoding this polypeptide is shown in Figure 11 (SEQ ID NO:3). Three potential reading frames are shown for this sequence, as shown in Figure 12.  
20 For clarity, the amino acid sequence is indicated below the nucleotide sequence in all three reading frames. These reading frames are designated as "a," "b," and "c," also as shown in SEQ ID NOS:4, 5, and 6, respectively. A possible start codon is encoded at nucleotide position 84 in reading frame "c." The coding region could end at position 1501 in reading frame "b." Early stop codons, indicated by asterisks in this figure,  
25 occur in all three reading frames between nucleotide position 337-350.

Further downstream, the protein sequence appears to be encoded by different reading frames, as none of the three frames is uninterrupted by stop codons. Furthermore, peptide sequences from purified protein are encoded in all three frames. Therefore, this gene appears to contain intervening sequences, or in the alternative, the  
30 RNA is edited. Other possibilities include ribosomal frame-shifting or sequence errors.

However, the homology to the La-protein sequence remains of significant interest. Again, in *Euplotes*, the "UGA" codon encodes a cysteine residue.

#### **EXAMPLE 12: Amino Acid and Nucleic Acid Comparisons**

In this Example, comparisons between various reported sequences and the sequences of the *Euplotes* 123 kDa and 43 kDa telomerase subunit polypeptides were made.

##### **Comparisons with the 123 kDa *E. aediculatus* Telomerase Subunit**

The amino acid sequence of the 123 kDa *Euplotes aediculatus* polypeptide was compared with the sequence of the 80 kDa telomerase protein subunit of *Tetrahymena thermophila* (GenBank accession #U25641) to investigate their similarity. The nucleotide sequence as obtained from GenBank (SEQ ID NO:51) encoding this protein is shown in Figure 19. The amino acid sequence of this protein as obtained from GenBank (SEQ ID NO:52) is shown in Figure 20. The sequence comparison between the 123 kDa *E. aediculatus* and 80 kDa *T. thermophila* is shown in Figure 13. In this figure, the *E. aediculatus* sequence is the upper sequence (SEQ ID NO:223), while the *T. thermophila* sequence is the lower sequence (SEQ ID NO:224). In this Figure, as well as Figures 14-16, identities are indicated by vertical bars, while single dots between the sequences indicate somewhat similar amino acids, and double dots between the sequences indicate more similar amino acids. The observed identity was determined to be approximately 19%, while the percent similarity was approximately 45%, values similar to what would be observed with any random protein sequence.

The amino acid sequence of the 123 kDa *Euplotes aediculatus* polypeptide was also compared with the sequence of the 95 kDa telomerase protein subunit of *Tetrahymena thermophila* (GenBank accession #U25642), to investigate their similarity. The nucleotide sequence as obtained from GenBank (SEQ ID NO:53) encoding this protein is shown in Figure 21. The amino acid sequence of this protein as obtained from GenBank (SEQ ID NO:54) is shown in Figure 22. This sequence comparison is shown in Figure 14. In this figure, the *E. aediculatus* sequence is the upper sequence (SEQ ID NO:225), while the *T. thermophila* sequence is the lower

sequence (SEQ ID NO:226). The observed identity was determined to be approximately 20%, while the percent similarity was approximately 43%, values similar to what would be observed with any random protein sequence.

Significantly, the amino acid sequence of the 123 kDa *E. aediculatus* polypeptide contains the five motifs (SEQ ID NOS:227-230) characteristic of RTs. The 123 kDa polypeptide was also compared with the polymerase domains of various RTs (SEQ ID NOS:231-247). Figure 17 shows the alignment of the 123 kDa polypeptide with the putative yeast homolog (L8543.12 or EST2p)(SEQ ID NOS:244-247). The amino acid sequence of L8543.12 (or EST2p) obtained from GenBank is shown in Figure 23 (SEQ ID NO:55).

Four motifs (A, B, C, and D) were included in this comparison. In this Figure 17, highly conserved residues are indicated by white letters on a black background. Residues of the *E. aediculatus* sequences that are conserved in the other sequence are indicated in bold; the "h" indicates the presence of a hydrophobic amino acid. The numerals located between amino acid residues of the motifs indicates the length of gaps in the sequences. For example, the "100" shown between motifs A and B reflects a 100 amino acid gap in the sequence between the motifs.

As noted above, Genbank searches identified a yeast protein (Genbank accession #U20618), and gene L8543.12 (Est2), containing or encoding an amino acid sequence that shows some homology to the *E. aediculatus* 123 kDa telomerase subunit. Based on the observations that both proteins contain RT motifs in their C-terminal regions; both proteins share similarity in regions outside the RT motif; the proteins are similarly basic (pI = 10.1 for *E. aediculatus* and pI=10.0 for the yeast); and both proteins are large (123 kDa for *E. aediculatus* and 103 kDa for the yeast), these sequences comprise the catalytic core of their respective telomerases. It was contemplated based on this observation of homology in two phylogenetically distinct organisms as *E. aediculatus* and yeast, that human telomerase would contain a protein that has the same characteristics (*i.e.*, RT motifs, is basic, and large [ $> 100$  kDa]).

**Comparisons with the 43 kDa *E. aediculatus* Telomerase Subunit**

The amino acid sequence of the "La-domain" of the 43 kDa *Euplotes aediculatus* polypeptide was compared with the sequence of the 95 kDa telomerase protein subunit of *Tetrahymena thermophila* (described above) to investigate their similarity. This sequence comparison is shown in Figure 15. In this figure, the *E. aediculatus* sequence is the upper sequence (SEQ ID NO:9), while the *T. thermophila* sequence is the lower sequence (SEQ ID NO:10). The observed identity was determined to be approximately 23%, while the percent similarity was approximately 46%, values similar to what would be observed with any random protein sequence.

The amino acid sequence of the "La-domain" of the 43 kDa *Euplotes aediculatus* polypeptide was compared with the sequence of the 80 kDa telomerase protein subunit of *Tetrahymena thermophila* (described above) to investigate their similarity. This sequence comparison is shown in Figure 16. In this figure, the *E. aediculatus* sequence is the upper sequence (SEQ ID NO:11), while the *T. thermophila* sequence is the lower sequence (SEQ ID NO:12). The observed identity was determined to be approximately 26%, while the percent similarity was approximately 49%, values similar to what would be observed with any random protein sequence.

The amino acid sequence of a domain of the 43 kDa *E. aediculatus* polypeptide (SEQ ID NO:23) was also compared with La proteins from various other organisms (SEQ ID NOS:24-27). These comparisons are shown in Figure 18. In this Figure, highly conserved residues are indicated by white letters on a black background. Residues of the *E. aediculatus* sequences that are conserved in the other sequence are indicated in bold.

**EXAMPLE 13: Identification of Telomerase Protein Subunits in *Oxytricha trifallax***

In this Example, the sequences identified in the previous Examples above were used to identify the telomerase protein subunits of *Oxytricha trifallax*, a ciliate that is very distantly related to *E. aediculatus*. Primers were chosen based on the conserved region of the *E. aediculatus* 123 kDa polypeptide which comprised the RT domain

motifs. Suitable primers were synthesized and used in a PCR reaction with total DNA from *Oxytricha*. The *Oxytricha* DNA was prepared according to methods known in the art. The PCR products were then cloned and sequenced using methods known in the art.

5           The oligonucleotide sequences used as the primers were as follows: 5'-(T/C)A(A/G)AC(T/A/C)AA(G/A)GG(T/A/C)AT(T/C)CC(C/T/A)(C/T)A(G/A)GG-3' (SEQ ID NO:56) and 5'-(G/A/T)GT(G/A/T)ATNA(G/A)NA(G/A)(G/A)TA(G/A)TC (G/A)TC-3' (SEQ ID NO:57). Positions that were degenerate are shown in parenthesis, with the alternative bases shown within the parenthesis. "N" represents any of the four  
10       nucleotides.

          In the PCR reaction, a 50 µl reaction contained 0.2 mM dNTPs, 0.3 µg *Oxytricha trifallax* chromosomal DNA, 1 µl *Taq* polymerase (Boehringer-Mannheim), 2 micromolar of each primer, 1x reaction buffer (Boehringer-Mannheim). The reaction was incubated in a thermocycler (Perkin-Elmer) under the following conditions: 5 min  
15       at 95°C; 30 cycles consisting of 1 min at 94°C, 1 min at 53°C, and 1 min at 72°C; followed by a 10 min at 72°C. The PCR-product was gel-purified and sequenced by the dideoxy-method (e.g., Sanger (1977) *Proc. Natl. Acad. Sci. USA* 74:5463-5467).

          The deduced amino acid sequence of the PCR product was determined and compared with the *E. aediculatus* sequence. Figure 24 shows the alignment of these  
20       sequences, with the *O. trifallax* sequence (SEQ ID NO:58) shown in the top row, and the *E. aediculatus* sequence (SEQ ID NO:59) shown in the bottom row. As can be seen from this Figure, there is a great deal of homology between the *O. trifallax* polypeptide sequence identified in this Example with the *E. aediculatus* polypeptide sequence. Thus, it is clear that the sequences identified in the present invention are useful for the  
25       identification of homologous telomerase protein subunits in other eukaryotic organisms. Indeed, development of the present invention has identified homologous telomerase sequences in multiple, diverse species, as described above.

**EXAMPLE 15: Identification of *Tetrahymena* Telomerase Sequences**

In this Example, a *Tetrahymena* clone was produced that shares homology with the *Euplotes* sequences, and EST2p.

This experiment utilized PCR with degenerate oligonucleotide primers directed  
5 against conserved motifs to identify regions of homology between *Tetrahymena*,  
*Euplotes*, and EST2p sequences. The PCR method used in this Example is a novel  
method designed to amplify specifically rare DNA sequences from complex mixtures.  
This method avoids the problem of amplification of DNA products with the same PCR  
primer at both ends (*i.e.*, single primer products) commonly encountered in PCR  
10 cloning methods. These single primer products produce unwanted background and can  
often obscure the amplification and detection of the desired two-primer product. The  
method used in this experiment preferentially selects for two-primer products. In  
particular, one primer is biotinylated and the other is not. After several rounds of PCR  
amplification, the products are purified using streptavidin magnetic beads and two  
15 primer products are specifically eluted using heat denaturation. This method finds use  
in settings other than the experiments described in this Example. Indeed, this method  
finds use in application in which it is desired to specifically amplify rare DNA  
sequences, including the preliminary steps in cloning methods such as 5' and 3'; RACE,  
and any method that uses degenerate primers in PCR.

20 A first PCR run was conducted using *Tetrahymena* template macronuclear DNA  
isolated using methods known in the art, and the 24-mer forward primer with the  
sequence 5' biotin-GCCTATTT(TC)TT(TC)TA(TC)(GATC) (GATC)(GATC)AC  
(GATC)GA-3' (SEQ ID NO:70) designated as "K231," corresponding to the FFYXTE  
region (SEQ ID NO:71), and the 23-mer reverse primer with the sequence 5'-  
25 CCAGATAT(GATC)A(TGA)(GATC)A(AG)(AG)AA(AG)TC(AG)TC- 3' (SEQ ID  
NO:72), designated as "K220," corresponding to the DDFL(FIL)I region (SEQ ID  
NO:73). This PCR reaction contained 2.5 µl DNA (50 ng), 4 µl of each primer (20  
µM), 3 µl 10x PCR buffer, 3 µl 10x dNTPs, 2 µl Mg, 0.3 µl *Taq*, and 11.2 µl dH<sub>2</sub>O.  
The mixture was cycled for 8 cycles of 94°C for 45 seconds, 37°C for 45 seconds, and  
30 72°C for 1 minute.

This PCR reaction was bound to 200 µl streptavidin magnetic beads, washed with 200 µl TE, resuspended in 20 µl dH<sub>2</sub>O and then heat-denatured by boiling at 100°C for 2 minutes. The beads were pulled down and the eluate removed. Then, 2.5 µl of this eluate was subsequently reamplified using the above conditions, with the exception being that 0.3 µl of gamma-<sup>32</sup>P dATP was included, and the PCR was carried out for 33 cycles. This reaction was run a 5% denaturing polyacrylamide gel, and the appropriate region was cut out of the gel. These products were then reamplified for an additional 34 cycles, under the conditions listed above, with the exception being that a 42°C annealing temperature was used.

10 A second PCR run was conducted using *Tetrahymena* macronuclear DNA template isolated using methods known in the art, and the 23-mer forward primer with the sequence 5'-ACAATG(CA)G(GATC)(TCA)T(GATC)(TCA)T(GATC)CC (GATC)AA(AG)AA-3' (SEQ ID NO:74), designated as "K228," corresponding to the region R(LI)(LI)PKK (SEQ ID NO:75), and a reverse primer with the sequence 5'-  
15 ACGAATC(GT)(GATC)GG(TAG)AT(GATC)(GC)(TA)(AG)TC(AG)TA(AG)CA 3' (SEQ ID NO:76), designated "K224," corresponding to the CYDSIPR region (SEQ ID NO:77). This PCR reaction contained 2.5 µl DNA (50 ng), 4 µl of each primer (20 µM), 3 µl 10x PCR buffer, 3 µl 10x dNTPs, 2 µl Mg, 0.3 µl gamma-<sup>32</sup>P dATP, 0.3 µl *Taq*, and 10.9 µl dH<sub>2</sub>O. This reaction was run on a 5% denaturing polyacrylamide gel, and the appropriate region was cut out of the gel. These products were reamplified for an additional 34 cycles, under the conditions listed above, with the exception being that a 42°C annealing temperature was used.

25 Ten µl of the reaction product from run 1 were bound to streptavidin-coated magnetic beads in 200 µl TE. The beads were washed with 200 µl TE, and then then resuspended in 20 µl of dH<sub>2</sub>O, heat denatured, and the eluate was removed. Next, 2.5 µl of this eluate was reamplified for 33 cycles using the conditions indicated above. The reaction product from run 2 was then added to the beads and diluted with 30 µl 0.5x SSC. The mixture was heated from 94°C to 50°C. The eluate was removed and the beads were washed three times in 0.5x SSC at 55°C. The beads were then

resuspended in 20  $\mu$ l dH<sub>2</sub>O, heat denatured, and the eluate was removed, designated as "round 1 eluate" and saved.

To isolate the *Tetrahymena* band, the round 1 eluate was reamplified with the forward primer K228 (SEQ ID NO:74) and reverse primer K227 (SEQ ID NO:78) with the sequence 5'-CAATTCTC(AG)TA(AG)CA(GATC)(CG)(TA)(CT)TT(AGT)AT(GA)TC-3' (SEQ ID NO:78), corresponding to the DIKSCYD region (SEQ ID NO:79). The PCR reactions were conducted as described above. The reaction products were run on a 5% polyacrylamide gel; the band corresponding to approximately 295 nucleotides was cut from the gel and sequenced.

The clone designated as 168-3 was sequenced. The DNA sequence (including the primer sequences) was found to be:

GATTACTCCCGAAGAAAGGATCTTCCGTCCAATCATGACTTTCTTAAGAAA  
GGACAAGCAAAAAAATATTAAGTTAAATCTAAATTAAATTCTAATGGATAG  
CCAACTTGTGTTTAGGAATTTAAAAGACATGCTGGGATAAAAGATAGGATA  
CTCAGTCTTTGATAATAAACAAATTTTCAGAAAAATTTGCCTAATTCATAGAG  
AAATGGAAAAATAAAGGAAGACCTCAGCTATATTATGTCACTCTAGACATA  
AAGACTTGCTAC (SEQ ID NO:80).

Additional sequence of this gene was obtained by PCR using one unique primer designed to match the sequence from 168-3 ("K297" with the sequence 5'-

GAGTGACATAATATACGTGA-3'; SEQ ID NO:111), and the K231 (FFYXTE; SEQ ID NO:71) primer. The sequence of the fragment obtained from this reaction, together with 168-3 is as follows (without the primer sequences):

AAACACAAGGAAGGAAGTCAAATATTCTATTACCGTAAACCAATATGGAA  
ATTAGTGAGTAAATTAAGTAACTATTGTCAAAGTAAGAATTTAGTTTTCTGAAAAG  
AATAAATAAATGAAAAATAATTTTTATCAAAAAATTTAGCTTGAAGAGGAG  
AATTTGGAAAAAGTTGAAGAAAAATTGATACCAGAAGATTCATTTTAGAAA  
TACCCTCAAGGAAAGCTAAGGATTATACCTAAAAAAGGATCTTCCGTCCA  
ATCATGACTTTCTTAAGAAAGGACAAGCAAAAAAATATTAAGTTAAATCTA  
AATTAAATTCTAATGGATAGCCAACTTGTGTTTAGGAATTTAAAAGACATG  
CTGGGATAAAAGATAGGATACTCAGTCTTTGATAATAAACAAATTTTCAGAA

AAATTTGCCTAATTCATAGAGAAATGGAAAAATAAAGGAAGACCTCAGCTA  
TATTATGTCACTCTA (SEQ ID NO:81).

The amino acid sequence corresponding to this DNA fragment was found to be:  
KHKEGSQIFYRKPIWKLVSKLTIVKVRIQFSEKNKQMKNNFYQKIQLEENLE  
5 KVEEKLIPEDSFQKYPQGKLRIPKKGSFRPIMTFLRKDKQKNIKLNLNQILMDS  
QLVFRNLKDMLGQKIGYSVFDNKQISEKFAQFIEKWKNKGRPQLYYVTL (SEQ  
ID NO:85).

This amino acid sequence was then aligned with other telomerase genes  
(EST2p, and *Euplotes*). The alignment is shown in Figure 31. A consensus sequence is  
10 also shown in this Figure.

#### **EXAMPLE 16: Identification of *Schizosaccharomyces pombe* Telomerase Sequences**

In this Example, the *tez1* sequence of *S. pombe* was identified as a homolog of  
15 the *E. aediculatus* p123, and *S. cerevisiae* Est2p.

Figure 33 provides an overall summary of these experiments. In this Figure, the  
top portion (Panel A) shows the relationship of two overlapping genomic clones, and  
the 5825 bp portion that was sequenced. The region designated at "*tez1*+" is the protein  
coding region, with the flanking sequences indicated as well, the box underneath the  
20 5825 bp region is an approximately 2 kb *HindIII* fragment that was used to make the  
*tez1* disruption construct, as described below.

The bottom half of Figure 33 (Panel B) is a "close-up" schematic of this same  
region of DNA. The sequence designated as "original PCR" is the original degenerate  
PCR fragment that was generated with a degenerate oligonucleotide primer pair  
25 designed based on *Euplotes* sequence motif 4 (B') and motif 5 (C), as described.

#### **PCR With Degenerate Primers**

PCR using degenerate primers was used to find the homolog of the *E.*  
*aediculatus* p123 in *S. pombe*. Figure 34 shows the sequences of the degenerate  
primers (designated as "poly 4" and "poly 1") used in this reaction. The PCR runs were  
30 conducted using the same buffer as described in previous Examples (See e.g., Example

10, above), with a 5 minute ramp time at 94°C, followed by 30 cycles of 94°C for 30 seconds, 50°C for 45 seconds, and 72°C for 30 seconds, and 7 minutes at 72°C, followed by storage at 4°C. PCR runs were conducted using varied conditions, (*i.e.*, various concentrations of *S. pombe* DNA and MgCl<sub>2</sub> concentrations). The PCR products were run on agarose gels and stained with ethidium bromide as described above. Several PCR runs resulted in the production of three bands (designated as "T," "M," and "B"). These bands were re-amplified and run on gels using the same conditions as described above. Four bands were observed following this re-amplification ("T," "M1," "M2," and "B"), as shown in Figure 35. These four bands were then re-amplified using the same conditions as described above. The third band from the top of the lane in Figure 35 was identified as containing the correct sequence for a telomerase protein. The PCR product designated as M2 was found to show a reasonable match with other telomerase proteins, as indicated in Figure 36. In addition to the alignment shown, this Figure also shows the actual sequence of *tez1*. In this Figure, the asterisks indicate residues shared with all four sequences (*Oxytricha* "Ot"; *E. aediculatus* "Ea\_p123"; *S. cerevisiae* "Sc\_p103"; and M2), while the circles (*i.e.*, dots) indicate similar amino acid residues.

### 3' RT PCR

To obtain additional sequence information, 3' and 5' RT PCR were conducted on the telomerase candidate identified in Figure 36. Figure 37 provides a schematic of the 3' RT PCR strategy used. First, cDNA was prepared from mRNA using the oligonucleotide primer "Q<sub>T</sub>," (5'-CCA GTG AGC AGA GTG ACG AGG ACT CGA GCT CAA GCT TTT TTT TTT TTT TT-3'; SEQ ID NO:102), then using this cDNA as a template for PCR with "Q<sub>O</sub>" (5'-CCA GTG AGC AGA GTG ACG-3'; SEQ ID NO:103), and a primer designed based on the original degenerated PCR reaction (*i.e.*, "M2-T" with the sequence 5'-G TGT CAT TTC TAT ATG GAA GAT TTG ATT GAT G-3' (SEQ ID NO:109)). The second PCR reaction (*i.e.*, nested PCR) with "Q<sub>I</sub>" (5'-GAG GAC TCG AGC TCA AGC-3'; SEQ ID NO:104), and another PCR primer designed with sequence derived from the original degenerate PCR reaction or "M2-T2" (5'-AC CTA TCG TTT ACG AAA AAG AAA GGA TCA GTG-3'; SEQ ID NO:110).

The buffers used in this PCR were the same as described above, with amplification conducted beginning with a ramp up of 94° for 5 min, followed by 30 cycles of 94° for 30 sec, 55°C for 30 sec, and 72°C for 3 min), followed by 7 minutes at 72°C. The reaction products were stored at 4°C until use.

## 5 Screening of Genomic and cDNA Libraries

After obtaining this additional sequence information, several genomic and cDNA libraries were screened to identify any libraries that contain this telomerase candidate gene. The approach used, as well as the libraries and results are shown in Figure 38. In this Figure, Panel A lists the libraries tested in this experiment; Panel B shows the regions used; Panels C and D show the dot blot hybridization results obtained with these libraries. Positive libraries were then screened by colony hybridization to obtain genomic and cDNA version of *tez1* gene. In this experiment, approximately 3 x 10<sup>4</sup> colonies from the *Hind*III genomic library were screened and six positive clones were identified (approximately 0.01%). DNA was then prepared from two independent clones (A5 and B2). Figure 39 shows the results obtained with the *Hind*III-digested A5 and B2 positive genomic clones.

In addition, cDNA REP libraries were used. Approximately 3 x 10<sup>5</sup> colonies were screened, and 5 positive clones were identified (0.002%). DNA was prepared from three independent clones (2-3, 4-1, and 5-20). In later experiments, it was determined that 2-3 and 5-20 contained identical inserts.

## 5' RT PCR

As the cDNA version of gene produced to this point was not complete, 5' RT-PCR was conducted to obtain a full length clone. The strategy is schematically shown in Figure 40. In this experiment, cDNA was prepared using DNA oligonucleotide primer "M2-B" (5'-CAC TGA TCC TTT CTT TTT CGT AAA CGA TAG GT-3'; SEQ ID NO:105) and "M2-B2" (5'-C ATC AAT CAA ATC TTC CAT ATA GAA ATG ACA-3'; SEQ ID NO:106), designed from known regions of *tez1* identified previously. An oligonucleotide linker PCR Adapt SfiI with a phosphorylated 5' end ("P") (P-GGG CCG TGT TGG CCT AGT TCT CTG CTC-3'; SEQ ID NO:107) was then ligated at the 3' end of this cDNA, and this construct was used as the template

for nested PCR. In the first round of PCR, PCR Adapt SFI and M2-B were used as the primers; while PCR Adapt SfiII (5-GAG GAG GAG AAG AGC AGA GAA CTA GGC CAA CAC GCC CC-3'; SEQ ID NO:108), and M2-B2 (SEQ ID NO:106) were used as primers in the second round. Nested PCR was used to increase specificity of reaction.

### Sequence Alignments

Once the sequence of *tez1* was identified, it was compared with sequences previously described. Figure 41 shows the alignment of RT domains from telomerase catalytic subunits of *S. pombe* ("S.p. Tez1p"), *S. cerevisiae* ("S.c. Est2p"), and *E. aediculatus* p123 ("E.a. p123"). In this Figure, "h" indicates hydrophobic residues, while "p" indicates small polar residues, and "c" indicates charged residues. The amino acid residues indicated above the alignment show a consensus RT motif described by Xiong (1990) *EMBO J.* 9: 3353-3362. The asterisks indicate the residues that are conserved for all three proteins. "Motif O" is identified herein and in Figure 41 as a motif specific to this telomerase subunit and not found in RTs in general. It is therefore valuable in identifying other amino acid sequences as telomerase catalytic subunits.

Figure 42 shows the alignment of entire sequences from *Euplotes* ("Ea\_p123"), *S. cerevisiae* ("Sc\_Est2p"), and *S. pombe* ("Sp\_Tez1p"). In Panel A, the shaded areas indicate residues shared between two sequences. In Panel B, the shaded areas indicate residues shared between all three sequences.

### Genetic Disruption of *tez1*

In this Example, the effects of disruption of *tez1* were investigated. As telomerase is involved in telomere maintenance, it was hypothesized that if *tez1* were indeed a telomerase component, disruption of *tez1* would cause gradual telomere shortening.

In these experiments, homologous recombination was used to disrupt the *tez1* gene in *S. pombe* specifically. This approach is schematically illustrated in Figure 43. As indicated in Figure 43, wild type *tez1* was replaced with a fragment containing the *ura4* or *LEU2* marker.

The disruption of *tez1* gene was confirmed by PCR (Figure 44) , and Southern blot was performed to check for telomere length. Figure 45 shows the Southern blot results for this experiment. Because an *ApaI* restriction enzyme site is present immediately adjacent to telomeric sequence in *S. pombe*, *ApaI* digestion of *S. pombe* genomic DNA preparations permits analysis of telomere length. Thus, DNA from *S. pombe* was digested with *ApaI* and the digestion products were run on an agarose gel and probed with a telomeric sequence-specific probe to determine whether the telomeres of disrupted *S. pombe* cells were shortened. The results are shown in Figure 45. From these results, it was clear that disruption of the *tez1* gene caused a shortening of the telomeres.

**EXAMPLE 17: Cloning and Characterization of Human Telomerase Reverse Transcriptase Protein and cDNA**

In this Example, the nucleic and amino acid sequence information for human telomerase reverse transcriptase was determined. Partial homologous human sequences were first identified in a BLAST search of the dbEST (expressed sequence tag) Genbank database, designated Genbank AA28196 (SEQ ID NO:62), which was conducted using the *Euplotes* 123 kDa peptide and nucleic acid sequences, as well as *Schizosaccharomyces* protein and corresponding cDNA (*tez1*) sequences. EST GenBank accession #AA281296, also referred to as "hTCP1.1," is a partial cDNA clone.

The AA281296 EST (SEQ ID NO:62) is 389 nucleotides long and its residue positions in hTERT cDNA clone (SEQ ID NO:117) are from residues 1679 to 2067:

--1679

GCCAAGTTCC TGCACCTGGCT GATGAGTGTG TACGTCGTCG AGCTGCTCAG 1728  
 GTCTTTCTTT TATGTCACGG AGACCACGTT TCAAAAGAAC AGGCTCTTTT 1778  
 TCTACCGGAA GAGTGTCTGG AGCAAGTTGC AAAGCATTGG AATCAGACAG 1828  
 5 CACTTGAAGA GGGTGCAGCT GCGGGAGCTG TCGGAAGCAG AGGTCAGGCA 1878  
 GCATCGGGAA GCCAGGCCCCG CCCTGCTGAC GTCCAGACTC CGCTTCATCC 1928  
 CCAAGCCTGA CGGGCTGCGG CCGATTGTGA ACATGGACTA CGTCGTGGGA 1978  
 GCCAGAACGT TCCGCAGAGA AAAGARGGCC GAGCGTCTCA CCTCGAGGGT 2028  
 GAAGGCACTG TTCAGCGTGC TCAACTACGA GCGGGCGCG 2067

10 (SEQ ID NO:62)--

A clone containing the AA28196 EST sequence, designated clone #712562 (SEQ ID NO:122), was obtained from the I.M.A.G.E. Consortium (Human Genome Center, DOE, Lawrence Livermore National Laboratory, Livermore, CA). This clone was obtained from a cDNA library of germinal B cells derived by flow sorting of tonsil  
 15 cells. Complete sequencing of this hTRT cDNA clone #712562 (SEQ ID NO:122, Figure 59), and analysis of the deduced translation product (SEQ ID NO:123, Figure 59) showed that it encoded all eight telomerase RT (TRT) motifs. In contrast to the polypeptide encoded by the hTRT open reading frame of the cDNA in pGRN121 (discussed below), clone #712562 did not encode a contiguous portion of a TRT,  
 20 because 182 base pairs are missing in clone 712562 that are present in the hTRT encoded in pGRN121. The coding sequence in clone #712562 encodes a 259 residue protein with a calculated molecular weight of approximately 30 kD (hereinafter, "712562 hTRT"). The 712562 hTRT polypeptide contains motifs T, 1,2, and A, but not motifs B', C, D and E, because RT motifs B', C, D, and E, are contained in a  
 25 different open reading frame than the more N-terminal RT motifs. In addition, the distance between RT motifs A and B was substantially shorter than that of the three previously known (non-human) TRTs.

Amino acid sequences from clone #712562 (SEQ ID NO:123) were aligned with the sequences determined as described in previous Examples. Figure 25 shows the  
 30 sequence alignment of the *Euplotes* ("p123"), *Schizosaccharomyces* ("tez1"), Est2p (*i.e.*, the *S. cerevisiae* protein encoded by the *Est2* nucleic acid sequence, and also

referred to herein as "L8543.12"), and the human homolog identified in this comparison search. The amino acid sequence of this aligned portion is provided in SEQ ID NO:67 (the cDNA sequence is provided in SEQ ID NO:62), while the portion of *tez1* shown in Figure 25 is provided in SEQ ID NO:63. The portion of Est2 shown in this Figure is also provided in SEQ ID NO:64, while the portion of p123 shown is also provided in SEQ ID NO:65. Figure 29 shows the amino acid sequence of *tez1* (SEQ ID NO:69), while Figure 30 shows the DNA sequence of *tez1* (SEQ ID NO:68). In Figure 30, the introns and other non-coding regions, are shown in lower case, while the exons (*i.e.*, coding regions) are shown in upper case.

As shown in Figure 25, there are regions that are highly conserved among these proteins. For example, as shown in this Figure, there are regions of identity in "Motif 0," "Motif 1," "Motif 2," and "Motif 3." The identical amino acids are indicated with an asterisk (\*), while the similar amino acid residues are indicated by a dot ( . ). This indicates that there are regions within the telomerase motifs that are conserved among a wide variety of eukaryotes, ranging from yeast to ciliates to humans. It is contemplated that TRT genes of additional organisms will likewise contain such conserved regions of sequence. Figure 27 shows a partial amino acid sequence (SEQ ID NO:67, see also Figure 25) of clone #712562 (SEQ ID NO:123) which encodes human telomerase motifs, while Figure 28 shows the corresponding DNA sequence (SEQ ID NO:62).

Sanger dideoxy sequencing and other methods were used as known in the art to obtain complete sequence information of clone 712562. Some of the primers used in the sequencing are shown in Table 3. These primers were designed to hybridize to the clone based on sequence complementarity to either plasmid backbone sequence or the sequence of the human cDNA insert in the clone.

Table 3. Primers

Primer	Sequence	SEQ ID NO:
TCP1.1	GTGAAGGCACTG TTCAGCG	SEQ ID NO:87
TCP1.2	GTGGATGATT TCTTGTTGG	SEQ ID NO:88
TCP1.3	ATGCTCCTGCGTTTGGTGG	SEQ ID NO:89
TCP1.4	CTGGACACTCAGCCCTTGG	SEQ ID NO:90
TCP1.5	GGCAGGTGTGCTGGACACT	SEQ ID NO:91
TCP1.6	TTTGATGATGCTGGCGATG	SEQ ID NO:92
TCP1.7	GGGGCTCGTCTTCTACAGG	SEQ ID NO:93
TCP1.8	CAGCAGGAGGATCTTGTAG	SEQ ID NO:94
TCP1.9	TGACCCCAGGAGTGGCACG	SEQ ID NO:95
TCP1.10	TCAAGCTGACTCGACACCG	SEQ ID NO:96
TCP1.11	CGGCGTGACAGGGCTGC	SEQ ID NO:97
TCP1.12	GCTGAAGGCTGAGTGTCC	SEQ ID NO:98
TCP1.13	TAGTCCATGTT CACAATCG	SEQ ID NO:99

From these experiments, it was determined that the EcoRI-NotI insert of clone 712562 contains only a partial open reading frame for the human telomerase protein, although it may encode an active fragment of that protein. The open reading frame in the AA281296 clone encodes an approximately 63 kD protein. The sequence of the longest open reading frame identified is shown in Figure 47 (SEQ ID NO:100). The ORF begins at the ATG codon with the "met" indicated in the Figure. The poly A tail at the 3' end of the sequence is also shown.

Figure 48 shows a tentative alignment, based on a preliminary sequence analysis, of the telomerase reverse transcriptase protein coding sequence from clone 712562 (human Telomerase Core Protein 1, "Hs TCP1"), *E. aediculatus* p123 ("Ep p123"), *S. pombe* tez1 ("Sp Tez1"), *S. cerevisiae* EST2 (Sc Est2"), and consensus sequence. In this Figure various motifs are indicated.

## PATENT

To obtain a full-length clone, probing of a cDNA library and 5'-RACE were used to obtain clones encoding portions of the previously uncloned regions. In these experiments, RACE (Rapid Amplification of cDNA Ends; *See e.g., M.A. Frohman, "RACE: Rapid Amplification of cDNA Ends," in Innis et al. (eds), PCR Protocols: A*  
5 *Guide to Methods and Applications*, 1990, pp. 28-38; and Frohman (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) was used to generate material for sequence analysis. Four such clones were generated and used to provide additional 5' sequence information (pFWRP5, 6, 19, and 20).

In addition, human cDNA libraries (inserted into lambda) were probed with the  
10 *EcoRI*-*NotI* fragment of clone 712562 (containing AA281296). One lambda clone, designated "lambda 25-1.1," (ATCC accession # 209024) was identified as containing complementary sequences. Figure 54 shows a restriction map of this lambda clone. The human cDNA insert from this clone was subcloned as an *EcoRI* restriction  
fragment into the *EcoRI* site of commercially available phagemid pBluescriptIISK+  
15 (Stratagene), to create the plasmid "pGRN121," which was deposited with the ATCC (ATCC accession #209016). Preliminary results indicated that plasmid pGRN121 contains the entire open reading frame (ORF) sequence encoding the human telomerase protein.

The cDNA insert of plasmid pGRN121 was sequenced using techniques known  
20 in the art. Figure 49 provides a restriction site and function map of plasmid pGRN121 identified based on this preliminary work. The results of this preliminary sequence analysis are shown in Figure 50.

From this analysis, and as shown in Figure 49, a putative start site for the coding region was identified at approximately 50 nucleotides from the *EcoRI* site  
25 (located at position 707), and the location of the telomerase-specific motifs, "FFYVTE" (SEQ ID NO:112), "PKP," "AYD," "QG", and "DD," were identified, in addition to a putative stop site at nucleotide #3571 (*See*, Figure 51). Figure 51 shows the DNA and corresponding amino acid sequences for the open reading frames in the sequence ("a" (SEQ ID NOS:316-343), "b" (SEQ ID NOS:344-356), and "c" (SEQ ID NOS:357-

365)). However, due to the preliminary nature of the early sequencing work, the reading frames for the various motifs were found not to be in alignment.

Additional analysis conducted on the pGRN121 indicated that the plasmid contained significant portions from the 5'-end of the coding sequence not present on the 712562 clone. Furthermore, pGRN121 was found to contain a variant coding sequence that includes an insert of approximately 182 nucleotides. This insert was found, as noted above, to be absent from clone 712562. As with the *E. aediculatus* sequences, such variants can be tested in functional assays, such as telomerase assays, to detect the presence of functional telomerase or a partial TRT activity in a sample.

A preliminary sequence analysis showed cDNA sequence and an open reading frame (SEQ ID NO:117 and 118, as shown in Figure 58). Further sequence analysis resolved the cDNA sequence (nucleotide sequence) of pGRN121, as shown in Figure 53 (SEQ ID NOS:117). A refined restriction and function map of pGRN121 based on this analysis, is provided in Figure 52. Analysis of this cDNA shows a contiguous open reading frame encoding a protein of molecular weight of approximately 127,000 daltons, and 1132 amino acids (SEQ ID NO:118):

```

MPRAPRCRAVRSLLRSHYREVLPLATFVRRLLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDA
RPPPAAPSFRQVSCLELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTV
TDALRGSGAWGLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHA
SGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGASRSRSLPLPKRPRRGAAPERTPVGGQ
SWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDT
PCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQR
YWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRL
VQLLRQHSSPWQVYGFVRACLRLVPPGLWGSRHNERFLRNTKKFISLGKHAKLSLQELTWK
MSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSEFFYVTETTFQKNRLFF
YRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPVNM DYV
GARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRWRTFVLRVRAQDPPP
ELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYA VVQKAAHGHVRKAFKSHVSTLTD
LQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQ
GSILSTLLCSLCYGD MENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVV
NLRKTVVNFVPEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNR
GFKAGRNMRRKLFGLVRLKCHSLFLDLQVNSLQTVCTNIYKILLQAYRFHACVLQLPFHQV

```

WKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLCLKLTRHRVTY  
VPLLGSRLTAQTQLSRKLP GTTLTALEAAANPALPSDFKTILD SEQ ID NO:118

5 A variant hTRT polypeptide with therapeutic and other activities may be  
expressed from a nucleic acid similar to the pGRN121 cDNA but lacking the 182 base  
pairs missing in clone 712562 (SEQ ID NO:122). This nucleic acid (hereinafter,  
"pro90 hTRT"), which may be synthesized using routine synthetic or recombinant  
methods as described herein, encodes a protein of 807 residues (calculated molecular  
weight of approximately 90 kD) that shares the same amino terminal sequence as the  
10 hTRT protein encoded by SEQ ID NO:118, but diverges at the carboxy-terminal region  
(the first 763 residues are common, the last 44 residues of pro90 hTRT are different  
than "full-length" hTRT). The pro90 hTRT polypeptide contains motifs T, 1, 2, and A,  
but not motifs B, C, D, E, and is thus expected to have some, but not all telomerase  
activities.

15 The invention provides still other recombinant, isolated or purified forms of  
naturally occurring hTRT species or non-naturally occurring variants. One example of a  
naturally occurring hTRT species not previously discussed results from ribosome  
frameshifting of mRNA encoded by the clone 712562 (SEQ ID NO:122) or hTRT  
cDNA (SEQ. ID. NO:117) sequence may result in the synthesis of hTRT polypeptides  
20 containing all the TRT motifs (see, *e.g.*, Tsuchihashi (1990) *Proc. Nat'l. Acad. Sci. USA*  
87:2516; Craigengen (1987) *Cell* 50:1; Weiss (1990) *Cell* 62:117). Ribosome  
frameshifting occurs when specific mRNA sequences and secondary structures cause  
the ribosome to "stall" and jump one nucleotide forwards or back in the sequence.  
Thus, a ribosome frameshift event on an mRNA corresponding to the hTRT sequence  
25 of clone 712562 would cause the synthesis of an approximately 523 residue  
polypeptide. A ribosome frameshift event on the pro90 sequence would result in a  
protein with approximately 1071 residues. It will be appreciated that hypothetical  
proteins resulting from ribosome frameshifting can also be expressed by routine  
synthetic or recombinant techniques.

**Example 18. Cloning and Sequencing Species of Telomerase**

The invention provides a genus of telomerases including telomerase species of human and non-human origin. The invention provides examples of a representative number of telomerase species of the genus and a recitation of structural features common to the members of the genus to be used in the detection and identification of telomerase isoforms and homologs and telomerases of other species and genera of eukaryotic organisms. Members of the genus of telomerase species of the instant invention include telomerase isolated from *Euplotes aediculatus* p123 gene (SEQ ID NO:1), *Oxytricha* (encoding SEQ ID NO:58), *Saccharomyces cerevisiae* (SEQ ID NO:66), *Tetrahymena*, and *Schizosaccharomyces pombe*, *trt1* (SEQ ID NO:68).

The present invention provides reagents and methods for identifying and cloning novel TRTs using: nucleic acid probes and primers generated or derived from the TRT polynucleotides for cloning TRT genes and cDNAs; and, antibodies that specifically recognize TRTs, including the motifs or other TRT epitopes for expression cloning of TRT genes or identification and purification of the genus of TRT polypeptides.

The hTRT nucleic acid sequence (from cDNA of SEQ ID NO:117) and protein sequence information (SEQ ID NO:118) provide PCR primers and oligonucleotides for the identification of telomerase gene(s) and cDNA. PCR primer pairs that can amplify sequences conserved amongst members of the TRT genus are preferred reagents of the invention to amplify new TRT isoforms and TRT species from other organisms directly.

Alternatively, oligonucleotides are useful to detect telomerase-encoding nucleic acids using a variety of hybridization techniques and conditions. These oligonucleotides can be generated using any known technique, including PCR, enzymatic restriction digestion of isolated DNA, or organic synthesis. These nucleic acids are labeled for detection and hybridized to DNA by any known technique, as described above.

Total RNA is extracted and enriched for mRNA using the QuickPrep Micro mRNA Purification Kit (Pharmacia, Piscataway, NJ) according to the manufacturer's instructions. The mRNA is then used to make cDNA templates by reverse transcription

using, for example, the avian myeloblastosis virus (AMV) reverse transcriptase (Pharmacia) as described by Sambrook. PCR is performed on the cDNA using, for example, a Techne PHC-3 thermal cycler (Techne, Princeton, NJ) using any set of primers whose sequence is based on a known hTRT sequence. PCR can also be used to  
5 amplify telomerase sequences from genomic DNA. Alternative variations of traditional PCR can be used, such as RACE, as described above. PCR amplification can use a variety of annealing conditions. For example, hTRT is amplified using the following cycling protocol: denaturing at 94°C, 45 seconds; annealing at 60°C, 45 seconds; and extension at 72°C, 90 seconds. This is repeated for a total of about 30 to 40 cycles,  
10 yielding a DNA product, which is purified. The PCR product can be sequenced by any known technique, such as the dideoxy-chain termination method using a Dye Terminator Cycle Sequencing Kit™ Ready Reaction Kit (Applied Biosystems, Foster City, CA) and a Model 373A DNA Sequencer (Applied Biosystems). The PCR product, once identified as a human telomerase sequence, is further labeled and used as  
15 a hybridization probe, as described above.

The invention provides for probes of TRT that are particularly useful for screening, including full length TRT cDNA (SEQ ID NOS:1, 3, 51, 53, 117) and various fragments of TRT cDNA. One such probe includes a portion of TRT encompassing approximately the first third of the cDNA (SEQ ID NO:117) (Figure 53).  
20 This region is more GC rich than the rest of TRT and can be especially useful in detecting non-human telomerase sequences. Therefore one can screen with probes to this region to minimize unwanted clones. Useful examples of this region include: a 1203 base pair Eco47 III fragment of pGRN121 (position 729 to 1932 of SEQ ID NO:117), and a 1530 base pair Pml1/Sph1 fragment of pGRN121 (position 748 to 2278  
25 of SEQ ID NO:117).

Another embodiment provides for a probe including a portion of TRT encompassing approximately the middle third of a TRT cDNA (*i.e.*, SEQ ID NO:117). This region encodes the RT motifs and is believed to be a highly conserved region. A useful example of the telomerase RT region includes a 1143 bp Sph1/Xmn1 fragment  
30 of pGRN121 (position 2278 to 3421 of SEQ ID NO:117).

An additional embodiment provides for a probe that is a portion of TRT encompassing approximately the last third of the TRT cDNA (*i.e.*, SEQ ID NO:117). This region encodes the region of hTRT that is least conserved among TRTs. A useful example of this region includes a 760 bp Xmn1/Msc1 fragment of pGRN121 (position  
5 3421 to 4594 of SEQ ID NO:117).

The experiment can be performed with a mix of the probes to ensure the detection of at least one clone. Once a clone is identified it can be screened with each probe independently to identify the region it encompasses. Then the probes can be used independently to find other related regions. When a clone is identified, a screen of a  
10 mouse (and other mammalian) genomic library can be performed using the mTRT clone as a probe. The initial hybridization using TRT probes should be performed at reduced stringency. As isoforms of TRT genes are expected to be about 60-95% identical to the TRT probe sequence, appropriate hybridization conditions are calculated; see for example, Sambrook.

15 Computer databases and programs can be used to analyze the resultant DNA sequence for its sequence identity, or homology, to known telomerase sequences, as described above. For example, PC/Gene™ software (IntelliGenetics Inc., Mountain View, CA) aligns sequences and displays open reading frames. BLAST N and BLAST D search algorithms can be employed to search the GenBank database (NIH, Bethesda,  
20 MD) for any matches between the derived telomerase sequence and known sequences.

### **Cloning of Mouse Telomerase-Encoding Sequences**

The hTRT and other TRT polynucleotides (*e.g.*, *Euplotes* 123 and 43 kDa encoding sequences, pGRN121) can be used to clone homologous TRTs from other  
25 species. In this example, the cloning of mouse TRT using hTRT probes is described.

To obtain a clone of telomerase from another organism, a hybridization experiment is typically performed. A probe from a TRT, which could be a PCR fragment(s) of a TRT cDNA or a region of a TRT gene, or a restriction fragment(s) of a plasmid, such as pGRN121, that includes all or part of a TRT coding sequence, is

hybridized to DNA from the target organism. Alternatively, as described above, antibody probes can be used.

A mouse TRT cDNA clone was obtained by plaque screening of a mouse  
lambda gt10 cDNA library (made using RNA from the D3 line of pluripotent embryonic  
stem cells) using a 1203 bp Eco47 III fragment of pGRN121 (position 729 to 1932 of  
5 pGRN121) and a 1143 bp Sph1/Xmn1 fragment of pGRN121 (position 2278 to 3421 of  
pGRN121) as probes. The mouse TRT (mTRT) clone sequence was subcloned into the  
EcoR1 site of pBluescript II KS (Stratagene, San Diego, CA). The subclone was  
sequenced and approximately 2 kilobases of 5' sequence obtained (nucleotides 1-2009  
10 of SEQ ID NO:124, as shown in Figure 60).

PCR amplification of mouse cDNA generated from oligo-dT primed mouse  
testis RNA was used to clone additional mTRT gene sequence. The primers used were  
mTRT.9 (5'-CTTTTACATCACAGAGAGCAC) (SEQ ID NO:125) and hTRT.28 (5'-  
CTCGGACCAGGGTCCTGAGGAA) (SEQ ID NO:126). Probe mTRT.9 was  
15 designed to position 1682-1702 of mTRT (Figure 60). Probe hTRT.28 was designed to  
position 2702-2723 of hTRT. The amplification of the mouse TRT gene using a primer  
designed from human TRT gene sequence is illustrative of the utility of the TRT  
sequences or the invention in obtaining clones from other organisms, especially  
mammals, such as mice, and other non-human animals (such as primates). The  
20 amplified DNA was cloned and sequenced (nucleotides 1682-2695 of SEQ ID NO:124,  
as shown in Figure 60).

Additional mTRT sequence was obtained from a BAC clone identified by  
hybridization screening of a pooled BAC library using a 760 bp Xmn1/Msc1 fragment  
of pGRN121 (position 3421 to 4181 of pGRN121). A 1.3 Kb PstI fragment from a  
25 positive BAC clone (BAC 495-M5) was identified as containing mTRT coding  
sequence by a Southern hybridization experiment using the 760 bp Xmn1/Msc1  
fragment as a probe. The Pst1 fragment was subcloned into the Pst1 site of pBluescript  
II KS (Stratagene) and sequenced (nucleotides 2890-3025 of SEQ ID NO:124, as  
shown in Figure 60). The additional portion of clone 495-2A2 contains a sequence  
30 non-homologous to hTRT and is believed to be an intron or vector sequence.

In Figure 60, "X"s represent uncloned regions of the mTRT gene and "Xs" represent cloned but unsequenced regions (with lengths determined by analogy to hTRT). The mTRT gene sequence can be extended to encode the carboxyl terminus of mTRT protein plus and a 3' untranslated region by standard methods known in the art.

5

*Applications of Mouse Telomerase-Encoding Sequences*

Mouse cDNA and genomic clones of telomerase are provided by the invention and can be used to construct homozygous deletions of mTRT; characterize mTRT biochemistry and biology; construct knockouts of both mTRT and the mouse equivalent of hTR (mTR); and, express hTRT and hTR in mouse transgenic knockouts of mTRT or mTRT/mTR. The mouse DNA could be genomic DNA, a genomic DNA library, RNA, cDNA, a cDNA library, or others. In one embodiment, a mouse cDNA library is screened to obtain a fragment of mTRT cDNA. This sequence can in turn be used to find a genomic clone or further cDNA clones. This approach may be preferred in the event the hTRT probe hybridizes to mouse cDNA than mouse genomic DNA due to introns in the genomic DNA library. The source of the cDNA library is important; it should preferably be from a tissue known to possess telomerase activity. A mouse embryonic stem cell cDNA library is a particularly good choice, as expression of telomerase in stem cells is relatively high compared to normal diploid cells.

15

20

25

The mouse genomic clone provides constructs useful to target and knockout the mTRT gene, in accordance with the discussion above concerning knockout procedures. To clone an entire telomerase gene, such as mTRT, large multiple genomic lambda clones can be used to span the entire genomic sequence. The mouse ES library used to isolate the mouse clone was the Mouse Embryonic Stem Cell 5'-STRETCH cDNA library, cat # ML1049a, from CLONTECH, average insert size 1.6 Kb (0.8 - 4.5 Kb range), vector = lgt10, oligo dT and random hexamer primed with EcoR I linkers, RNA source = D3 cell line (pluripotent ES cells) (Doetschman, T.C., et al. (1985) J. Embryol. Exp. Morphol. 87:27-45).

**Example 18. Identification of the Human Homologue of 43 kDa Telomerase**

The *Euplotes aediculatus* polynucleotide sequence (SEQ ID NO:3) encoding the 43 kDa polypeptide (SEQ ID NO:152-222 and SEQ ID NO:9) can be used to clone homologous TRTs from other species. Furthermore, antibodies that specifically recognize TRTs, including the 43 kDa TRT, can be used to identify additional isoforms and species from other organisms. The scientific and patent literature describes use of antibodies to identify closely related, cross-reactive species using a variety of techniques, for example, expression cloning of TRT genes or identification and purification of 43 kDa TRT polypeptides can be used to isolate the human homologue of the *Euplotes* p43 (43kDa) telomerase subunit gene.

In this illustrative example, the cloning of the gene encoding the human homologue of the *E. aediculatus* 43 kDa (p43) TRT using *E. aediculatus* oligonucleotide probes and antibodies reactive with *E. aediculatus* 43 kDa TRT is described.

***Production of 43 kDa-Specific Antibodies***

For generation of an antibody reactive with 43 kDa polypeptides, the following peptide was designed for use as an immunogen: CGGQKQLEFYFSDANLYNDSFL (SEQ ID NO:127). This peptide was conjugated to KLH (keyhole limpet hemocyanin) and BSA (bovine serum albumin). The peptide immunogen was used to generate murine and rabbit polyclonal antisera. After only two bleeds, the antisera with the highest titer was  $4.1 \times 10^4$ . The animals were boosted, using the same protocol. Peak bleed titers were at  $8 \times 10^5$  or better. Antibodies are isolated from the antisera using conventional techniques, such as immunogen peptide affinity columns. Monoclonal antibodies reactive to 43 kDa polypeptides are generated using standard techniques, including techniques which select antibodies from libraries of recombinant antibodies displayed in phage or similar on cells, as discussed above.

**Example 19: Design and Production of Yeast TRT-Specific Peptides**

The *S. cerevisiae* TRT polynucleotide sequence (SEQ ID NO:66) encoding the yeast TRT polypeptide (SEQ ID NO:64) can be also be used to clone homologous TRTs from other species. Antibodies that specifically recognize yeast TRT can be used to identify additional TRT isoforms and species from other organisms. In this illustrative example, antibodies specific for the yeast TRT polypeptides are generated.

For generation of an antibody reactive with *S. cerevisiae* TRT polynucleotide, the following peptide was designed for use as an immunogen:

NFNHSMRIIPKKSNNFRII (designated “yIPKK”) (SEQ ID NO:128)

and CLPELYFMKFDVKSCYDSIPRMECMRILK (designated “yCYDS”) (SEQ ID NO:129). These peptides were conjugated to KLH (keyhole limpet hemocyanin) and BSA (bovine serum albumin). The peptide immunogens were used to generate murine and rabbit polyclonal antisera.. The animals were immunized and boosted using the same protocol described for generation of *Euplotes* anti-p43 (43kDa) antibodies. Peak bleed titers were at  $8 \times 10^5$  or better. Antibodies are isolated from the antisera using conventional techniques, such as immunogen peptide affinity columns. Monoclonal antibodies reactive to *S. cerevisiae* TRT polynucleotide are generated using standard techniques, as discussed above.

**Example 20: Design and Construction of Vectors for Expression of TRT Peptides and Polynucleotides**

This example details the design of TRT-expressing bacterial and eukaryotic cell expression vectors to produce large quantities of full-length, biologically active TRTs. Generation of biologically active TRT protein in this manner is useful for telomerase reconstitution assays, assaying for telomerase activity modulators, analysis of the activity of newly isolated species of TRT, identifying and isolating compounds which specifically associate with TRT, analysis of the activity of an TRT variant protein that has been site-specifically mutated, and as an immunogen, as a few examples.

***Expression of TRT in Bacteria*****pThioHis A/hTRT Bacterial Expression Vector**

To produce large quantities of full-length TRT, the bacterial expression vector pThioHis A (Invitrogen, San Diego, CA) was selected as an expression system. The hTRT-coding insert includes nucleotides 707 to 4776 of the hTRT insert (SEQ ID NO:117) in the plasmid pGRN121. This nucleotide sequence includes the complete coding sequence for the hTRT protein.

This expression vector of the invention is designed for inducible expression in bacteria. The vector can be induced to express, in *E. coli*, high levels of a fusion protein composed of a cleavable, HIS tagged thioredoxin moiety and the full length hTRT protein. The use of the expression system was in substantial accordance with the manufacturer's instructions. The amino acid sequence of the fusion protein encoded by the resulting vector of the invention is shown below; (-\*-) denotes an enterokinase cleavage site (SEQ ID NO:130):

MSDKIIHLTDDSFDTDVLKADGAILVDFWAHWCGPCKMIAPILDEIADEYQGK  
 LTVAKLRIDHNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDAN  
 LAGSGSGDDDDK-\* -VPMHELEIFEFAAASTQRCVLLRTWEALAPATPAMPRAP  
 RCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVC  
 VPWDARPPPAAPSFRQVSCLELVARVLQRLCERGAKNVLAFGFALLDGARG  
 GPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLV  
 APSCAYQVCGPLYQLGAATQARPPPHASGPRRLGCERAWNHSVREAGVPL  
 GLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSD  
 RGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPC  
 PPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTP  
 RRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAR  
 EKPQGSVAAPEEEDTDPRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGS  
 RHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPA  
 EHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKS VWSKLQ  
 SIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPVNM DYVV  
 GARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRWRTF

VLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVV  
 QKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNE  
 ASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGD MENKLF  
 AGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNF  
 5 PVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTF  
 NRGFKAGRNMRRKLFGLRLKCHSLFLDLQVNSLQTVCTNIYKILLQAYRFH  
 ACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLP  
 SEAVQWLCHQAFLKLTRHRVTYVPLLGSLRTAQTQLSRKLP GTTLTALEAAA  
 NPALPSDFKTILD

10

#### **pGEX-2TK with hTRT Nucleotides 3272 to 4177 of pGRN121**

This construct of the invention is used to produce fusion protein for, e.g., the purpose of raising polyclonal and monoclonal antibodies to TRT protein. Fragments of TRT can also be used for other purposes, such as to modulate telomerase activity, for example, as a dominant-negative mutant or to prevent the association of a telomerase component with other proteins or nucleic acids.

To produce large quantities of a TRT protein fragment, the *E. coli* expression vector pGEX-2TK (Pharmacia Biotech, Piscataway N.J) was selected, and used essentially according to manufacturer's instructions to make an expression vector of the invention. The resulting construct contains an insert derived from nucleotides 3272 to 4177 of the hTRT insert (SEQ ID NO:117) in the plasmid pGRN121. The vector directs expression in *E. coli* of high levels of a fusion protein composed of glutathione-S-transferase sequence (underlined below), thrombin cleavage sequence (double underlined), recognition sequence for heart muscle protein kinase (italicized), residues introduced by cloning in brackets ([GSVTK]; SEQ ID NO:20) and hTRT protein fragment (in bold) as shown below (SEQ ID NO:131):

MSPILGYWKIKGLVOPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP  
NLPYYIDGDVKLTQSMARIYIADKHNM LGGCPKERA EISMLEGAVLDIRYGVS  
RIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDAL  
 30 DVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKYLKSSKYIAWPLOGWQATFGG  
GDHPPKSDLVPRGSRRASV[GSVTK]**IPQGSILSTLLCSLCYGD MENKLFAGIR**

RDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNF  
 VEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASV  
 TFNRGFKAGRNMRRKLFGLRLKCHSLFLDLQVNSLQTVCTNIYKILLQ  
 AYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGA  
 5 KGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKL  
 PGTTLTALEAAANPALPSDFKTILD

When this fusion protein was expressed, it formed insoluble aggregates. It was treated generally as described above, in the section entitled purification of proteins from inclusion bodies. Specifically, induced cells were suspended in PBS (20 mM sodium phosphate, pH 7.4, 150 mM NaCl) and disrupted by sonication. NP-40 was added to 0.1%, and the mixture was incubated for 30 minutes at 4°C with gentle mixing. The insoluble material was collected by centrifugation at 25,000g for 30 minutes at 4°C. The insoluble material was washed once in 4M urea in PBS, collected by centrifugation, then washed again in PBS. The collected pellet was estimated to contain greater than 75% fusion protein. This material was dried in a speed vacuum, then suspended in adjuvant for injection into mice and rabbits for the generation of antibodies.

#### 20 **pGEX-2TK with hTRT Nucleotides 2426 to 3274 of pGRN121 with HIS-8 Tag**

To produce large quantities of a fragment of TRT, another *E. coli* expression vector pGEX-2TK construct was prepared. This construct contains an insert derived from nucleotides 2426 to 3274 of the hTRT insert (SEQ ID NO:117) in the plasmid pGRN121 and a sequence encoding eight consecutive histidine residues (HIS-8 Tag). To insert the HIS-8 TAG, the pGEX-2TK vector with hTRT nucleotides 2426 to 3274 of pGRN121 was linearized with BamH1. This opened the plasmid at the junction between the GST-thrombin-heart muscle protein kinase and the hTRT coding sequence. A double stranded oligonucleotide with BamH1 compatible ends was ligated to the linearized plasmid resulting in the in-frame introduction of eight histidine residues upstream of the hTRT sequence.

The vector directs expression in *E. coli* of high levels of a fusion protein composed of glutathione-S-transferase sequence (underlined); thrombin cleavage

sequence (double underlined); recognition sequence for heart muscle protein kinase (italicized); a set of three and a set of five residues introduced by cloning are in brackets ([GSV] and [GSVTK]; SEQ ID NO:20); eight consecutive histidines (also double underlined); and hTRT protein fragment (in bold) (SEQ ID NO:132):

5 MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP  
NLPYYIDGDVKLTQSMAIRYIADKHNMMLGGCPKERAEISMLEGAVLDIRYGVS  
RIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDEMLYDAL  
DVVLVMDPMDCLDAFPKLVCFKKRIEAIPOIDKYLKSSKYIAWPLOGWOATFGG  
GDHPPKSDLVPRGSRRASV[GSV]HHHHHHHHH[GSVTK]**MSVYVVELLRSFFYV**  
10 **TETTFQKNRLFFYRPSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARP**  
**ALLTSRLRFIPKPDGLRPVNM DYVVGARTFRREKRAERLTSRVKALFSVL**  
**NYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTG**  
**AYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTL**  
**TDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHA**  
15 **VRIRGKSYVQCQGI**

Each of the pGEX-2TK vectors of the invention can be used to produce fusion protein for the purpose of raising polyclonal and monoclonal antibodies to hTRT protein. Additionally, this fusion protein can be used to affinity purify antibodies  
20 raised to TRT peptides that are encompassed within the fusion protein. Separation of the recombinant protein from the glutathione S-transferase moiety can be accomplished by site-specific proteolysis using thrombin according to manufacturer's instructions.

#### **pGEX-2TK with hTRT Nucleotides 2426 to 3274 of pGRN121, no HIS-8 Tag**

25 To produce large quantities of a fragment of TRT, another *E. coli* expression vector pGEX-2TK construct was prepared.

This construct contains an insert derived from nucleotides 2426 to 3274 of the hTRT insert (SEQ ID NO:117) in the plasmid pGRN121, but without the HIS-8 tag of the construct described above. The vector directs expression in *E. coli* of high levels of  
30 a fusion protein composed of glutathione-S-transferase (underlined), thrombin cleavage sequence (double underlined), recognition sequence for heart muscle protein kinase (italicized), residues introduced by cloning in brackets ([GSVTK]; SEQ ID NO:20) and hTRT protein fragment (in bold) (SEQ ID NO:133):

MSPILGYWKIKGLVOPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP  
 NLPYYIDGDVKLTQSMARIYIADKHNMLGGCPKERAISMLEGAVLDIRYGVS  
 RIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDAL  
 DVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKYLKSSKYIAWPLOGWQATFGG  
 5 GDHPPKSDLVPRGSRRASV[GSVTK]MSVYVVELLRSFFYVTETTFQKNRLFF  
 YRPSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPK  
 PDGLRPIVNMMDYVVGARTFRREKRAERLTSRKALFSVLNYERARRPGLLG  
 ASVLGLDDIHRAWRTFVLRVRAQDPPPEYFVKVDVTGAYDTIPQDRLTEVI  
 ASIIKPQNTYCVRRYAVVQKAAHGVRKAFAKSHVSTLTDLQPYMRQFVAHL  
 10 QETSPLRDAVVIEQSSSLNEASGLFDVFLRFMCHHAVRIRGKSYVQCQGI

#### pGEX-2TK with hTRT Nucleotides 1625 to 2458 of pGRN121

To produce large quantities of a fragment of TRT protein, another *E. coli* expression vector pGEX-2TK construct was prepared.

15 This construct contains an insert derived from nucleotides 1625 to 2458 of the  
 hTRT insert (SEQ ID NO:117) in the plasmid pGRN121. The vector directs expression  
 in *E. coli* of high levels of a fusion protein composed of glutathione-S-transferase,  
 (underlined), thrombin cleavage sequence (double underlined), recognition sequence  
 for heart muscle protein kinase (italicized) residues introduced by cloning in brackets  
 20 ([GSVTK]; SEQ ID NO:20) and hTRT protein fragment (in bold) (SEQ ID NO:134):

MSPILGYWKIKGLVOPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP  
 NLPYYIDGDVKLTQSMARIYIADKHNMLGGCPKERAISMLEGAVLDIRYGVS  
 RIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDAL  
 DVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKYLKSSKYIAWPLOGWQATFGG  
 25 GDHPPKSDLVPRGSRRASV[GSVTK]ATSLEGALSGTRHSHPSVGRQHHAGPP  
 STSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRL  
 VETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLL  
 KTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRLVQLLRQHSSPW  
 QVYGFVRACLRLVPPGLWGSRHNERFLRNTKKFISLGKHAKLSLQELT  
 30 WKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELL  
 RS

#### pGEX-2TK with hTRT Nucleotides 782 to 1636 of pGRN121

35 To produce large quantities of a fragment of TRT protein, another *E. coli*  
 expression vector pGEX-2TK construct was prepared.

This construct contains an insert derived from nucleotides 782 to 1636 of the  
 hTRT insert (SEQ ID NO:117) in the plasmid pGRN121. The vector directs expression

in *E coli* of high levels of a fusion protein composed of glutathione-S-transferase, (underlined), thrombin cleavage sequence (double underlined), recognition sequence for heart muscle protein kinase (italicized) residues introduced by cloning in brackets ([GSVTK]; SEQ ID NO:20) and hTRT protein fragment (in bold) (SEQ ID NO:135):

5 MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFP  
NLPYYIDGDVKLTQSMAIRYIADKHNMILGGCPKERAISMLEGAVLDIRYGVS  
RIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDAL  
DVVLVMDPMCLDAFPKLVCFKKRIEAIPOIDKYLKSSKYIAWPLOGWQATFGG  
GDHPPKSDLVPRGSRRASV[GSVTK]**MPRAPRCRAVRSLLSHYREVLPLATFV**  
10 **RRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPAAPSRQVSC**  
**ELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEATTSVRSYLPNTVTD**  
**ALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPCAYQVCGPPLYQLG**  
**AATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSAS**  
15 **RSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPA**  
**EEATSL**

#### **pT7FLhTRT with hTRT cDNA Lacking 5'-Non-Coding Sequence**

As described above, in one embodiment, the invention provides for an TRT that is modified in a site-specific manner to facilitate cloning into bacterial, mammalian, yeast and insect expression vectors without any 5' untranslated TRT sequence. In some circumstances, minimizing the amount of non-protein encoding sequence allows for improved protein production (yield) and increased mRNA stability. In this embodiment of the invention, the TRT gene's 5' non-coding region was removed before cloning into a bacterial expression vector.

25 This was effected by engineering an additional restriction endonuclease site just upstream (5') to the start (ATG) codon of the hTRT coding sequence (Figure 53, SEQ ID NO:117). The creation of a restriction site just 5' to the coding region of the protein allows for efficient production of a wide variety of vectors that encode fusion proteins, such as fusion proteins comprising labels and peptide TAGs, for immunodetection and  
30 purification.

Specifically, the oligonucleotide 5'-CCGGCCACCCCCCATATGCCGCGCGCTCCC-3' (SEQ ID NO:136) was used as described above to modify hTRT cDNA nucleotides 779 to 781 of the hTRT cDNA

(SEQ ID NO:117) from GCG to CAT. These 3 nucleotides are the last nucleotides before the ATG start codon so they do not modify the protein sequence. The change in sequence results in the creation of a unique NdeI restriction site in the hTRT cDNA.

Single-stranded hTRT DNA was used as a DNA source for the site directed  
5 mutagenesis. The resulting plasmid was sequenced to confirm the success of the mutagenesis.

This modification allowed the construction of the following plasmid of the invention, designated pT7FLhTRT. The site-specifically modified hTRT sequence (addition of the NdeI restriction site) was digested with NdeI and NotI (and filled in  
10 with Klenow fragment to generate a blunt ended DNA) to generate an hTRT encoding nucleic acid fragment. The fragment was then cloned into a pSL3418 plasmid previously restriction digested with NdeI and SmaI (also a blunt ended cutter). pSL 3418 is a modified pAED4 plasmid into which a FLAG sequence (Immunex Corp, Seattle WA) and an enterokinase sequence are inserted just upstream from the above-  
15 referenced NdeI site. This plasmid, designated pT7FLhTR, allows the expression of full length hTRT (with a Flag-Tag at its 5' end) in an *E.coli* strain expressing the T7 RNA polymerase.

#### **Plasmids with hTRT cDNA Lacking 3'-Non-Coding Sequence**

20 As discussed above, the invention provides for expression vectors containing TRT-encoding nucleic acids in which some or all non-coding sequences have been deleted. In some circumstances, minimizing the amount of non-protein encoding sequence allows for improved protein production (yield) and increases mRNA stability. In this embodiment of the invention, the 3' untranslated region of TRT is deleted before cloning into a bacterial  
25 expression plasmid.

The plasmid pGRN121, containing the full length hTRT cDNA, as discussed above, was first deleted of all ApaI sites. This was followed by deletion of the MscI-HincII hTRT restriction digest enzyme fragment containing the 3'UTR. The NcoI-XbaI restriction digest fragment containing the stop codon of hTRT was then inserted  
30 into the NcoI-XbaI site of pGRN121, designated pGRN124, except lacking the 3'UTR.

**Bacterial Expression Vectors Using Antibiotic Selection Markers**

The invention also provides for bacterial expression vectors that can contain selection markers to confer a selectable phenotype on transformed cells and sequences coding for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode antibiotic resistance, particularly resistance to chloramphenicol (see Harrod (1997) *Nucleic Acids Res.* 25: 1720-1726), kanamycin, G418, bleomycin and hygromycin, to permit selection of those cells transformed with the desired DNA sequences, see for example, Blondelet-Rouault (1997) *Gene* 190:315-317; and Mahan (1995) *Proc Natl Acad Sci U S A* 92:669-673.

In one embodiment of the invention, the full length hTRT was cloned into a modified BlueScript plasmid vector (Stratagene, San Diego, CA), designated pBBS235, into which a chloramphenicol antibiotic resistance gene had been inserted. The NotI fragment from pGRN124 (discussed above) containing the hTRT ORF into the NotI site of pBBS235 so that the TRT ORF is in the opposite orientation of the vector's Lac promoter. This makes a plasmid that is suitable for mutagenesis of plasmid inserts, such as TRT nucleic acids of the invention. This plasmid construct, designated pGRN125, can be used in the methods of the invention involving mutagenesis of telomerase enzyme and TRT protein coding sequences and for *in vitro* transcription of hTRT using the T7 promoter (and *in vitro* transcription of antisense hTRT using the T3 promoter).

In another embodiment of the invention, NotI restriction digest fragments from pGRN124 containing the hTRT ORF were subcloned into the NotI site of pBBS235 (described above) so the TRT ORF is in the same orientation as the vector's Lac promoter. This makes a plasmid, designated pGRN126, that can be used for expression of full length hTRT in *E. coli*. The expressed product will contain 29 amino acids encoded by the vector pBBS235, followed by 18 amino acids encoded by the 5'UTR of hTRT, followed by the full length hTRT protein.

In a further embodiment of the invention, *in vitro* mutagenesis of pGRN125 was done to convert the hTRT initiating ATG codon into a Kozak consensus and create EcoRI and BglII restriction digest sites to facilitate cloning into expression vectors. The oligonucleotide 5'-TGCGCACGTGGGAAGCCCTGGCagatctgAatt

CCaCcATGCCGCGCGCTCCCCGCTG-3' (altered nucleotides in lower case) (SEQ ID NO:137) was used in the mutagenesis procedure. The resulting expression vector was designated pGRN127.

5 In another embodiment of the invention, the second Asp of the TRT "DD motif" was converted to an alanine to create a non-functional telomerase enzyme, thus creating a mutant TRT protein for use as a dominant/negative mutant. The hTRT coding sequence was mutagenized *in vitro* using the oligonucleotide 5'-CGGGACGGGCTGCTCCTGCGTTTGGTGGAcGcgTTCTTGTTGGTGACACCTCA  
10 CCTCACC-3' (SEQ ID NO:138) to convert the asparagine codon for residue 869 (Asp869) to an alanine (Ala) codon. This also created an MluI restriction enzyme site. The resulting expression plasmid was designated GRN130, which also contains the Kozak consensus sequence as described for pGRN127.

In another embodiment of the invention, oligonucleotide 5'-TGCGCACGTGGGAAGCCCTGGCagatctgAattCCaCcATGCCGCGCGCTCCCCGCTG-  
15 3' (SEQ ID NO:137) was used in an *in vitro* mutagenesis procedure to convert the hTRT initiating ATG codon into a Kozak consensus sequence and to create EcoRI and BglII restriction sites for cloning.

The invention also provides a vector designed to express an antisense sequence fragment of hTRT. The pGRN126 plasmid was cut to completion with MscI and SmaI  
20 restriction enzymes and religated to delete over 95% of the hTRT ORF. One SmaI-MscI fragment was re-inserted during the process to recreate CAT activity. This unpurified plasmid was then redigested with SalI and EcoRI and the fragment containing the initiating codon of the hTRT ORF was inserted into the SalI-EcoRI sites of pBBS212 to make an antisense expression plasmid expressing the antisense sequence spanning the 5'UTR and  
25 73 bases pair residues of the hTRT ORF. This plasmid was designated pGRN135.

***Expression of hTRT Telomerase in Yeast***

The present invention also provides TRT-expressing yeast expression vectors to produce large quantities of full-length, biologically active TRT.

5 **Pichia pastoris Expression Vector pPICZ B and Full Length hTRT**

To produce large quantities of full-length, biologically active TRT, the *Pichia pastoris* expression vector pPICZ B (Invitrogen, San Diego, CA) was selected. The hTRT-coding sequence insert was derived from nucleotides 659 to 4801 of the hTRT insert (SEQ ID NO:117) in plasmid pGRN121. This nucleotide sequence includes the full-length  
 10 sequence encoding hTRT. This expression vector is designed for inducible expression in *P. pastoris* of high levels of full-length, unmodified hTRT protein. Expression is driven by a yeast promoter, but the expressed sequence utilizes the hTRT initiation and termination codons. No exogenous codons were introduced by the cloning. The resulting pPICZ B/hTRT vector was used to transform the yeast.

15

**Pichia pastoris Expression Vector hTRT-His6/pPICZ B**

A second *Pichia pastoris* expression vector of the invention derived from pPICZ B, also contains the full-length sequence encoding hTRT derived from nucleotides 659 to 4801 of the hTRT insert (SEQ ID NO:117) in the plasmid pGRN121. This  
 20 hTRT-His6/pPICZ B expression vector encodes full length hTRT protein fused at its C-terminus to the Myc epitope and His6 reporter tag sequences. The hTRT stop codon has been removed and replaced by vector sequences encoding the Myc epitope and the His6 reporter tag as well as a stop codon. This vector is designed to direct high-level inducible expression in yeast of the following fusion protein, which consists of hTRT sequence  
 25 (underlined), vector sequences in brackets ([L] and [NSAVD]; SEQ ID NO:21) the Myc epitope (double underlined), and the His6 tag (italicized) (SEQ ID NO:140):

30 MPRAPRCRAVRSLLRSHYREVLPLATFVRRLLGPOGWRLVQRGDPAAFRALVA  
OCLVCVPWDARPPPAAPSFQVSLKELVARVLQRLCERGAKNVLAFGFALL  
DGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARC  
ALFVLVAPSCAYOVCGPPLYQLGAATOARPPPHASGPRRRRLGCERAWNHSVR  
EAGVPLGLPAPGARRRGGSASRSLPLKPRRRGAAPERTPVGOGSWAHPGR  
TRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGROHHAGPPSTSRPPR

PWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRP  
 WMPGTPRRLPRLPORYWQMRPLFLELLGNHAOCPYGVLLKTHCPLRAAVTPA  
 AGVCAREKPOGSVAAPEEEDTDPRLVOLLROHSSPWQVYGFVRACLRLRVP  
 PGLWGSRHNERFLRNTKKFISLGKHAKLSLOELTWKMSVRDCAWLRRSPGV  
 5 GCVPAAEHRLREEILAKFLHWLMSVYVVELLRSEFFYVTETTFQKNRLEFFYRKS  
 VWSKLQSIGIROHLKRVOLRELSAEVROHREARPALLTSRLRFIPKPDGLRPIV  
 NMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIH  
 RAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPODRLTEVIASIIKPONTYCV  
 RRYAVVOKAAHGHVRKAFKSHVSTLTDLOPYMRQFVAHLOETSPLRDAVVIE  
 10 QSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVOCQGIPOGSILSTLLCSLCYGD  
 MENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLR  
 KTVVNFVVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSI  
 RASLTENRGFKAGRNMRRKLFGLRLKCHSLFLDLQVNSLOTVCTNIYKILLLO  
 AYRFHACVLQLPFHQOVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGA  
 15 AGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGLSLRTAQTQLSRKLPGTTLTA  
 LEAAANPALPSDFKTILD[L]EQKLISEEDL[NSAVD]HHHHHH

Separation of the recombinant protein from the glutathione S-transferase moiety  
 is accomplished by site-specific proteolysis using thrombin according to manufacturer's  
 20 instructions.

### Expression of TRT in Insect Cells

The present invention also provides TRT telomerase-expressing insect cell  
 expression vectors that produce large quantities of full-length, biologically active TRT.  
 25

### Baculovirus Expression Vector pVL1393 and Full Length TRT

The TRT coding sequence of interest was cloned into the baculovirus expression  
 vector pVL1393 (Invitrogen, San Diego, CA). This construct was subsequently  
 cotransfected into *Spodoptera frugiperda* (sf-9) cells with linearized DNA from  
 30 *Autographa californica* nuclear polyhedrosis virus (Baculogold-AcMNPV). The recombinant  
 baculoviruses obtained were subsequently plaque purified and expanded following  
 standard protocols.

This expression vector provides for expression in insect cells of high levels of  
 full-length TRT protein. Expression is driven by a baculoviral polyhedrin gene promoter.  
 35 No exogenous codons were introduced by the cloning.

### **Baculovirus Expression Vector pBlueBacHis2 B and Full Length hTRT**

To produce large quantities of full-length, biologically active TRT, the baculovirus expression vector pBlueBacHis2 B (Invitrogen, San Diego, CA) was selected as a source of control elements. The hTRT-coding insert consisted of nucleotides 707 to 4776 of the hTRT insert (SEQ ID NO:117) in plasmid pGRN121.

A full length hTRT with a His6 and Anti-Xpress tags (Invitrogen) was also constructed. This vector also contains an insert consisting of nucleotides 707 to 4776 of the hTRT insert from the plasmid pGRN121. The vector directs expression in insect cells of high levels of full length hTRT protein fused to a cleavable 6-histidine and Anti-Xpress tags, and the amino acid sequence of the fusion protein is shown below; (-\*-) denotes enterokinase cleavage site (SEQ ID NO:141):

```

MPRGSHHHHHHGMASMTGGQQMGRDLYDDDDL-*--DPSSRSAAGTMEFAAA
STQRCVLLRTWEALAPATPAMPRAVRSLLRSHYREVLPLATFVRRLLGP
QGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSKELVARVL
QRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAW
GLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPH
ASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGA
APEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHS
HPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSS
LRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQ
CPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRLVQLLRQH
SSPWQVYGFRACLRLVPPGLWGSRHNERFLRNTKKFISLGKHAKLSLQEL
TWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSF
FYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARP
ALLTSRLRFIPKPDGLRPVNM DYVVGARTFRREKRAERLTSRVKALFSVLNVE
RARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIP
QDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMR
QFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQC
QGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTF
LRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLL
DTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGLVRLKCHSLFLDL
QVNSLQTVCTNIYKILLQAYRFHACVLQLPFHQVWKNPTFFLRVISDTASLC
YSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGS
LRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD

```

### **Baculovirus Expression Vector pBlueBac4.5 and Full Length hTRT Protein**

To produce large quantities of full-length, biologically active TRT, a second baculovirus expression vector, pBlueBac4.5 (Invitrogen, San Diego, CA) was constructed.

The hTRT-coding insert also consisted of nucleotides 707 to 4776 of the hTRT (SEQ ID NO:117) from the plasmid pGRN121.

### **Baculovirus Expression Vector pMelBacB and Full Length TRT Protein**

5           To produce large quantities of full-length, biologically active TRT, a third baculovirus expression vector, pMelBacB (Invitrogen, San Diego, CA) was constructed. The hTRT-coding insert also consists of nucleotides 707 to 4776 of the hTRT insert from the plasmid pGRN121.

          pMelBacB directs expression of full length TRT in insect cells to the  
10   extracellular medium through the secretory pathway using the melittin signal sequence. High levels full length TRT are thus secreted. The melittin signal sequence is cleaved upon excretion, but is part of the protein pool that remains intracellularly. For that reason, it is indicated in parentheses in the following sequence. The sequence of the fusion protein encoded by the vector is shown below (SEQ ID NO:142):

15   (MKFLVNVALVFMVVYISYIYA)-\*-DPSSRSAAGTMEFAAASTQRCVLLRTWE  
ALAPATPAMP RAPRCRAVRSLLRSHYREVLPLATFVRR LGPQGWRLVQR GDP  
AAFRALVAQCLVCVPWDARPPPAAPSFQV SCLKELVARVLQRLCERGAKNV  
LAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGGDVL  
VHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRLGCERA  
20   WNHVSREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGS  
WAHPGRTRGPSDRGFCVVS PARPAEEATSLEGALSGTRHSHPSVGRQHHAGPP  
STSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVET  
IFLGSRPWMPGT PRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLR  
AAVTPAAGVCAREKPQGSVA APEEEDTDPRRLVQLLRQHSSPWQVYGFVRAC  
25   LRRLVPPGLWGSRHNERFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWL  
RRSPGVGCVPA AEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRL  
FFYRKS VWSKLQSIGIRQHLKRVQLRELSAEVRQHREARPALLTSRLRFIPKPD  
GLRPVNM DYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVL  
GLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIP  
30   QNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLR  
DAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLC  
SLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYG  
CVVNLRKTVVNFVPEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYS  
SYARTSIRASLTFNRGFKAGRNMRRLFGVLR LKCHSLFLDLQVNSLQTVCTNI  
35   YKILLQAYRFHACVLQLPFHQVWKNPTFFLRVISDTASLCYSILKAKNAGMS  
LGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLP  
GTTLTAL EAAANPALPSDFKTILD

### **Expression of TRT in Mammalian Cells**

The present invention also provides vectors to produce TRT in large quantities as full-length, biologically active protein in a variety of mammalian cell lines, which is useful  
5 in many embodiments of the invention, as discussed above.

### **MPSV-TRT Expression Plasmids**

The invention also provides for an expression system for use in mammalian cells that give the highest possible expression of recombinant protein, such as telomerase,  
10 without actually modifying the coding sequence (*e.g.* optimizing codon usage). In one embodiment, the invention provides MPSV mammalian expression plasmids (using a system described by Lin J-H (1994) *Gene* 47:287-292) capable of expressing the TRTs of the invention. The MPSV plasmids can be expressed either as stable or transient clones.

In this expression system, while the hTRT coding sequence itself is unchanged,  
15 exogenous transcriptional control elements are incorporated into the vector. The myeloproliferative sarcoma virus (MPSV) LTR (MPSV-LTR) promoter, enhanced by the cytomegalovirus (CMV) enhancer, is incorporated for transcriptional initiation. This promoter consistently shows higher expression levels in cell lines (see Lin J-H (1994) *supra*). A Kozak consensus sequence can be incorporated for translation initiation (see  
20 Kozak (1996) *Mamm. Genome* 7:563-574). All extraneous 5' and 3' untranslated hTRT sequences can be removed to insure that these sequences do not interfere with expression, as discussed above. The MPSV plasmid containing the complete hTRT coding sequence, but with all extraneous sequences removed, is designated pGRN133. A control, hTRT “antisense” plasmid was also constructed. This vector is identical to pGRN133 except that  
25 the TRT insert is the antisense sequence of hTRT (the antisense, which control can be used as a vector is designated pGRN134).

Two selection markers, PAC (Puromycin-N-acetyl-transferase = Puromycin resistance) and HygB (Hygromycin B = Hygromycin resistance) are present for selection of the plasmids after transfection (see discussion referring to selectable markers, above).  
30 Double selection using markers on both sides of the vector polylinker should increase the

stability of the hTRT coding sequence. A DHFR (dihydrofolate reductase) encoding sequence is included to allow amplification of the expression cassette after stable clones are made. Other means of gene amplification can also be used to increase recombinant protein yields.

5           The invention also provides for MPSV mammalian expression plasmids containing TRT fusion proteins. In one embodiment, the TRT sequence, while retaining its 5' untranslated region, is linked to an epitope flag, such as the IBI FLAG (International Biotechnologies Inc. (IBI), Kodak, New Haven, CT) and inserted into the MPSV expression plasmid (designated pGRN147). This particular construct contains a Kozak  
10 translation initiation site. The expressed fusion protein can be purified using the M-1 anti-FLAG octapeptide monoclonal antibody (IBI, Kodak, supra).

          In another embodiment, TRT is site-specifically altered. One amino acid residue codon is mutagenized, changing the aspartic acid at position 869 to an alanine. This Asp869->Ala hTRT mutant, retaining its 5' untranslated region and incorporating a Kozak  
15 sequence, was inserted into an MPSV expression plasmid, and designated pGRN146. The Asp869->Ala hTRT mutant was further engineered to contain the FLAG sequence, as described above, and the insert cloned into an MPSV expression plasmid. This expression plasmid was designated pGRN154. Specifically, for pGRN154, an Eam1105I restriction digest fragment from pGRN146 containing the Kozak sequence-containing "front end" (5'  
20 segment) of hTRT was cloned into the Eam1105I sites of pGRN147 (see above) to make an MPSV expression plasmid capable of expressing hTRT with a Kozak sequence, the above-described D869->A mutation, and the IBI flag.

          Another embodiment of the invention is an expression plasmid derived from pGRN146. The mammalian expression plasmid, designated pGRN152, was generated by  
25 excising the EcoRI fragment from plasmid pGRN146 (containing the TRT ORF in mammalian cells) and cloned into the EcoRI site of pBBS212 to remove the 5'UTR of hTRT. The hTRT is oriented so that its expression is controlled by the MPSV promoter. This makes a mammalian expression plasmid that expresses hTRT with a Kozak consensus sequence and the D869->A mutation, and uses the MPSV promoter.

## PATENT

The invention provides for a mammalian expression vector in which TRT is oriented so that the TRT coding sequence is driven by the MPSV promoter. For example, an EcoR1 restriction digest fragment from pGRN137 containing the hTRT open reading frame (ORF) was cloned into the EcoR1 site of pBBS212 (see below), thus removing the 5' untranslated region (5'-UTR) of hTRT. pGRN137 was constructed by excising a Sall-Sse8387I fragment from pGRN130, described below, containing the Kozak mutation of hTRT into the Sal 1-SSE 8387I sites of pGRN136, making a mammalian expression plasmid expressing hTRT containing a Kozak consensus sequence off the MPSV promoter. Plasmid pGRN136 was constructed by excising a HindIII Sall fragment from pGRN126 containing the hTRT ORF and cloning it into the HindIII Sall sites of plasmid, pBBS242, making a mammalian expression plasmid expressing hTRT off the MPSV promoter). This makes a mammalian expression plasmid, designated pGRN145, that expresses hTRT with a Kozak consensus sequence using the MPSV promoter. See also the pGRN152 MPSV promoter-driven mammalian expression vector described below.

15

### **TRT Expressed in 293 Cells using Episomal Vector pEBVHis**

An episomal vector, pEBVHis (Invitrogen, San Diego, CA) was engineered to express an TRT fusion protein comprising hTRT fused to an N-terminal extension epitope tag, the Xpress epitope (Invitrogen, San Diego, CA) (designated pGRN122). The NotI hTRT fragment from pGRN121 containing the hTRT ORF was cloned into the NotI site of pEBVHisA so that the hTRT ORF is in the same orientation as the vector's Rous Sarcoma Virus (RSV) promoter. In this orientation the His6 flag was relatively closer to the N-terminus of hTRT.

A vector was also constructed containing as an insert the antisense sequence of TRT and the epitope tag (the plasmid designated pGRN123, which can be used as a control). The vector was transfected into 293 cells and translated hTRT identified and isolated using an antibody specific for the Xpress epitope. pEBVHis is a hygromycin resistant EBV episomal vector that expresses the protein of interest fused to a N-terminal peptide. Cells carrying the vector are selected and expanded, then nuclear and cytoplasmic extracts prepared. These and control extracts are immunoprecipitated with anti-Xpress

30

antibody, and the immunoprecipitated beads are tested for telomerase activity by conventional assay.

#### **Expression Recombinant TRT in Mortal, Normal Diploid Human Cells**

5           In one embodiment of the invention, recombinant TRT and necessary telomerase enzyme complex components can be expressed in normal, diploid mortal cells to increase their proliferative capacity, thereby creating a state of indefinite proliferation, or to immortalize them, or to facilitate immortalizing them. This allows one to obtain diploid indefinitely proliferating or immortal cells with an otherwise normal phenotype and  
10       karotype. As discussed above, this use of telomerase and TRT has enormous commercial utility.

          Sense hTRT (Figure 16) and antisense hTRT were cloned into a CMV vector. These vectors were purified and transiently transfected into two normal, mortal, diploid human cell clones. The human clones were young passage diploid human BJ and IMR90  
15       cell strains.

          Analysis of telomerase activity using a TRAP assay utilizing the TRAPeze™ Kit (Oncor, Inc., Gaithersburg, MD) showed that transfection of sense hTRT - but not antisense hTRT - generated telomerase activity in both the BJ and IMR90 cell strains.

#### **20       Expression of Recombinant TRT in Immortalized IMR90 Human Cells**

          Using the same TRT sense construct cloned into CMV vectors used in the above described diploid human BJ and IMR90 cell strains studies, immortalized SW13 ALT pathway cell line (an IMR90 cell immortalized with SV40 antigen) was transiently transfected. A TRAP assay (TRAPeze, Oncor, Inc, Gaithersburg, MD) demonstrated that  
25       telomerase activity was generated in the sense construct transfected cells.

#### **Vectors for Regulated Expression of hTRT in Mammalian Cells: Inducible and Repressible Expression of hTRT**

          The invention provides vectors that can be manipulated to induce or repress the  
30       expression of the TRTs of the invention, such as hTRT. For example, the hTRT coding

## PATENT

sequence can be cloned into the Ecdysone-Inducible Expression System from Invitrogen (San Diego, CA) and the Tet-On and Tet-off tetracycline regulated systems from Clontech Laboratories, Inc. (Palo Alto, CA). Such inducible expression systems are provided for use in the methods of the invention where it is important to control the level or rate of transcription of transfected TRT. For example, the invention provides for cell lines immortalized through the expression of TRT; such cells can be rendered “mortal” by inhibition of TRT expression by the vector through transcriptional controls, such as those provided by the Tet-Off system. The invention also provides for methods of expressing TRT only transiently to avoid the constitutive expression of TRT, which may lead to unwanted cell proliferation or “immortalization” of the transfected cells, as discussed above.

The Ecdysone-Inducible Mammalian Expression System is designed to allow regulated expression of the gene of interest in mammalian cells. The system is distinguished by its tightly regulated mechanism that allows almost no detectable basal expression and greater than 200-fold inducibility in mammalian cells. The expression system is based on the heterodimeric ecdysone receptor of *Drosophila*. The Ecdysone-Inducible Expression System uses a steroid hormone ecdysone analog, muristerone A, to activate expression of TRT via a heterodimeric nuclear receptor. Expression levels have been reported to exceed 200-fold over basal levels with no effect on mammalian cell physiology “Ecdysone-Inducible Gene Expression in Mammalian Cells and Transgenic Mice” (1996) *Proc. Natl. Acad. Sci. USA* 93, 3346-3351). Once the receptor binds ecdysone or muristerone, an analog of ecdysone, the receptor activates an ecdysone-responsive promoter to give controlled expression of the gene of interest. In the Ecdysone-Inducible Mammalian Expression System, both monomers of the heterodimeric receptor are constitutively expressed from the same vector, pVgRXR. The ecdysone-responsive promoter, which ultimately drives expression of the gene of interest, is located on a second vector, pIND, which drives the transcription of the gene of interest.

The TRT coding sequence is cloned in the pIND vector (Clontech Laboratories, Inc, Palo Alto, CA), which contains 5 modified ecdysone response elements (E/GREs) upstream of a minimal heat shock promoter and the multiple cloning site. The construct

is then transfected in cell lines which have been pre-engineered to stably express the ecdysone receptor. After transfection, cells are treated with muristerone A to induce intracellular expression from pIND.

5 The Tet-on and Tet-off expression systems (Clontech, Palo Alto, CA) give access to the regulated, high-level gene expression systems described by Gossen (1992) "Tight control of gene expression in mammalian cells by tetracycline responsive promoters" *Proc. Natl. Acad. Sci. USA* 89:5547-5551, for the Tet-Off transcription repression system; and Gossen (1995) "Transcriptional activation by tetracycline in mammalian cells" *Science* 268:1766-1769, for the Tet-On inducible transcriptional system. In "Tet-Off" transformed  
10 cell lines, gene expression is turned on when tetracycline (Tc) or doxycycline ("Dox;" a Tc derivative) is removed from the culture medium. In contrast, expression is turned on in Tet-On cell lines by the addition of Tc or Dox to the medium. Both systems permit expression of cloned genes to be regulated closely in response to varying concentrations of Tc or Dox.

15 This system uses the "pTRE" as a response plasmid that can be used to express a gene of interest. Plasmid pTRE contains a multiple cloning site (MCS) immediately downstream of the Tet-responsive PhCMV\*-1 promoter. Genes or cDNAs of interest inserted into one of the sites in the MCS will be responsive to the tTA and rtTA regulatory proteins in the Tet-Off and Tet-On systems, respectively. PhCMV\*-1 contains the  
20 Tet-responsive element (TRE), which consists of seven copies of the 42-bp tet operator sequence (tetO). The TRE element is just upstream of the minimal CMV promoter (PminCMV), which lacks the enhancer that is part of the complete CMV promoter in the pTet plasmids. Consequently, PhCMV\*-1 is silent in the absence of binding of regulatory proteins to the tetO sequences. The cloned insert must have an initiation codon. In some  
25 cases, addition of a Kozak consensus ribosome binding site may improve expression levels; however, many cDNAs have been efficiently expressed in Tet systems without the addition of a Kozak sequence. pTRE-Gene X plasmids are cotransfected with pTK-Hyg to permit selection of stable transfectants.

30 Setting up a Tet-Off or Tet-On expression system generally requires two consecutive stable transfections to create a "double-stable" cell line that contains integrated

copies of genes encoding the appropriate regulatory protein and TRT under the control of a TRE. In the first transfection, the appropriate regulatory protein is introduced into the cell line of choice by transfection of a "regulator plasmid" such as pTet-Off or pTet-On vector, which expresses the appropriate regulatory proteins. The hTRT cloned in the pTRE  
5 "response plasmid" is then introduced in the second transfection to create the double-stable Tet-Off or Tet-On cell line. Both systems give very tight on/off control of gene expression, regulated dose-dependent induction, and high absolute levels of gene expression.

### **Expression Recombinant TRT With DHFR and Adenovirus Sequences**

10 The pGRN155 plasmid construct was designed for transient expression of hTRT cDNA in mammalian cells. A Kozak consensus is inserted at the 5' end of the hTRT sequence. The hTRT insert contains no 3' or 5' UTR. The hTRT cDNA is inserted into the EcoRI site of p91023(B) (Wong (1985) *Science* 228:810-815). The hTRT insert is in the same orientation as the DHFR ORF. This makes the expression vector particularly  
15 useful for transient expression.

Plasmid pGRN155 contains the SV40 origin and enhancer just upstream of an adenovirus promoter, a tetracycline resistance gene, an *E. coli* origin and an adenovirus VAI and VAI gene region. This expression cassette contains, in the following order: the adenovirus major late promoter; the adenovirus tripartite leader; a hybrid intron consisting  
20 of a 5' splice site from the first exon of the tripartite leader and a 3' splice site from the mouse immunoglobulin gene; the hTRT cDNA; the mouse DHFR coding sequence; and, the SV40 polyadenylation signal.

The adenovirus tripartite leader and the VA RNAs have been reported to increase the efficiency with which polycistronic mRNAs are translated. DHFR sequences have  
25 been reported to enhance the stability of hybrid mRNA. DHFR sequences also can provide a marker for selection and amplification of vector sequences. See Logan (1984) *Proc. Natl. Acad. Sci. USA* 81:3655; Kaufman (1985) *Proc. Natl. Acad. Sci. USA* 82: 689 ; and Kaufman (1988) *Focus* (Life Technologies, Inc.), Vol.10, no. 3).

**Other expression plamids of the invention are described for illustrative**  
30 **purposes.**

**pGRN121**

The EcoRI fragment from lambda clone 25-1.1.6 containing the entire cDNA encoding hTRT protein was inserted into the EcoRI site of pBluescriptIISK+ such that the 5' end of the cDNA is near the T7 promoter in the vector. The selectable marker that is used with this vector is ampicillin.

**pGRN122**

The NotI fragment from pGRN121 containing the hTRT ORF was inserted into the NotI site of pEBVHisA so that the coding sequence is operably linked to the RSV promoter. This plasmid expresses a fusion protein composed of a His6 flag fused to the N-terminal of the hTRT protein. The selectable marker that is used with this vector is ampicillin or hygromycin.

**pGRN123**

The NotI fragment from pGRN121 containing the hTRT ORF was inserted into the NotI site of pEBVHisA so that the coding sequence is in the opposite orientation as the RSV promoter, thus expressing *antisense* hTRT.

**pGRN124**

Plasmid pGRN121 was deleted of all ApaI sites followed by deletion of the MscI-HincII fragment containing the 3'UTR. The Nco-XbaI fragment containing the stop codon of the hTRT coding sequence was then inserted into the Nco-XbaI sites of pGRN121 to make a plasmid equivalent to pGRN121 except lacking the 3'UTR, which may be preferred for increased expression levels in some cells.

**pGRN125**

The NotI fragment from pGRN124 containing the hTRT coding sequence was inserted into the NotI site of pBBS235 so that the open reading frame is in the opposite orientation of the Lac promoter. The selectable marker that is used with this vector is chloramphenicol.

**pGRN126**

The NotI fragment from pGRN124 containing the hTRT coding sequence was inserted into the NotI site of pBBS235 so that the hTRT coding sequence inserted is in the same orientation as the Lac promoter.

**pGRN127**

The oligonucleotide 5'-TGCGCACGTGGGAAGCCCTGGCagatctgAattCCaCcATGC  
CGCGCGCTCCCCGCTG-3' (SEQ ID NO:137) was used *in vitro* mutagenesis of  
pGRN125 to convert the initiating ATG codon of the hTRT coding sequence into a Kozak  
5 consensus sequence and create EcoRI and BglII sites for cloning. Also, oligonucleotide  
COD2866 was used to convert AmpS to AmpR (ampicillin resistant) and oligonucleotide  
COD1941 was used to convert CatR (chloramphenicol resistant) to CatS (chloramphenicol  
sensitive).

**pGRN128**

10 The oligonucleotide 5'-TGCGCACGTGGGAAGCCCTGGCagatctgAattCCaCcATG  
CCGCGCGCTCCCCGCTG-3' (SEQ ID NO:137) was used in *in vitro* mutagenesis to  
convert the initiating ATG codon of hTRT into a Kozak consensus and create EcoRI and  
BglII sites for cloning.

Also, oligo 5'-CTGCCCTCAGACTTCAAGACCATCCTGGACTACAA  
15 GGACGACGATGACAAATGAATTCAGATCTGCGGCCGCCACCGCGGTGGAG  
CTCCAGC-3' (SEQ ID NO:145) was used to insert the IBI Flag (International  
Biotechnologies Inc. (IBI), Kodak, New Haven, CT) at the C-terminus and create EcoRI  
and BglII sites for cloning. Also, COD2866 was used to convert AmpS to AmpR and  
COD1941 was used to convert CatR to CatS.

20 **pGRN129**

The oligonucleotide 5'-CGGGACGGGCTGCTCCTGCGTTTGGTGGAcGcgTTCTTG  
TTGGTGACACCTCACCTCACC-3' (SEQ ID NO:138) was used by *in vitro* mutagenesis  
to convert Asp869 to an Ala codon (i.e. the second Asp of the DD motif was converted to  
an Alanine to create a dominant/negative hTRT mutant). This also created a MluI site.  
25 Also, oligonucleotide 5'-CTGCCCTCAGACTTCAAGACCATCCTGGACTACAAGG  
ACGACGATGACAAATGAATTCAGATCTGCGGCCGCCACCGCGGTGGAGCTC  
CAGC-3' (SEQ ID NO:145) was used to insert the IBI Flag at the C-terminus and create  
EcoRI and BglII sites for cloning. Also, COD2866 was used to convert AmpS to AmpR  
and COD1941 was used to convert CatR to CatS.

**pGRN130**

The oligonucleotide 5'-CGGGACGGGCTGCTCCTGCGTTTGGTGGAcGcgTTCTT GTTGGTGACACCTCACCTCACC-3' (SEQ ID NO:138) was used in *in vitro* mutagenesis to convert the Asp869 codon into an Ala codon (i.e. the second Asp of the DD motif was converted to an Alanine to make a dominant/negative variant protein). This also created an MluI site.

Also, the oligonucleotide 5'-TGCGCACGTGGGAAGCCCTGGCagatctgAatt CCAcCtATGCCGCGCGCTCCCCGCTG-3' (SEQ ID NO:137) was used in *in vitro* mutagenesis to convert the initiating ATG codon of the hTRT coding sequence into a Kozak consensus sequence and create EcoRI and BglII sites for cloning. Also, COD2866 was used to convert AmpS to AmpR and COD1941 was used to convert CatR.

**pGRN131**

The EcoRI fragment from pGRN128 containing the hTRT ORF with Kozak sequence and IBI Flag mutations is inserted into the EcoRI site of pBBS212 so that the hTRT ORF is expressed off the MPSV promoter. Plasmid pBBS212 contains a MPSV promoter, the CMV enhancer, and the SV40 polyadenylation site.

**pGRN132**

The EcoRI fragment from pGRN128 containing the hTRT ORF with Kozak sequence and IBI Flag mutations is inserted into the EcoRI site of pBBS212 so that the antisense of the hTRT ORF is expressed off the MPSV promoter.

**pGRN133**

The EcoRI fragment from pGRN121 containing the hTRT coding sequence was inserted into the EcoRI site of pBBS212 so that the hTRT protein is expressed under the control of the MPSV promoter.

**pGRN134**

The EcoRI fragment from pGRN121 containing the hTRT coding sequence was inserted into the EcoRI site of pBBS212 so that the *antisense* of the hTRT coding sequence is expressed under the control of the MPSV promoter. The selectable markers used with this vector are Chlor/HygB/PAC.

**pGRN135**

Plasmid pGRN126 was digested to completion with MscI and SmaI and religated to delete over 95% of the hTRT coding sequence inserted. One SmaI-MscI fragment was re-inserted during the process to recreate the Cat activity for selection. This unpurified  
5 plasmid was then redigested with SalI and EcoRI and the fragment containing the initiating codon of the hTRT coding sequence was inserted into the SalI-EcoRI sites of pBBS212. This makes an *antisense* expression plasmid expressing the antisense of the 5'UTR and 73 bases of the coding sequence. The selectable markers used with this vector are Chlor/HygB/PAC.

10 **pGRN136**

The HindIII-SalI fragment from pGRN126 containing the hTRT coding sequence was inserted into the HindIII-SalI sites of pBBS242.

**pGRN137**

15 The SalI-Sse8387I fragment from pGRN130 containing the Kozak sequence was inserted into the SalI-Sse8387I sites of pGRN136.

**pGRN138**

The EcoRI fragment from pGRN124 containing hTRT minus the 3'UTR was inserted into the EcoRI site of pEGFP-C2 such that the orientation of the hTRT is the same as the EGFP domain.

20 **pGRN139**

The oligonucleotide 5'- CTGCCCTCAGACTTCAAGACCATCCTGGACTACAAGG  
ACGACGATGACAAATGAATTCAGATCTGCGGCCGCCACCGCGGTGGAGCTC  
CAGC-3 (SEQ ID NO:145) was used to insert the IBI Flag at the C-terminus of hTRT in  
pGRN125 and create EcoRI and BglII sites for cloning. Also, COD2866 was used to  
25 convert AmpS to AmpR and COD1941 was used to convert CatR to CatS.

**pGRN140**

The NcoI fragment containing the upstream sequences of genomic hTRT and the first intron of hTRT from lambdaG55 was inserted into the NcoI site of pBBS167. The fragment is oriented so that hTRT is in the same direction as the Lac promoter.

**pGRN141**

The NcoI fragment containing the upstream sequences of genomic hTRT and the first intron of hTRT from lambdaG55 was inserted into the NcoI site of pBBS167. The fragment is oriented so that hTRT is in the opposite direction as the Lac promoter.

5 **pGRN142**

This vector was constructed for the expression and mutagenesis of TRT sequences in *E. coli*. The promoter clone from lambda Gφ5 (lac orientation) was used. The selectable marker that is used with this vector is ampicillin. The NotI fragment from lambdaGphi5 containing the complete ~15 kbp genomic insert including the hTRT gene promoter region was inserted in the NotI site of plasmid pBBS185. The fragment is oriented so that the hTRT ORF is in the opposite orientation as the Lac promoter.

10 **pGRN143**

This vector was constructed for the expression and mutagenesis of TRT sequences in *E. coli*. The NotI fragment from lambdaGphi5 containing the complete ~15 kbp genomic insert including the hTRT gene promoter region was inserted in the NotI site of plasmid pBBS185. The fragment is oriented so that the hTRT ORF is in the same orientation as the Lac promoter. The selectable marker that is used with this vector is ampicillin.

15 **pGRN144**

SAL1 deletion of pGRN140 to remove lambda sequences.

20 **pGRN145**

This vector was constructed for the expression of hTRT sequences in mammalian cells. The EcoRI fragment from pGRN137 containing the hTRT coding sequence was inserted into the EcoRI site of pBBS212 to remove the portion of the sequence corresponding to the 5'UTR of hTRT mRNA. The hTRT coding sequence is oriented so that it is expressed under the control of the MPSV promoter. The selectable markers used with this vector are Chlor/HygB/PAC.

25 **pGRN146**

This vector was constructed for the expression of hTRT sequences in mammalian cells. The Sse8387I-NotI fragment from pGRN130 containing the D869A mutation of hTRT was

inserted into the Sse8387I-NotI sites of pGRN137. The selectable markers used with this vector are Ampicillin/HygB/PAC.

**pGRN147**

5 The Sse8387I-NotI fragment from pGRN139 containing the IBI Flag was inserted into the Sse8387I-NotI sites of pGRN137.

**pGRN148**

The BglII-Eco47III fragment from pGRN144 containing the promoter region of hTRT was inserted into the BglII-NruI sites of pSEAP2 to make an hTRT promoter/reporter construct.

10 **pGRN149**

This vector was constructed for the expression and mutagenesis of TRT sequences in *E. coli*. The mutagenic oligo 5'-cttcaagaccatcctggactttcgaacgcggccgccaccgcggtggagctcc-3' (SEQ ID NO:22) was used to add a CSP45I site at the C-terminus of hTRT by *in vitro* mutagenesis of pGRN125. The "stop" codon of hTRT was deleted and replaced with a  
15 Csp45I site. The selectable marker that is used with this vector is ampicillin.

**pGRN150**

The BglII-FspI fragment from pGRN144 containing the promoter region of hTRT was inserted into the BglII-NruI sites of pSEAP2 to make an hTRT promoter/reporter construct.

20 **pGRN151**

This vector was constructed for the expression of hTRT sequences in mammalian cells. The EcoRI fragment from pGRN147 containing the hTRT coding sequence was inserted into the EcoRI site of pBBS212 to remove the portion of the sequence corresponding to the 5'UTR of the hTRT mRNA. The hTRT coding sequence is oriented so that it is  
25 expressed under the control of the MPSV promoter. The selectable markers used with this vector are Chlor/HygB/PAC.

**pGRN152**

The EcoRI fragment from pGRN146 containing the hTRT coding sequence was inserted into the EcoRI site of pBBS212 to remove the portion of the sequence corresponding to

the 5'UTR of the hTRT. The hTRT coding sequence is oriented so that it is expressed under the control of the MPSV promoter.

**pGRN153**

5 The StyI fragment from pGRN130 containing the D869-->A mutation of hTRT (hTRT variant coding sequence) was inserted into the StyI sites of pGRN158 to make a plasmid containing the hTRT coding sequence with a Kozak consensus sequence at its 5'-end, an IBI FLAG sequence at its 3'-end (the C-terminus encoding region), and the D869-->A mutation.

**pGRN154**

10 This vector was constructed for the expression of hTRT sequences in mammalian cells. The EcoRI fragment of pGRN153 containing the hTRT gene was inserted into the EcoRI site of plasmid pBS212 in an orientation such that the hTRT ORF is oriented in the same direction as the MPSV promoter. This makes an MPSV-directed expression plasmid that expresses the hTRT protein with a Kozak consensus sequence at its amino-terminal end,  
15 an IBI FLAG at its carboxy-terminal end, and the D869-->A mutation. The selectable markers used with this vector are Ampicillin/HygB/PAC.

**pGRN155**

This vector was constructed for the expression of hTRT sequences in mammalian cells. The insert included full length cDNA of hTRT minus 5' and 3' UTR, and Kozak sequences.  
20 The EcoRI fragment from pGRN145 containing the hTRT cDNA with the Kozak consensus and no 3' or 5' UTR was inserted into the EcoRI site of p91023(B) such that the hTRT is in the same orientation as the DHFR ORF. This makes a transient expression vector for hTRT. The selectable marker used with this vector is tetracycline.

**pGRN156**

25 This vector was constructed for the expression of hTRT sequences in mammalian cells. The EcoRI fragment from pGRN146 containing the D869A mutation of the hTRT cDNA with the Kozak consensus and no 3' or 5' UTR was inserted into the EcoRI site of p91023(B) such that the hTRT is in the same orientation as the DHFR ORF. This makes a transient expression vector for hTRT. The insert included full length cDNA of hTRT

minus 5' and 3' UTR, D869A, and Kozak sequences. The selectable marker used with this vector is tetracycline.

**pGRN157**

This vector was constructed for the expression of hTRT sequences in mammalian cells.

- 5 The EcoRI fragment from pGRN147 containing the hTRT cDNA with the IBI FLAG at the C-terminus; the Kozak consensus and no 3' or 5' UTR into the EcoRI site of p91023(B) such that the hTRT is in the same orientation as the DHFR ORF. This makes a transient expression vector for hTRT. The insert included full length cDNA of hTRT minus 5' and 3' UTR, the IBI FLAG sequence, and Kozak sequences. The selectable marker used with  
10 this vector is tetracycline.

**pGRN158**

This vector was constructed for the expression and mutagenesis of TRT sequences in *E. coli*. The EcoRI fragment from pGRN151 containing the hTRT ORF was inserted into the

- 15 EcoRI site of pBBS183 so that the hTRT ORF is oriented in the opposite direction as the Lac promoter. The insert included full length cDNA of hTRT minus 5' and 3' UTR, IBI FLAG sequence, and Kozak sequences. The hTRT coding sequence is driven by a T7 promoter. The selectable marker used with this vector is ampicillin.

**pGRN159**

This vector was constructed for the expression and mutagenesis of TRT sequences in *E.*

- 20 *coli*. The NheI-KpnI fragment from pGRN138 containing the EGFP to hTRT fusion was inserted into the XbaI-KpnI sites of pBluescriptIIKS+. This makes a T7 expression vector for the fusion protein (the coding sequence is driven by a T7 promoter). The insert included full length cDNA of hTRT minus the 3' UTR as a fusion protein with EGFP. The selectable marker used with this vector is ampicillin.

25 **pGRN160**

This vector was constructed for the expression of *antisense* hTR sequences in mammalian cells. The coding sequence is operably linked to an MPSV promoter. The XhoI-NsiI fragment from pGRN90 containing the full length hTR ORF was inserted into the SalI-Sse8387I sites of pBBS295. This makes a transient/stable vector expressing hTR antisense

RNA. A GPT marker was incorporated into the vector. The selectable markers used with this vector are Chlor/gpt/PAC.

**pGRN161**

5 This vector was constructed for the expression of *sense* hTR sequences in mammalian cells. The XhoI-NniI fragment from pGRN89 containing the full length hTR ORF was inserted into the SalI-Sse8387I sites of pBBS295. This makes a transient/stable vector expressing hTR in the sense orientation. The coding sequence is driven by an MPSV promoter. A GPT marker was incorporated into the vector. The selectable markers used with this vector are Chlor/gpt/PAC.

10 **pGRN162**

The XhoI-NsiI fragment from pGRN87 containing the full length hTR ORF was inserted into the SalI-Sse8387I sites of pBBS295. This makes a transient/stable vector expressing truncated hTR (from position +108 to +435) in the sense orientation.

**pGRN163**

15 This vector was constructed for the expression and mutagenesis of TRT sequences in *E. coli*. The coding sequence is driven by a T7 promoter. Oligonucleotide RA45 (5'-GCCACCCCCGCGCTGCCTCGAGCTCCCCGCTGC-3') (SEQ ID NO:151) is used is used in *in vitro* mutagenesis to change the initiating met in hTRT to Leu and introduce an XhoI site in the next two codons after the Leu. Also COD 1941 was used to change  
20 CatR to CatS, and introduces a BSPH1 site, and COD 2866 was used to change AmpS to AmpR, introducing an FSP1 site. The selectable marker used with this vector is ampicillin.

**pGRN164**

This vector was constructed for the expression of hTR sequences in *E. coli*. Primers  
25 hTR+1 5'-GGGGAAGCTTTAATACGACTCACTATAGGGTTGCGGAGGGTGG  
GCCTG-3' (SEQ ID NO:40) and hTR+445 5'-  
CCCCGGATCCTGCGCATGTGTGAGCCGAGTCCTGGG-3' (SEQ ID NO:5) were used  
to amplify by PCR a fragment from pGRN33 containing the full length hTR with the T7  
promoter on the 5' end (as in hTR+1). A BamHI-HindIII digest of the PCR product was

put into the BamHI-HindIII sites of pUC119. The coding sequence operably linked to a T7 promoter. The selectable marker used with this vector is ampicillin.

**pGRN165**

5 This vector was constructed for the expression and mutagenesis of hTRT sequences in *E. coli*. The coding sequence is operably linked to a T7 promoter. The EcoRI fragment from pGRN145 containing the hTRT ORF with a Kozak front end was inserted into the EcoRI site of pBluescriptIISK+ so that the hTRT is oriented in the same direction as the T7 promoter. The selectable marker used with this vector is ampicillin.

**pGRN166**

10 This vector was constructed for the expression and mutagenesis of TRT sequences in mammalian cells. The coding sequence is operably linked to a T7 promoter. The EcoRI fragment from pGRN151 containing the hTRT ORF with a Kozak front end and IBI flag at the back end was inserted into the EcoRI site of pBluescriptIISK+ so that the hTRT ORF is oriented in the same direction as the T7 promoter. The insert included full length cDNA  
15 of hTRT minus 5' and 3' UTR, FLAG sequence (Immunex Corp, Seattle WA), and Kozak sequences. The selectable marker used with this vector is ampicillin.

**pGRN167**

AvRII-StuI fragment from pGRN144 containing the 5' end of the hTRT ORF was inserted into the XbaI-StuI sites of pBBS161.

20 **pGRN168**

This vector was constructed for the expression of hTRT sequences in mammalian cells. The EcoRI fragment from pGRN145 containing the optimized hTRT expression cassette was inserted into the EcoRI site of pIND such that the hTRT coding sequence is in the same orientation as the miniCMV promoter. The selectable markers used with this vector  
25 are ampicillin/neomycin/kanamycin.

**pGRN169**

This vector was constructed for the expression of *antisense* hTRT sequences in mammalian cells. The EcoRI fragment from pGRN145 containing the optimized hTRT expression cassette was inserted into the EcoRI site of pIND such that the hTRT is in the reverse  
30 orientation from the miniCMV promoter. The hTRT was cloned into the

## PATENT

Ecdysone-Inducible Expression System from Invitrogen. The insert included full length cDNA of hTERT minus 5' and 3' UTR, and Kozak sequences. The selectable markers used with this vector are ampicillin/neomycin/kanamycin.

### **pGRN170**

- 5 This vector was constructed for the expression of *antisense* hTERT sequences in mammalian cells. The EcoRI fragment from pGRN145 containing the optimized hTERT expression cassette was inserted into the EcoRI site of pIND(sp1) such that the hTERT is in the opposite orientation from the miniCMV promoter. The hTERT was cloned into the Ecdysone-Inducible Expression System from Invitrogen, with a pIND(sp1) sequence. The  
10 insert included full length cDNA of hTERT minus 5' and 3' UTR, and Kozak sequences. The selectable markers used with this vector are ampicillin/neomycin/kanamycin.

### **pGRN171**

The Eco47III-NarI fragment from pGRN163 was inserted into the Eco47III-NarI sites of pGRN167, putting the M1L mutation into a fragment of the hTERT genomic DNA.

### **pGRN172**

15 The BamHI-StuI fragment from pGRN171 containing the Met to Leu mutation in the hTERT ORF was inserted into the BglII-NruI sites of pSEAP2-Basic.

### **pGRN173**

- This vector was constructed to analyze the transcriptional activity of TERT sequences; specifically, this is an intron construct to determine whether the first hTERT intron has  
20 promoter activity. The EcoRV-Eco47III fragment from pGRN144 containing the 5' end of the hTERT promoter region was inserted into the SrfI-Eco47III sites of pGRN172. This makes a promoter reporter plasmid that contains the promoter region of hTERT from approximately 2.3 kb upstream from the start of the hTERT ORF to just after the first intron  
25 in the coding region, with the Met1-->Leu mutation. The selectable marker used with this vector is ampicillin.

### **pGRN174**

- This vector was constructed for the expression of hTERT sequences in mammalian cells, and is an inducible hTERT expression vector. The EcoRI fragment from pGRN145  
30 containing the "optimized" hTERT expression cassette was inserted into the EcoRI site of

## PATENT

pIND(sp1) such that the hTERT is in the same orientation as the miniCMV promoter. This makes a promoter reporter plasmid that contains the promoter region of the hTERT gene from approximately 2.3 kb upstream from the start of the hTERT ORF to just after the first intron in the coding region. The insert included full length cDNA of hTERT minus 5' and  
5 3' UTR, and Kozak sequences. The selectable markers used with this vector are ampicillin/neomycin/kanamycin.

From the above, it is clear that the present invention provides nucleic acid and amino acid sequences, as well as other information regarding telomerase, telomerase  
10 protein subunits, and motifs from various organisms, in addition to methods for identification of homologous structures in other organisms in addition to those described herein.

All publications and patents mentioned in the above specification are herein  
15 incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various  
20 modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.